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Chapter 1
Introduction

Introduction
Liver cancer is one of the five types of cancer most associated with cancer-
related mortality, accounting for 610000 deaths each year world-wide [140].
The growth of tumor cells in the liver can originate from the liver tissue
(primary tumors), or can be the result of cell spread from elsewhere in the body
(metastases). A subgroup of patients in whom tumor growth is limited to the liver
can be treated with curative intent, usually by surgery. The majority of people
in whom tumor growth is limited to the liver are treated for liver metastases
resulting from a controlled cancer of the colon or rectum. Unfortunately, most
patients are not eligible for surgery because of unfavorable tumor factors or their
poor general condition. For these patients, other local treatment techniques,
among which radiofrequency ablation (RFA) is the most widely used, offer a high
rate of local control [32, 46]. However, RFA is currently limited to smaller tumors
(commonly <3 cm) and cannot be delivered in the proximity of critical structures
[32]. Traditionally, owing to the low tolerance of the whole liver to irradiation,
non-invasive radiotherapy has played only a limited role in the treatment of liver
tumors. However, in the 1990s, groups from the Karolinska Hospital (Stockholm,
Sweden) and Michigan Medical School (Ann Arbor, USA) demonstrated that
large doses of ionizing radiation can be delivered safely to localized targets in the
liver [9, 88]. The method required highly focused beams of ionizing radiation,
directed at the tumor from different angles, and precise localization of the tumor
relative to the beams. Another local treatment technique for liver tumors was
thus introduced which became known as Stereotactic Body Radiation Therapy
(SBRT).
SBRT is an external beam radiation therapy (EBRT) method used to deliver
a high dose of radiation very precisely to an extracranial target within the
body, using either a single dose or a small number of fractions [102]. The term
stereotactic refers to the use of an external three-dimensional reference system for
positioning of the tumor in the treatment beams, and was adopted from the precise
treatment practice applied to cranial tumors. In order to obtain the targeting
precision required for the delivery of very high doses per fraction, SBRT requires
specialized dose planning and treatment procedures.
In preparation for the treatment, a patient-specific dose plan is made using the
patient’s CT scan and specialized software. Typically over 10 beams are pointed
at the tumor from different directions (non-coplanar) to create a dose distribution
with steep dose fall-off towards healthy tissues and a high dose region in the central
part of the tumor, which may possibly contain hypoxic cells with reduced radio-
sensitivity [16, 36, 100, 155]. Although the total dose is sometimes delivered in a
single fraction [50, 61, 117], often 3-6 high-dose fractions are used to allow for some
healthy tissue recovery [26, 30, 42]. Using multiple fractions may also improve
tumor cell kill [65]. Because of the inherent time lag between treatment planning
and dose delivery (typically 1-2 weeks), the position of the tumor during planning
will generally not be the same at time of treatment. Image-guided procedures are
used to correct tumor motion, but some residual uncertainty will always remain.
Therefore, residual uncertainty is taken into account in a treatment plan by adding
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a safety margin to the clinical target volume (CTV), resulting in the planning
target volume (PTV) [67, 68]. The minimum dose required for the tumor is then
prescribed to the PTV. Obviously, the larger the CTV-PTV margin is, the larger
the probability of covering the tumor with the prescribed dose will be, but also,
the larger the dose deposited in healthy tissues will be. In addition, limiting
the PTV volume may allow for higher doses to the tumor, which increases the
probability of tumor control [95].
To allow the safe use of small CTV-PTV margins, SBRT procedures employ
specialized technology to limit uncertainties in tumor targeting. The liver
moves with respiration, and can change shape and position depending on filling
or peristalsis in adjacent anatomical structures such as the stomach, bowel,
gallbladder and colon. To limit various positional uncertainties, the Karolinska
group developed a Stereotactic Body Frame (SBF), which provided a 3D reference
system, patient fixation, and abdominal compression to reduce respiratory
motion [10, 82]. Based on fluoroscopic measurements of diaphragm motion and
measurements of tumor displacements in CT, CTV-PTV margins of 10 mm
cranial-caudal (CC) and 5 mm in axial directions were proposed [10]. Later,
German groups [60, 61, 146, 147] pioneered treatment with similar devices and
further investigated the day-to-day residual mobility of patient and liver. Wulf
et al. [146, 147] introduced a procedure to correct for day-to-day motion of the
tumor by acquiring CT scans before each treatment fraction, while adopting the
CTV-PTV margins from Karolinska.
At Erasmus MC we have been treating patients with liver tumors using the
commercialized version of Karolinska’s SBF (Figure 1.1, Elekta AB, Stockholm,
Sweden) since 2002. Our initial treatment procedure was based on the experience
of Wulf et al. [146, 147]. With the aim of improving treatment precision, in
most of these patients we have been implanting fiducial markers (gold cylinders
5 mm × 1 mm ∅) in the liver since 2004. Fiducial markers can be imaged with
kV X-ray equipment, and used to measure liver motion. In 2005, a multi-slice CT
scanner was introduced to improve the CT-guided treatment set-up procedure.
Although the pioneering work of the Swedish and German groups had shown
potential sources of tumor position uncertainties and provided several procedures
to manage these uncertainties, it was unclear to what extent the introduction of
CT guidance, and the presence of various inaccuracies, impacted on the CTV-PTV
margin requirements. Moreover, in these studies measurement had been limited
by the use of a single-slice CT scanner, which cannot avoid the introduction
of imaging artifacts due to residual respiratory motion. Knowledge of overall
treatment inaccuracy is required to create adequate CTV-PTV margins, to allow
objective comparisons between various SBRT procedures [7, 38, 49, 87, 109, 138],
and to effectively steer scientific developments.
The purposes of the research reported in this thesis were, 1) to measure the
overall tumor positioning accuracy that can be achieved during dose delivery for
an SBF-based procedure supported by abdominal compression, 2) to investigate
improvements that can be obtained by implanting gold markers to guide the
4
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Figure 1.1: A patient set-up for treatment in the stereotactic body frame (SBF)
supported by abdominal compression and positioned at the couch of a treatment unit
(linac)
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liver SBRT treatment set-up, and 3) to investigate the required CTV-PTV
margins. In parallel, clinical output was evaluated [92, 91], Chapter 2, and liver
SBRT treatment planning strategies were optimized [34, 35, 36, 95]. Although
geometrical uncertainty, treatment planning and clinical outcomes eventually all
connect, in this thesis the emphasis is on geometrical precision, which is evaluated
in its own context.
This thesis comprises scientific publications (Chapters 2–5,7–9), a patent
description of a respiration sensor developed in-house (Chapter 6), and a general
discussion including the most recent findings, implications for SBRT in practice,
and ideas for future directions (Chapter 10). Chapter 2 presents the clinical
outcome of our treatment of colorectal metastases in the liver. In Chapter 3 a
CT-guided SBRT set-up procedure, using a single slice CT scanner, is analyzed,
and a CTV-PTV margin recipe is proposed. The impact of this procedure on
dose distributions within the target and organs at risk is analyzed in Chapter 4.
Chapter 5 reports on the reduction in respiration-induced liver motion that was
achieved by applying abdominal compression. Chapter 6 describes the respiration
sensor used in Chapter 5. The potentials and limitations of guiding treatment
set-up using liver-implanted fiducial markers are studied in Chapter 7. Chapter
8 describes how CT scans acquired during breath-hold were used to compare the
day-to-day tumor motion with the motion of tumor surrogates such as implanted
markers, the diaphragm, and the bony anatomy. The set-up error variance of
marker-guided treatments is related to the distance between the tumor and the
implanted markers. Modeling this type of dependency requires an extension of
the existing set-up error paradigm, which is introduced in Chapter 9.
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Abstract
Background: Stereotactic body radiation therapy (SBRT) is a treatment option
for colorectal liver metastases. Local control, patient survival and toxicity were
assessed in an experience of SBRT for colorectal liver metastases.
Methods: SBRT was delivered with curative intent to 20 consecutively treated
patients with colorectal hepatic metastases who were candidates for neither
resection nor radiofrequency ablation (RFA). The median number of metastases
was 1 (range 1-3) and median size was 2.3 (range 0.7-6.2) cm. Toxicity was scored
according to the Common Toxicity Criteria version 3.0. Local control rates were
derived on tumour-based analysis.
Results: Median follow-up was 26 (range 6-57) months. Local failure was
observed in nine of 31 lesions after a median interval of 22 (range 12-52) months.
Actuarial 2-year local control and survival rates were 74% and 83% respectively.
Hepatic toxicity grade 2 or less was reported in 18 patients. Two patients had an
episode of hepatic toxicity grade 3.
Conclusion: SRBT is a treatment option for patients with colorectal liver
metastases, who are not candidates for resection or RFA.
SBRT for colorectal liver metastases
2.1 Introduction
Colorectal cancer is a common malignancy and the second leading cause of cancer-
related death in the USA and Europe [70]. Liver metastases develop in 50-
70% of patients with colorectal cancer during the course of the disease [76].
Resection of colorectal liver metastases is still the ‘gold standard’ treatment, with
5-year survival rates ranging from 35% to 60% in highly selected patients [104].
Unfortunately, most patients are not eligible for surgery because of unfavourable
tumour factors or poor general condition. Other local treatment techniques,
among which radiofrequency ablation (RFA) is the most widely used, offer a
high rate of local control in inoperable patients with liver metastases [33, 46].
However, RFA is preferably carried out for metastases that are smaller than 3 cm
and not located in the proximity of major blood vessels, the main biliary tract or
gallbladder, or just beneath the diaphragm [33].
Traditionally, radiotherapy has had a limited role in the treatment of
intrahepatic malignancies owing to the low tolerance of the whole liver to
irradiation. However, since the 1990s, groups from the Karolinska Hospital and
Michigan Medical School (Ann Arbor) have demonstrated that large doses of
conformal radiation can be delivered safely to localized targets in the liver [9, 88].
Stereotactic body radiation therapy (SBRT) is a non-invasive technique that
delivers very large doses of radiation in a few fractions [125]. Advances in
tumour imaging, motion management, radiotherapy planning and dose delivery
have allowed safe use of high-dose conformal radiation therapy in liver tumours
[28]. Several papers have reported outcomes after SBRT for liver metastases
from various primary tumours [59, 72, 83, 145]. This study assessed local control,
survival and toxicity after SBRT in a cohort of 20 patients with 31 liver metastases
only from colorectal origin only.
2.1.1 Radiotherapy
Patients were positioned in a stereotactic body frame (Elekta Oncology Systems,
Stockholm, Sweden) with maximum tolerated abdominal compression to reduce
respiratory tumour motion for planning and treatment purposes [82]. Three
computed tomographies (CT) scans per patient were acquired: two contrast-
enhanced scans in the arterial and venous phases for tumour definition and one
large-volume scan for dose planning. The border of contrast enhancement was
taken as the boundary of the metastasis. The tumour delineations were reviewed
by an experienced radiologist. The tumour volume was then expanded with safety
margins to compensate for the residual breathing motion and other uncertainties
in tumour position, resulting in the planning target volume (PTV). Initially, equal
safety margins were selected for all patients based on the Karolinska experience
(5 mm in the left-right and anterior-posterior directions, and 10 mm in the
craniocaudal direction) [82]. Later, the margin was individualized in all three
directions by measuring the residual motion of fiducials implanted around the
9
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tumour using video fluoroscopy registrations.
Up to June 2006, patients received three fractions of SBRT starting at 12.5 Gy,
according to a phase I-II design [91]. Thereafter, doses were escalated based on
published data [73]. Treatment plans were generated with the CadPlan treatment
planning system (Varian Oncology Systems, Palo Alto, California, USA) with a
median of 7 (4-10) beams. The dose was prescribed in such a way that at least
95% of the PTV received a dose of 12.5 Gy (15 Gy in two patients). The length
of the treatment course was 5-6 days and the dose was delivered in fractions every
other day.
2.1.2 Follow-up
Treatment results and side-effects were evaluated prospectively by clinical and
laboratory examination and CT or magnetic resonance imaging at 1 and 3 months
after irradiation, followed by further examinations every 3 months during the
first 2 years, and every 6 months thereafter. Toxicity was evaluated with the
Common Toxicity Criteria (CTC), version 3.0, of the National Cancer Institute
(http://ctep.cancer.gov). Local failure was defined as an increase in tumour size
or tumour regrowth, with rates calculated on a tumour basis. Patients were
monitored for local control even if distant or new liver metastases developed.
Progressive disease included any intrahepatic or extrahepatic disease progression.
If local failure or progressive disease was diagnosed, the date of recurrence was
defined as the first date on which an abnormality was recognized on CT.
2.1.3 Statistical analysis
To assess local control and survival, Kaplan-Meier analyses were generated using
SPSS version 15.0 software (SPSS, Chicago, Illinois, USA). The log rank test was
used to identify variables associated with local control.
2.2 Results
Between December 2002 and July 2008, SBRT was administered to 20 consecu-
tively treated patients with 31 lesions. In 19 patients the metastases were not
amenable to resection or RFA owing to an unfavourable location and/or limited
liver remnant. One patient had cardiac co-morbidity and non-invasive treatment
was preferred.
One patient received radiotherapy three times for recurrent lesions, first
elsewhere and the second and third times at this centre. Characteristics of the
31 metastases treated with SBRT are shown in Table 2.1. The median number of
metastases was 1 (range 1-3) and median size was 2.3 (range 0.7-6.2) cm.
10
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Table 2.1: Patient, target and treatment characteristics of 20 patients with 31 hepatic
metastases.
patients 20 
 sex ratio (m : f) 
 median (range) age (years) 
15 : 5 
72 (45–81) 
location of primary tumor 
 rectum 
 colon 
 
5 
15 
metastases 31 
 site (Couinaud segments)  
  I 
  II 
  III 
  IV 
  IV/V 
  V 
  VI 
  VI/VII 
  VII 
  VIII 
3 
0 
1 
3 
1 
3 
1 
1 
5 
13 
dose fractionation 
 3 × 12.5 Gy 
 3 × 15 Gy 
 
29 
2 
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2.2.1 Local control
Thirteen patients had SBRT as a second-line treatment after resection, isolated
hepatic perfusion, RFA or SBRT elsewhere. None of the 20 patients received
adjuvant chemotherapy after SBRT. Fourteen patients had complete local control
of all 22 lesions. Size of metastases was not a predictive factor of outcome. Local
failure occurred in nine lesions in six patients after a median interval of 22 (range
12-52) months. One patient who had two local failures in two lesions received
chemotherapy, with an excellent response. This allowed extended liver surgery
with curative intent. Three patients received palliative chemotherapy and died,
and a further two patients were still receiving chemotherapy at the time of writing.
Actuarial, 1 and 2-year local control rates were 100% and 74% respectively (Fig.
2.1a).
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Figure 2.1: (a) Local control rate and (b) overall survival after stereotactic body
radiation therapy (SBRT).
2.2.2 Overall survival
Nine patients had died after a median follow-up of 26 (range 6-57) months. Median
time to progression of disease was 11 (range 1-52) months. Median overall survival
was 34 months, and actuarial 1 and 2-year survival rates were 100% and 83%
respectively (Fig. 2.1b).
2.2.3 Toxicity
Eighteen patients had hepatic toxicity of grade 2 or less, whereas two patients
had grade 3 toxicity (CTC version 3.0) with an increase in γ-glutamyl transferase
level. One patient showed no changes in liver function parameters but developed
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portal hypertension syndrome with oesophageal varices (grade 1 toxicity) with
one episode of melaena, and was treated conservatively. After the second
radiation treatment this patient presented with hepatic toxicity and ascites (both
grade 2), which responded well to temporary diuretic medication. Oesophageal
bleeding evidenced by melaena occurred again, and the varices were treated with
endoscopic band ligation. One patient became physically weak (grade 3) during
the first month after treatment but recovered spontaneously during the second
month. Grade 2 pain owing to rib fractures occurred in one patient 10 months
after irradiation of a subcapsular liver metastasis located in the vicinity of the
ribs. No grade 4 or 5 (death), or stomach, bowel, kidney or spinal cord toxicity
was found.
2.3 Discussion
The present study has shown that SBRT for colorectal liver metastases can
achieve 2-year local control and survival rates of 74% and 83% respectively with
acceptable toxicity in patients who are not eligible for surgery or RFA. Three
patients developed CTC toxicity grade 3, and late toxicity of grade 1 and 2 was
reported in two patients.
Resection should be regarded as the standard curative treatment in patients
with hepatic metastases from colorectal cancer. However, only a minority of
patients are suitable for liver resection [22]. RFA has certain advantages over
hepatic resection, such as a shorter hospital stay and a lower complication rate
[46, 142], although the authors do not advocate it as an alternative to hepatic
resection as it is associated with a higher local recurrence rate, with median
time to local tumour progression between 4 and 9 months [115]. RFA should be
reserved for those in whom resection of all metastases is not possible [1]. SBRT
has been used for liver metastases that are unsuitable for or refractory to liver
resection or RFA in an attempt to control disease locally.
SBRT involves the precise delivery of large doses of highly conformal radiation
to extracranial targets using a small number of fractions. This treatment has
several advantages over RFA. Owing to the heat-sink effect of large vessels, tissue
close to the vessels is not amenable to RFA and major bile ducts are at increased
risk of heat injury during ablation [142]. To avoid these problems, centrally
located liver lesions and metastases near large vessels may be treated with SBRT
instead of RFA. SBRT is non-invasive and can be offered to patients who are
not eligible for invasive or minimal invasive interventions; it is also feasible in the
outpatient setting, with no requirement for hospitalization or general anaesthesia.
SBRT may be as effective as RFA for small tumours but may be less suitable for
multiple tumours.
Herfarth and Debus [59] reported poorer local control of colorectal metastases
than of tumours with other histology (45% versus 91% after 18 months). This is in
line with other studies that showed a lower local control or survival rate in patients
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with metastases from colorectal cancer compared with metastases from other
primary tumours [83, 94]. In contrast, Rusthoven and co-workers [107] reported
an improved median survival of 32 months after treatment of liver metastases from
favourable primaries (breast, colorectal, renal, carcinoid, gastrointestinal stromal
tumour and sarcoma), compared with the median survival of 12 months for those
from unfavourable primary sites (primary tumours of the lung, ovary and non-
colorectal gastrointestinal malignancies). This raises the question of whether it is
justified to group liver metastases from primary colorectal cancer together with
those from other primary cancers when evaluating the results of SBRT. Therefore,
the present study focused on colorectal metastases only.
A 2-year local control rate of 74% was achieved for colorectal metastases
generally treated with 3 × 12.5 Gy, with a median survival of 34 months.
Previous studies describing the outcomes of SBRT for colorectal liver metastases
are summarized in Table 2.2. Hoyer and colleagues [66] achieved a 2-year local
control rate of 86% after SBRT with 3 × 15 Gy for colorectal metastases in the
liver, lung or suprarenal lymph nodes, or at two of these sites; median follow-
up was 4.3 years. When liver metastases were analysed separately, a 2-year local
control rate of 78% was noted (M. Hoyer, personal communication). This is in line
with the present results, probably because the dose was similar in the two studies
and median follow-up was adequate (more than 2 years). Rusthoven and co-
workers [107] reported a 2-year local control rate of 92% in liver metastases from
a variety of primary tumours treated with 36-60 Gy. This clinical experience is
consistent with the knowledge that escalated doses of radiation are associated with
improved local control and survival [94, 29]. Dose escalation in the present cohort
was limited owing to the small functional liver remnant because most patients
had already undergone several partial liver resections and RFA procedures before
SBRT. However, it is generally difficult to compare studies on SBRT for liver
tumours. Conflicting results regarding patient outcome might be explained by
differences in patient selection criteria, site of metastases, dose prescription,
assessments of local failure or control, and duration of follow-up. In the present
series median follow-up was 26 months and the median time to local failure was
22 (range 12-52) months. Median follow-up in the series of Rusthoven et al. [107]
was only 16 months, which may be too short to allow reliable estimation of local
control.
Only a minority of patients with colorectal liver metastases in this clinic were
treated with SBRT. The 20 patients in this study represent a negative selection
as they were not eligible for surgery and/or RFA because of tumour size and/or
location. Lesions were centrally located or near to biliary ducts and vessels. In
this respect, these patients represent a group with a poor prognosis.
Median survival of patients with stage IV colorectal cancer is about 24 months
with modern chemotherapy [41, 126]. In the present series, median survival was
34 months after SBRT; no serious acute toxicity was encountered in keeping
with previous reports [59, 110, 148]; and none of the patients received adjuvant
chemotherapy. The low toxicity after SBRT, and at least comparable survival to
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Table 2.2: Reported local control rates after treatment of colorectal liver metastases
with stereotactic body radiation therapy.
 
 
reference no. of 
patients 
no. of 
lesions 
dose fractionation 
scheme 
median 
follow-up 
(months) 
actuarial local 
control (%) 
 actuarial 
survival (%) 
1 year 2 years  1 year 2 years 
[60] 35 – 1×20-26 Gy (80) 15* – 45†  – – 
[145] – 23 3-4×7-12,5 Gy (65) or 1×26 Gy (80) 15 88
‡ 56‡  – – 
[73] 20 – 7-20×2-6 Gy (80) 15 – –  80‡ 26‡ 
[83] 40 – 6×4.6-10 Gy (–) 11 – –  63 – 
present 
series 20 31 3×12.5-15 Gy (65) 26 100 74  100 83 
Values in parenthesis are percentage isodose. 
* Mean 
† Eighteen months 
‡ Data from figures 
 
that after systemic chemotherapy, may justify its use in this patient group. The
median time to disease progression after SBRT was 11 months, similar to that
after liver resection in the authors’ experience [37]. The lower median survival
of 34 months after SBRT, compared with 44 months after partial liver resection,
can be explained by the generally poorer prognosis of the cohort.
Further research is needed to define the role of SBRT within the treatment
armamentarium for colorectal liver metastases. A phase III trial has been
proposed by this centre among others (International Liver Group) to compare
SBRT in three fractions with RFA for the treatment of unresectable colorectal
liver metastases up to 4 cm in diameter. Combined treatment with radiation
sensitizers should be pursued in addition to randomized trials of SBRT for
colorectal liver metastases. It has already been hypothesized that the combination
of radiotherapy and angiogenesis inhibitors may have a synergistic effect [134].
Proper selection of patients for this treatment in high-volume hepatobiliary
centres with a multidisciplinary team is advocated.
In conclusion, SBRT is indicated in patients with unresectable colorectal liver
metastases or as a second-line therapy for recurrence after liver surgery [129].
SBRT achieves adequate local control, and appears to be safe with respect to
both acute and late toxicity in selected patients if normal tissue dose restrictions
are respected.
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Abstract
Purpose: To determine the effect of image-guided procedures (with computed
tomography [CT] and electronic portal images before each treatment fraction)
on target coverage in stereotactic body radiotherapy for liver patients using a
stereotactic body frame (SBF) and abdominal compression. CT guidance was
used to correct for day-to-day variations in the tumor’s mean position in the
SBF.
Methods and Materials: By retrospectively evaluating 57 treatment sessions,
tumor coverage, as obtained with the clinically applied CT guided protocol, was
compared with that of alternative procedures. The internal target volume-plus
(ITV+) was introduced to explicitly include uncertainties in tumor delineations
resulting from CT-imaging artifacts caused by residual respiratory motion. Tumor
coverage was defined as the volume overlap of the ITV+, derived from a tumor
delineated in a treatment CT scan, and the planning target volume. Patient
stability in the SBF, after acquisition of the treatment CT scan, was evaluated by
measuring the displacement of the bony anatomy in the electronic portal images
relative to CT.
Results: Application of our clinical protocol (with setup corrections following
from manual measurements of the distances between the contours of the planning
target volume and the daily clinical target volume in three orthogonal planes,
multiple two-dimensional) increased the frequency of nearly full (≥99%) ITV+
coverage to 77% compared with 63% without setup correction. An automated
three-dimensional method further improved the frequency to 96%. Patient
displacements in the SBF were generally small (≤2 mm, 1 standard deviation), but
large craniocaudal displacements (maximal 7.2 mm) were occasionally observed.
Conclusion: Daily, CT-assisted patient setup may substantially improve tumor
coverage, especially with the automated three-dimensional procedure. In the
present treatment design, patient stability in the SBF should be verified with
portal imaging.
Target coverage
3.1 Introduction
Stereotactic body radiotherapy (SBRT) involves “delivery of a high dose of
radiation to the target, utilizing either a single dose or a small number of
fractions with a high degree of precision within the body” (American Society
for Therapeutic Radiology and Oncology, American College of Radiology [102])
and was pioneered by Lax et al. [82] and Blomgren et al. [10, 9] from the
Karolinska Hospital in Sweden. They introduced the stereotactic approach, which
was already in use for cranial targets, for extracranial treatments and created
a stereotactic body frame (SBF) to immobilize the patient and target. The
treatment setup was based on a set of external rulers attached to the SBF. Using
an abdominal compression plate, the patient’s breathing motion was reduced
[82, 10]. The Stockholm experience has resulted in a commercially available
SBF (Elekta Instrument AB, Stockholm, Sweden), which is now used in several
institutes. Imaging studies yielded a margin prescription for the construction
of the planning target volume (PTV) (e.g., expansion of the clinical target
volume [CTV] by 5 mm in the radial and 10 mm in the craniocaudal direction,
with diaphragm motion reduced to <10 mm) [82, 10]. Similar prescriptions
have since been applied by other groups using a SBF for liver treatment
[60, 61, 146, 148, 147, 110].
In SBRT, small CTV-PTV margins are a prerequisite for the delivery of the
high fraction doses and high biologically equivalent total doses [82, 123, 16, 100,
45]. In addition to the use of a SBF with abdominal compression, the management
of respiratory motion to limit the CTV-PTV margins has been the interest of
various studies, as addressed in two review reports [114, 47]. These methods have
included breath holding, possibly supported with an active breathing coordinator,
respiratory gating and tracking techniques, shallow breathing with an oxygen
supply, and a double-vacuum body fixation system. Because SBRT sessions are
designed with a small number of fractions and steep dose gradients around the
PTV (surrounding isodose, 65-80%), accurate daily positioning of the tumor in
the high-dose volume is crucial.
Procedures to daily verify the patient or the target position have been
implemented by most groups using a SBF. It has been recognized that the patient
and tumor position in an SBF are subject to variation [82, 10, 86, 60, 146].
Studies on positioning reproducibility of the bony and soft-tissue landmarks have
revealed a poor correspondence between these structures [60, 146], suggesting day-
to-day variation of the organ position within the body. For this reason, computed
tomography (CT) scans have commonly been acquired before each treatment
fraction [60, 146, 147]. If necessary, the target can be realigned by adjusting the
SBF’s setup at the linear accelerator (linac). The involved shift was based on the
difference between the target position in the planning and treatment CT scans.
At the Erasmus Medical Center, SBRT of liver tumors is performed using
the Elekta SBF. Patients with primary tumors (hepatocellular carcinoma) or
metastases of ≤6 cm undergo external beam radiotherapy in three or five fractions
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at intervals of 1 or 2 days [91]. Before each fraction, a contrast-enhanced CT scan
(treatment CT scan) is acquired to verify and potentially adjust the planned
position of the SBF at the linac. A set-up correction accounts for possible shifts
of the CTV, as contoured on the treatment CT scan, relative to the planning
situation. The correction follows from manual distance measurements between
the PTV and treatment CTV contours in three orthogonal planes. Once the
SBF is positioned at the treatment unit, electronic portal images are acquired to
verify the stability of the patient’s position in the SBF during the period between
acquisition of the treatment CT scan and dose delivery at the linac. This period
includes the CT analysis and patient transport from the CT scanner to the linac.
In analyses of tumor coverage, all sources of possible geometric uncertainties
must be considered. These include residual respiratory tumor motion (with a
SBF, this motion cannot be fully suppressed) and methodologic uncertainties
in the procedure, such as finite precision in the SBF set-up at the linac. It is
well known that respiratory tumor motion may cause artifacts on a CT scan
[4, 11, 20]. Even in a SBF with abdominal compression, an acquired CT scan
might show such artifacts owing to the residual tumor motion. These artifacts
introduce uncertainties in the tumor size, shape, and location. As mentioned, our
image guidance procedure for tumor set-up relies on daily tumor localization on
a treatment CT scan. To date, published reports on tumor coverage in a SBF
have not explicitly analyzed the impact of the CT artifacts. Also, patient stability
in the SBF between CT scan acquisition and treatment, including the necessary
patient transport, has not yet been evaluated for the Elekta SBF.
The purpose of this study was to analyze the impact of the image-guided
procedures on the tumor coverage of our liver patients treated with SBRT in a
SBF. Two main issues were addressed.
First, to what extent does the clinically used method of measuring the tumor
displacement on the treatment CT scan relative to planning, and the subsequent
adjustment of the SBF’s set-up at the linac, improve tumor coverage? We also
compared the clinical protocol with alternative procedures, including an in-house-
developed automated three-dimensional (3D) method (center of mass [COM]
protocol). For these evaluations, the internal target volume-plus (ITV+) concept
was introduced. The ITV+ is constructed by expanding the CTV, as delineated
on the CT scan, with a margin to account for all geometric uncertainties related
to residual respiratory tumor motion.
Second, does the SBF allow for a stable position of the patient’s anatomy
between acquisition of the treatment CT scan and dose delivery at the linac? This
was analyzed by comparing the patient’s bony anatomy position on the treatment
CT scan with the position measured by electronic portal images acquired at the
linac. For correct interpretation of the observations, a multiobserver study and full
treatment simulations with an “Alderson” phantom were performed to estimate
the impact of methodologic uncertainties on the analyses.
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3.2 Methods and Materials
3.2.1 Patients
This study included 13 patients. Standard treatment was delivered in three
fractions of 12.5 Gy, prescribed at the 65% isodose line that encompassed the
PTV. For all fractions, a treatment CT scan was acquired in which the CTV
was outlined. A total of 57 CTV delineations from the treatment CT scans were
available, because of two CTVs outlined for 1 patient, a five-fraction treatment for
1 patient, a secondary treatment series for 3 patients, and two cancelled fractions
because of patient motion in the SBF.
3.2.2 Treatment preparation
Treatment preparation included acquisition of a magnetic resonance imaging
(MRI) scan, fluoroscopic analysis on a conventional simulator, and acquisition
of CT scans on a single-slice CT scanner. Patients were always positioned in the
SBF, except for MRI.
The set-up of the patient in the SBF and the level of maximal tolerable
abdominal compression were established at the conventional simulator. The
remaining craniocaudal (CC) diaphragm excursion was derived from movies
recorded during ≈20 s periods of continuous X-ray exposure. The patient
was breathing freely, while subject to maximal compression. The established
SBF settings were reproduced for each CT acquisition and dose delivery on the
preparation and treatment days. Details on the procedures specific to the SBF
can be found in Lax et al. [82] and Wulf et al. [146].
For delineation of the CTV, arterial and venous phase contrast-enhanced CT
scans of the tumor and surrounding liver tissue were acquired. A large-volume
planning CT scan was acquired for the delineation of other structures, such as the
organs at risk. During CT acquisition, the patients were breathing freely, while
positioned in the SBF with abdominal compression. The CTV was outlined in
both contrast-enhanced scans and reviewed by an experienced radiologist using
the MRI scan (acquired in breath hold). A composite CTV was then constructed
by summing the delineated volumes. The composite CTV was positioned on the
planning CT scan. Tumor motion in radial directions was estimated from an extra
series of CT slices, obtained with a fixed CT couch position during approximately
one breathing cycle (comparable to the method described by Wulf et al. [146]).
The selected cranial and caudal CTV-PTV margins were 10 mm if the
diaphragm excursion, as derived from fluoroscopy (see above), could be reduced
to an aimed range of 5 mm (15 of 16 PTVs), otherwise, it was 15 mm. A radial
margin of 5 mm (11 of 16 PTVs) was selected, if the observed excursions in the
fixed couch CT slices were <2.5 mm, otherwise it was 10 mm. This margin
prescription is consistent with published data [146, 61, 110].
Treatment plans were generated with 4-10 coplanar and noncoplanar beams,
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using the CadPlan planning system (Varian Oncology Systems, Palo Alto, CA).
The plans were designed such that ≥99% of the PTV received the prescription
dose or greater. For set-up verification at the linac, anterior and lateral digitally
reconstructed radiographs were produced using the ACQSim virtual simulation
software, version 4.9.1 (Philips Medical Systems, Best, The Netherlands).
3.2.3 Treatment execution
Before dose delivery, a contrast-enhanced CT scan was acquired, timed to scan the
contrast phase with optimal tumor visibility, as established in the planning phase.
Patients remained in the SBF until the end of treatment. Abdominal compression
was reduced after CT acquisition for patient comfort but reestablished before dose
delivery. The physician delineated the CTV (verified using the MRI scans) and
part of the spine. The treatment CT scan was registered to the planning CT scan
by aligning the SBF position indicators appearing in both scans. Axial, sagittal,
and coronal cross-sections of the treatment CTV delineation were projected in
corresponding cross-sections of the PTV on the planning CT scan, after which
the distances were measured between the CTV and PTV contours. From these
distances, the SBF set-up correction at the linac was derived for centering the
treatment CTV delineation in the PTV (Clinical protocol, see section 3.2.4).
In addition, part of the spine was contoured for verification of the stability
of patient set-up in the SBF. The SBF, including the patient, was moved to
a trolley and transported to the treatment room, where it was positioned on
the linac couch. The position of the spine was verified with electronic portal
images from an electronic portal imaging device (EPID, TheraView-NT, Cablon
Medical, Leusden, The Netherlands). Deviations from the expected position were
interpreted as movements of the patient in the SBF. In the case of an exceptional
deviation (>5 mm, two occurrences), treatment was canceled for that day. A
typical time for accomplishing the procedures after CT acquisition up to the
moment of portal imaging at the linac was 20 minutes. The portal imaging itself
took an additional 5 minutes and the following dose delivery typically took 20
minutes.
3.2.4 Tumor coverage according to treatment CT scans
Tumor coverage in treatment fractions was retrospectively evaluated using the
clinically applied PTVs and the CTVs delineated in treatment CT scans. A
treatment CTV delineation was first expanded with margins to create a structure,
designated the ITV+, that included all points with a nonzero probability of tumor
occurrence. The ITV+ construct is introduced in section 3.5 as an alternative
to the International Commission on Radiation Units and Measurements (ICRU)
Report 62, in the presence of CT imaging artifacts caused by residual respiratory
tumor motion. The margins explicitly account for these artifacts. Coverage was
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evaluated by determining the volume percentage of the ITV+ that was inside the
PTV:
ITV + coverage = volume(ITV
+ ∩ PTV )
volume(ITV +) · 100% (3.1)
Tumor excursions, needed for the construction of an ITV+ from a treatment
CTV delineation (see section 3.5), were not evaluated on the days of treatment.
Instead, it was assumed that the motion excursion (Ri) for a specific direction was
exactly one-half the selected CTV-PTV margin for that direction. The CTV-PTV
margins were based on measurements of respiratory-induced tumor excursions, as
estimated from fluoroscopic measurements and from CT on the day of treatment
preparation. Margins of at least twice these excursions (≥2 Ri) were selected for
PTV construction (see section 3.2.2). Assuming the reproducibility of breathing
motion at treatment, the motion excursions assumed for ITV+ construction can
thus be seen as worst-case estimates.
The ITV+ coverage was calculated using software developed in-house with a
combination of C++ and MATLAB (MathWorks, Natick, MA). This software
determines the surface of a structure in 3D, as defined by its contour points,
as a mathematical implicit function [128]. This allows a precise segmentation of
intersecting and nonintersecting parts of two partially overlapping structures. The
volume of any new structure created that way can be calculated, as well as the
COM of a structure. Coverage related to a specific treatment set-up is evaluated
with the PTV and the ITV+ contour points. Overlap between these structures is
determined after entering the protocol-specific set-up corrected coordinates that
define the position of the ITV+ in the frame of reference of the PTV. With the
extraction of the required volume information, ITV+ coverage is calculated using
Eq. 3.1. A tool for the visualization of structures and overlaps was added (Fig.
3.1).
For all analyses, the planning and corresponding treatment CT scans were first
registered using the SBF position indicators depicted in both scans. Coverage was
evaluated for the following set-up correction protocols:
Clinical protocol. This protocol refers to the set-up realized in clinical practice,
resulting from method described in section 3.2.3.
No protocol. For this protocol, the SBF set-up coordinates, as determined
from the planning CT scan, were consistently used during the full treatment
course, without daily image guidance. Thus, the SBF served as the definite
reference for the patient anatomy, similar to cranial stereotactic treatment
practice.
Bony protocol. For this protocol, the SBF set-up correction equaled the shift
in position of the spine between the treatment and planning CT scans, relative to
the SBF. This procedure simulated an on-line set-up correction protocol, in which
the corrections are based on registration of bony structures, which are visible on
digitally reconstructed radiographs and portal images measured with an EPID. In
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Figure 3.1: Example of offset in tumor position that could occur when the originally
planned stereotactic body frame set-up would not be adjusted for treatment. (a) Three-
dimensional impression and (b) axial plane, including the contours shown in panel (a).
Visualization is an integral part of our software application to interactively judge coverage
of two structures. PTV = planning target volume; ITV+ = Internal target volume-plus;
CTV = clinical target volume.
the CT analyses, the positional shift was estimated using three vertebral bodies in
the vicinity of the liver and a 3D gray-value matching algorithm in the “Fusion”
module of Exomio virtual simulation software, version 2.1.
COM protocol. This protocol used in-house developed software (see above),
and the positional difference between the COM of the treatment ITV+ and the
COM of the PTV was automatically established. The SBF was then translated
to ensure coincidence of the two COMs.
Tuned protocol. In cases in which 100% coverage could not be obtained with
one of the other protocols, the SBF set-up coordinates were interactively fine-
tuned in an effort to obtain greater coverage than that already achieved. The
visualization tool of the software was used to interactively shift the ITV+ with
respect to the corresponding PTV. The ITV+ and a semitransparent PTV are
shown in 3D to emphasize the regions in which the ITV+ was not covered by the
PTV (Fig. 3.1).
3.2.5 Patient stability in SBF between treatment CT scan
acquisition and dose delivery
Patient stability in the SBF between treatment CT scan acquisition and treatment
delivery was analyzed by comparing the position of the spine on the treatment CT
scan with its position in EPID images at the linac. To determine a displacement,
the treatment CT scan was compared with the planning CT scan, and the
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frontal and lateral EPID images were compared with the corresponding digitally
reconstructed radiographs derived from the planning scan. Measurements were
corrected for applied SBF set-up corrections, derived with the Clinical protocol.
The difference between the two assessments was an estimate of the displacement,
designated as the “raw” bony anatomy displacement. In the absence of any patient
movement and inaccuracies in the applied procedures, the raw bony anatomy
displacements should be equal to zero. Because of measurement inaccuracies and
technical imprecision, the measured raw displacement can be different from zero,
even if the patient has not moved in the SBF. Using the data for all fractions,
standard deviations (SDs) were derived describing the observed distributions of
raw bony anatomy displacements in the three principal directions, CC, left-right
(LR), and anterior-posterior (AP).
Two CT registrations, one for the SBF and one for the spine, were used
to assess, for each fraction, the spinal shift on the treatment CT scan relative
to the planning scan (the spinal shift in the SBF is the difference between
the two registrations). The shifts were the same as those used for the Bony
protocol. Inaccuracy in these registrations was evaluated by repetitive (10
times with varying startup conditions) volume registrations, for 3 patients
with obviously different vertebral anatomy. The inaccuracy in portal image
analyses was evaluated in an interobserver study, using all available (n = 53)
images and comparing the measurements of two additional observers with
the measurements obtained during treatment. Experiments with an Alderson
phantom were performed to investigate technical imprecision in the procedure,
independent of the anatomic shift measurements. The phantom was positioned
in the SBF and submitted to the full treatment procedure. Motion of the
phantom in the SBF during transport from the CT scanner to the linac could
be excluded. Nine independent simulations were performed. The SDs describing
the derived distributions of measurement and technical errors were “quadratically”
subtracted from those expressing the raw bony anatomy displacements (according
to SDprocessed =
√
SD2raw − SD2error), yielding a more precise estimate of the
bony anatomy displacements between acquisition of the treatment CT scan and
dose delivery.
3.3 Results
3.3.1 Tumor coverage according to treatment CT scans
For the Clinical image guidance protocol, and for each of the four alternative
protocols, the ITV+ coverage values, calculated using Eq. 3.1, are summarized
in Fig. 3.2. Each protocol was evaluated using the 57 treatment CTV outlines,
except for the Clinical protocol, which was evaluated using 54 cases, because
the data describing the clinically applied set-up corrections were lost for three
fractions. Application of the set-up protocols resulted in ITV+ coverage scores of
25
Chapter 3.
≥99% in 77% (Clinical), 63% (No), 67% (Bony), 96% (COM ), and 96% (Tuned)
of the total number of examined treatment CT scans. The minimal observed ITV+
coverage scores for each of these protocols were 79.2%, 80.3%, 73.1%, 98.5%, and
98.5% for the Clinical, No, Bony, COM, and Tuned protocols, respectively. In 49
of 52 analyzed cases, the Clinical protocol resulted in better or equal coverage
than the No protocol, which consistently applied the SBF set-up as established
with the planning CT scan. In 56 of 57 cases, the COM protocol improved the
coverage compared with the set-up according to the planning CT scan (the No
protocol). In 54 of 57 cases, the COM protocol resulted in the greatest ITV+
coverage achievable. For the 3 remaining cases, the coverage scores were already
≥99.8% with the COM protocol, and 100% coverage was achieved with the Tuned
protocol.
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Figure 3.2: Distributions of internal target volume-plus (ITV+) coverage values for five
set-up correction protocols. Along horizontal axis, coverage scores classified by categories:
100%, indicating full coverage, and (p, q], scores less than p% but at least q%.
Figure 3.3a-c compares the SBF set-up corrections for the Clinical and COM
protocols in the three principal directions (54 evaluations). The set-up corrections
for the Bony and COM protocols are compared in Fig. 3.3d-f (57 evaluations).
SDs describing the spread in the required SBF set-up corrections (with respect to
the planned set-up) are given in Table 3.1. The set-up corrections resulting from
the application of the Clinical and Bony protocols were compared with the COM
protocol by calculating the SDs of the differences in the corrected set-ups. The
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set-up corrections of the COM protocol were selected as the reference for these
analyses, because it provided an unbiased estimate of the median tumor positions
in the presence of positional uncertainties by CT imaging artifacts.
Table 3.1: Characteristics of distributions of derived set-up corrections in four set-up
protocols
protocol CC LR AP 
 standard deviation (mm) 
No 0* 0* 0* 
Clinical 4.2 2.9 2.3 
Bony 3.1 3.0 1.4 
COM 5.1 3.6 3.3 
Clinical − COM 2.9 2.3 2.7 
Bony − COM 4.7 4.0 3.5 
 correlation coefficient (r) 
Clinical, COM 0.83† 0.77† 0.59† 
Bony, COM 0.50† 0.24‡ 0.05§ 
Abbreviations: CC = cranial-caudal, LR = left-right, AP = anterior-posterior.  
* Inherent to the method equal to zero.  
† p < 0.01.  
‡ p = 0.08.  
§ p = 0.73. 
 
 
3.3.2 Patient stability in SBF between CT acquisition and
treatment
Vertebral column displacements were measured for 51 treatment fractions and 2
additional cancelled fractions. Table 3.2 shows the SDs of the distributions of raw
displacements, together with the SDs of the measurement and technical errors,
and the final SDs, 2.0 mm, 1.2 mm, and 0 mm, for the CC, LR, and AP directions,
respectively.
In addition, raw displacements were first corrected for the measurement
errors (by quadratic subtraction), and the resulting corrected displacements (not
given in Table 3.2) were then compared with the technical errors in an F-test.
Thus, we evaluated whether the technical errors could fully explain the corrected
displacements. At a 5% significance level, we found that only in the CC direction
was the final displacement different from zero. Thus, some patient movement in
the CC direction could not be excluded.
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Figure 3.3: (a-c) Comparisons of required stereotactic body frame set-up corrections
(in millimeters) in three principal directions for center of mass (COM) and Clinical
protocols. (d-f) Similar comparisons between COM and Bony protocols.
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Table 3.2: Vertebral column displacement in SBF between CT acquisition and
treatment, and errors describing uncertainties in observations
variable CC LR AP 
 standard deviation (mm) 
raw measurements 2.7 2.1 1.9 
measurement errors    
  computed tomography (CT) 0.8 0.5 0.6 
  portal image 0.6 0.8 1.1 
technical errors 1.5 1.5 1.7 
final standard deviations  2.0* 1.2 0† 
Abbreviations: CC = cranial-caudal, LR = left-right, AP = anterior-posterior.  
* Statistically significant (p = 0.05).   
† Residual displacement assigned 0, because result of quadratic subtraction was negative. 
 
3.4 Discussion
3.4.1 Tumor coverage according to treatment CT scans
The use of abdominal compression in SBRT does not, in general, fully eliminate
respiratory tumor motion. The ITV concept was introduced in ICRU Report 62
to extend delineations with margins to include this motion. The construction of
an ITV, however, requires the exact determination of the location of a tumor’s
motion range, which is not achievable using a single-slice CT scanning procedure
with contrast enhancement. For the construction of the ITV+, as introduced in
this chapter appendix (section 3.5), only the tumor’s excursion has to be identified.
Owing to the consideration of scan artifacts, the ITV+ is, in general, larger than
the ITV.
A 100% ITV+ coverage, as calculated with Eq. 3.1, guarantees that all parts
of the tumor are inside the PTV, and, consequently, the tumor dose delivery
is within prescription. With lower coverage, there is a nonzero probability for
a partial geometric miss. The greater the calculated ITV+ coverage, the lower
the risk of a miss. If, however the actual treatment geometry deviates from the
geometry on the treatment CT scan, the calculated ITV+ coverage values must be
considered with caution regarding the absolute interpretation. When comparing
different set-up protocols using CT, greater values do still imply a lower chance
of misses, but 100% coverage no longer guarantees the absence of misses.
In this study, the ITV+ concept was used to evaluate tumor coverage with
the clinically applied image-guided procedures and CTV-PTV margins, and to
compare this Clinical protocol with alternatives. The clinical CTV-PTV margins,
especially the CC extensions, were generous compared with the margin recipe that
has been recently derived (see section 3.5.3). It was clearly demonstrated that
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the Clinical protocol generally improved the tumor set-up compared with no daily
set-up corrections (No protocol).
The Clinical protocol also performed better than the Bony protocol. Other
investigators have already observed differences between bony anatomy displace-
ments in the SBF and displacements of the delineated tumors [60, 146, 147]
and concluded that measured bony anatomy displacements are not the choice
of preference for SBF set-up corrections. In their analyses, however, they did not
fully include imaging artifacts on the CT scans, related to residual respiratory
motion, which can occur for tumors, but are absent for bony anatomic structures
such as the spine. Taking into account the imaging artifacts, our results confirm
the observation that using delineated tumors in the planning and treatment CT
scans (Clinical protocol) is superior to using set-up corrections derived from
measured bony anatomy displacements (Bony protocol).
Both the Clinical set-up protocol and the COM protocol aim for positioning
of the center of the delineated treatment CTV in the center of the PTV. As
demonstrated in section 3.3, the fully automated, 3D COM protocol performs
much better than the Clinical protocol. The latter was based on analyses in three
orthogonal planes only (multiple two-dimensional) and distance measurements
performed by the treating physician. The set-up differences between the two
protocols in a single direction were as great as 2.9 mm (1 SD).
The most successful protocol was the Tuned protocol, for which the achieved
ITV+ coverage was always >98.5%, and for which, in 96% of the cases, coverage
of ≥99% was achieved. The data presented in section 3.3, however, demonstrated
that, compared with the COM protocol, the improvements in ITV+ coverage
obtained with the Tuned protocol were only minimal. Little was gained by
manually fine tuning the COM results. Because the COM protocol can be fully
automated, it should be preferred for clinical application rather than the Tuned
protocol.
Wulf et al. [146] have suggested using CTV-PTV margins of 4 mm in the radial
and 6 mm in the CC directions, if daily CT verification is performed. In section
3.5.3), we have shown that, in the case of residual respiratory tumor motion
of 5 mm (CC), a cranial-caudial CTV-PTV margin of ≥7.5 mm is required to
guarantee adequate coverage. In our experience, even such a 5 mm motion range
is not always easy to obtain because of patient discomfort with firm abdominal
compression. Possibly new developments, such as those described below, will
contribute to establishing safe treatments with smaller margins.
3.4.2 Patient stability in SBF between CT acquisition and
treatment
The ITV+ coverage scores, calculated with Eq. 3.1, were dependent on the specific
CTV delineations in the treatment CT scan. As explained, the interpretation of
coverage scores is less straightforward when the patient’s anatomy at the linac
deviates from the anatomy at the moment of acquisition of the treatment CT
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scan. Target localization and dose delivery are commonly performed in different
rooms, resulting in transportation of the patient and a time delay. Moreover,
for patient comfort, we also reduced abdominal compression during this interval.
Therefore, the stability of the patient anatomy is not trivial. Herfarth et al. [60]
have previously addressed this issue. They evaluated bony anatomy shifts in a
body frame comparable to the Elekta SBF, using portal image analyses. Although
no quantitative results about their patient group were provided, no anatomic shifts
were found.
Our measurement procedure quantifies vertebral displacements, which gener-
ally yielded nonzero observations. To judge to what extent these observed raw
displacements were caused by inherent measurement and technical inaccuracies,
these error sources were quantified. The final displacements resulting from the
analyses should be accounted for in the CTV-PTV margins. Nonzero final
displacements resulted for the CC and left-right directions, 2.0 mm, and 1.2 mm,
respectively (1 SD, Table 3.2). Only for the CC direction was the residual
displacement significantly different from zero. Two fractions were cancelled
because the observed CC displacements were >5 mm (raw observations of 6.8 mm
and 7.2 mm). It can be concluded that displacements of the patient in the SBF
are generally small, but verification with an EPID might prevent treatment with
occasional larger displacements. Future directions
The current procedures for SBRT of liver tumors have several limitations.
Although the clinical outcome with our treatment was very promising [91], several
possibilities to further improve the treatment technique exist.
Currently, registration of acquired CT scans with a corresponding MRI scan
is cumbersome, because CT scans and MRI scans are obtained with abdominal
compression and breath hold, respectively. Work on nonrigid registration may
ease this task.
If the exact midpoint of a tumor’s motion range or the ITV could be
determined at simulation and treatment time, a substantial reduction of the CTV-
PTV margin would be possible. It would then be sufficient to include only one-
half of the full tumor’s respiratory excursion (the ITV margin, see section 3.5)
as the CTV-PTV margin to compensate for residual respiratory tumor motion.
In section 3.5, one can see that in the presence of artifacts in the planning and
treatment CT scans (with a single-slice CT scanner) it is necessary to include 1.5
times the tumor’s excursion in the CTV-PTV margin. Therefore, two-thirds of
this CTV-PTV margin is abundant when scan artifacts are avoided and the ITV
is properly assessed (e.g., with four dimensionally reconstructed CT data from a
respiration correlated acquisition on a multislice CT scanner). Thus, the ITV+-
based concepts are appropriate with the application of a single-slice CT scanner
in a free breathing regimen, but the avoidance of scan artifacts and the concurrent
assessment of tumor motion are preferable. We are currently testing a 24-slice
CT scanner (Somatom Sensation Open, Siemens Medical Solutions, Erlangen,
Germany) for its feasibility.
For all analyses, we assumed that the residual respiratory tumor motion
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during the planning CT scan session was exactly reproduced during acquisition
of the treatment scans and during dose delivery at the linac. The validity of
the assumption that a single screw position, used for applying the abdominal
compression, will result in a reproducible residual tumor motion has not yet been
investigated. We have recently initiated a study, using implanted fiducials and
repeat fluoroscopy studies at the conventional simulator, to clarify this point.
The same study should provide information on the validity of our assumption
that bony anatomy measurements for checking patient stability in the SBF, can
also be used to verify CTV position stability. The use of fiducials might even
result in a treatment protocol with SBF set-up corrections entirely established
at the linac (in particular with kilovoltage-equipped linacs), thereby avoiding the
daily acquisition of a treatment CT scan. This would significantly reduce the
overall fraction time and would avoid the patient transport procedure.
3.5 Chapter appendix
3.5.1 Margin expansions for compensating for respiratory
motion-induced uncertainty in CT scans
Respiration-induced tumor motion causes artifacts in a scan acquired with a
single-slice CT scanner, regarding the validity of the size, shape, and location
of the depicted tumor [4, 11, 20]. The ITV+ is introduced here to deal with such
positional uncertainties. The ITV+ is the CTV (delineated gross tumor volume
plus margin for subclinical disease), expanded with a margin to include all points
with a nonzero probability of tumor occurrence. In a second step, the ITV+ is
used to derive a CTV-PTV margin recipe for image-guided SBRT using daily
acquired CT scans.
The analyses are one-dimensional. For targets without sharp edges, however,
the concepts are also applicable in three dimensions. From the available breath-
hold MRI scans of the patients in this study, it was concluded that all tumor
delineations could be used for 3D analyses. The only positional uncertainty
considered in this appendix was respiratory motion. For other uncertainties and
variations, an additional CTV-PTV margin extension would be required.
3.5.2 ITV+ margin recipe
As derived below, the margin, MITV +(i), needed for expansion of the scanned
CTV in the principal direction i to include all points that may contain tumor, is
given by
MITV +(i) = Ri (3.2)
where Ri is the top-top respiratory tumor excursion in direction i.
Figure 3.4 schematically shows some possible positions of a moving CTV with
length L and motion range R. We assume that R < L. Positions p and q
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indicate the left and right CTV edges, respectively. For the interval [pmax, qmin],
all points contain CTV, and in the intervals [pmin, pmax] and [qmin, qmax], the
probability of capturing the CTV, while scanning, gradually decreases from 1 in
the inner positions (pmax and qmin) to zero in the outer positions (pmin and qmax).
Therefore, the scanned CTV length may deviate from the real length, L, and the
observed COM may also shift (imaging artifacts). An example of the capturing
probability as a function of location is given in Fig. 3.4d. The observed CTV size
was minimal (length L − R) when it is only captured in the range [pmax, qmin].
The ITV+ was constructed to guarantee that all points with a nonzero probability
of CTV occurrence would be included. An extension with a margin R on both
sides of the observed CTV is required to create the ITV+, which will always
cover [pmin, qmax]. Only in the case of the observed CTV dimension equaling the
minimal range [pmax, qmin], will the ITV+ coincide with the ITV, as defined in
ICRU Report 62. In all other cases, the ITV+ is larger than the ITV, with a
maximal possible length of L+ 3R.
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Figure 3.4: Edges of clinical target volume (CTV) with respiratory motion range (R),
represented by solid vertical lines. (a) CTV in middle position, (b) CTV in left most
position, (c) CTV in right most position, and (d) example of CTV capturing probability
with CT acquisition.
3.5.3 CTV-PTV margin recipe
The CTV-PTV marginMPTV (i), required for expansion of the CTV, as observed
on the planning CT scan, should account for respiration artifacts on the planning
CT scan, as well as for artifacts on the treatment CT scans. A COM-based set-up
correction protocol centers the CTV, as delineated on the treatment CT scan, in
the PTV. Artifacts present on the treatment CT scans will cause uncertainty in
the set-up corrections that can be compensated for by an additional margin of
0.5· Ri. Extending the ITV+ with this margin then gives a total CTV to PTV
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margin of
MPTV (i) = 1.5 ·Ri. (3.3)
The extra 0.5·Ri contribution compared with Eq. 3.2 accounts for potential
discrepancies between the COM of the CTV, visualized on the treatment CT
scan, and the center of the corresponding treatment ITV. If the established
planning ITV+ is by chance minimally small (i.e., the planning ITV+ equals
the planning ITV [see above]), the maximal margin increase is required for such
a discrepancy. Consequently, the required CTV-PTV margin needs to be derived
for this situation.
In Fig. 3.4, the position of the ITV center,mITV , is given by 0.5·(pmin+qmax).
Rewritten this results inmITV = 0.5·(pmax+qmax)−0.5·R ormITV = 0.5·(pmin+
qmin)+0.5·R. The COM of the CTV, as observed on an acquired CT scan,mCTV ,
has a maximal displacement from the ITV center if the two CTV edges are scanned
in the left most positions (pmin and qmin, Fig. 3.4b) or the right most positions
(pmax and qmax, Fig. 3.4c). Hence, 0.5·(pmin+qmin) ≤ mCTV ≤ 0.5·(pmax+qmax)
or mITV −0.5 ·R ≤ mCTV ≤ mITV + 0.5 ·R. Thus, when we let the mCTV of the
treatment scan coincide with the center of the planning ITV to obtain the daily
treatment position, the treatment ITV is at most 0.5 · R translated with respect
to the planning ITV. To compensate for this displacement, the planning ITV, or
more usually, the planning ITV+, needs to be symmetrically extended with an
extra 0.5 ·R, yielding a total CTV to PTV margin of 1.5 ·R (Eq. 3.3).
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Abstract
Purpose: To assess day-to-day differences between planned and delivered target
volume (TV) and organs-at-risk (OAR) dose distributions in liver stereotactic
body radiation therapy (SBRT), and to investigate the dosimetric impact of set-
up corrections.
Methods and Materials: For 14 patients previously treated with SBRT, the
planning CT scan and three treatment scans (one for each fraction) were included
in this study. For each treatment scan, two dose distributions were calculated:
one using the planned set-up for the body frame (no correction), and one using the
clinically applied (corrected) set-up derived from measured tumor displacements.
Per scan, the two dose distributions were mutually compared, and the clinically
delivered distribution was compared with planning. Doses were recalculated in
equivalent 2 Gy fraction doses. Statistical analysis was performed with the linear
mixed model.
Results: With set-up corrections, the mean loss in TV coverage relative to
planning was 1.7%, compared to 6.8% without corrections. For calculated
equivalent uniform doses, these figures were 2.3% and 15.5%, respectively. As
for the TV, mean deviations of delivered OAR doses from planning were small
(between -0.4 Gy and +0.3 Gy), but the spread was much larger for the OARs.
In contrast to the TV, the mean impact of set-up corrections on realized OAR
doses was close to zero, with large positive and negative exceptions.
Conclusions: Daily correction of the treatment set-up is required to obtain
adequate TV coverage. Because of day-to-day patient anatomy changes, large
deviations in OAR doses from planning did occur. On average, set-up corrections
had no impact on these doses. Development of new procedures for image guidance
and adaptive protocols is warranted.
Impact of set-up corrections and anatomic variations on dose in OARs
4.1 Introduction
Stereotactic body radiation therapy (SBRT) for liver tumors has demonstrated a
high local control rate with an acceptable toxicity [66, 73, 91, 127, 145]. Because
large radiation doses are delivered in a few fractions, high precision is required
in tumor volume definition, daily set-up, and dose delivery to guarantee accurate
targeting and low toxicity. Precision in dose delivery is affected by anatomical
changes in the liver and organs at risk, such as variable filling, peristalsis, cardiac,
and (residual) respiratory motion [48, 149]. Day-to-day changes in the liver
position may impair target coverage in SBRT, as reported by several groups
[145, 38, 54, 151]. Therefore, the tumor position is commonly verified with CT-
guided treatment procedures to adjust, if necessary, the treatment set-up before
dose delivery [151]. Methods to reduce, control, or track the respiratory motion
have been developed, and are routinely used in SBRT [149, 24, 58, 82, 111].
For SBRT of liver tumors, little is known about the impact of the daily varying,
nonrigid patient anatomy and patient rotations on doses delivered to organs at risk
(OARs). Even in image-guided treatments, optimal sparing of OARs according to
the treatment plan is not guaranteed, because set-up corrections are fully based
on measured tumor displacements. Changes in OAR positions and shapes are not
explicitly accounted for in these procedures. Moreover, also with corrected tumor
set-ups, differences in radiological path lengths between planning and treatment,
resulting from patient anatomy variations or rotations, may jeopardize target dose
distributions.
The purpose of this study is to determine day-to-day dose deviations in the
target volume (TV) and OARs for SBRT of liver tumors, and to assess the
impact of daily tumor set-up corrections on these deviations. For a group of
14 patients, two dose distributions were retrospectively calculated for each of
the three treatment scans: one using the planned set-up for the body frame (no
correction), and one using the clinically applied (corrected) set-up. Per scan,
the two dose distributions were mutually compared, and the clinically delivered
distribution was also compared with the planning.
4.2 Methods and Materials
4.2.1 Patients
This study included 14 patients entered in a phase I-II study, with a total of
23 liver metastases, consecutively treated in our institution between April 2003
and November 2006 [91]. The patients were discussed in a multidisciplinary liver
tumor board, and were not considered eligible for other local treatments, including
surgery (due to limited remnant or co-morbidity) or radiofrequency ablation (due
to unfavorable location). Patient and tumor characteristics are presented in Table
4.1.
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Table 4.1: Demographics.
pt gender age (y) primary tumor tumor size (cm) tumor vol (cm3) liver segment liver vol (cm3) 
1 m 70 colorectal* 3.9, 1.5 53.4, 14.3 1, 8 1162.3 
2 m 75 colorectal 2.8 76.2 8 1469.7 
3 f 56 lung* 1.5, 0.5 7.2‡ 7, 7 1251.4 
4 m 81 colorectal 6.2 112.7 4 1765.8 
5 m 70 colorectal 2.3 26 1 1292.7 
6 m 44 colorectal* 2.8, 0.7 53.8, 3.2 1, 3 2412.1 
7 m 70 colorectal 4.7 183.5 4 2907.1 
8 m 53 colorectal* 4.1, 0.8 32, 8.7 7, 7 1166.6 
9 m 79 colorectal† 4.9, 3.7, 1.2 84.9, 58.4‡ 8, 6, 6 2060.7 
10 f 63 carcinoid 3.2 31.1 4 1095.1 
11 m 58 colorectal 2.4 13.8 1 1690.3 
12 m 72 colorectal* 3.3, 1.0 43.1, 12.2 1, 7 2190.3 
13 m 52 colorectal† 6, 3.9, 3.2 64.4, 17.4, 9.8 2, 4, 4 2343.3 
14 f 55 colorectal 3.4 35.8 4 1647.8 
Abbreviation: vol = volume 
* Two tumors treated 
† Three tumors treated 
‡ Due to close proximity of the tumors, they were considered as one volume for treatment 
 purposes 
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4.2.2 Treatment preparation
During (planning) CT scan acquisitions and treatments, patients were positioned
in a stereotactic body frame (SBF) (Elekta Instrument AB, Stockholm, Sweden)
with abdominal compression to reduce respiratory tumor motion. A large-volume
planning CT scan, and two contrast-enhanced CT scans in arterial and venous
phases were acquired for treatment preparation. The planning CT was matched
with the contrast CT scans by registering the SBF’s position indicators included
in the sidewalls [151]. The tumor was delineated in both contrast-enhanced CT
scans, after which the contoured volumes were joined to construct the composite
clinical target volume (CTV). For each patient an MRI scan was available to assist
tumor delineations. The planning target volume (PTV) was constructed from the
composite CTV, initially using margins adopted from the Karolinska experience
[82]. The margins were individualized once fiducial markers were implanted in the
patients’ livers, enabling measurement of residual breathing motion with a video
fluoroscopy system [149]. OARs were delineated in the planning CT scan.
Treatment was planned in 3 fractions, prescribing 12.5 Gy per fraction on
the 65% reference isodose surrounding the PTV (1 patient received 3 fractions
of 10 Gy because of a limited liver volume). The PTV coverage aimed for
was ≥95%. OAR constraints as used for treatment planning adopted from
Wulf et al. [91, 148] are presented in Table 4.2. OAR and PTV constraints
were carefully followed during the design of the treatment plan. However,
violations were occasionally accepted if not all constraints could practically be
met. Treatment plans were designed using the Cadplan treatment-planning
system (Varian Oncology Systems, Palo Alto, CA, USA) using a median of 8
(range 4-10) coplanar and non-coplanar beams.
Table 4.2: Dose constraints for the organs at risk (OARs) in absolute dose per fraction,
and recalculated as equivalent 2-Gy fraction (EQD2).
organ at risk dose parameter absolute dose (Gy) EQD2 (Gy) 
duodenum D5CC 7.0 13.4 
heart D5CC 7.0 14.8 
kidneys D33% 5.0 8.3 
liver D33% 7.0 14.0 
liver D50% 5.0 8.0 
esophagus D5CC 7.0 13.4 
spinal cord Dmax 5.0 8.8 
stomach D5CC 7.0 13.4 
Abbreviation: EQD2 = equivalent 2 Gy per fraction. 
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4.2.3 Treatment execution
On each treatment day, prior to dose delivery, a contrast-enhanced CT scan was
acquired to establish the position of the tumor in the SBF. In this so-called
treatment CT the physician delineated the CTV (treatment CTV). The treatment
CT was matched with the planning CT by registering the SBF position indicators
as previously described, such that the treatment CTV could be projected on the
planning CT. If the CTV appeared to have moved from the CTV position in
the planning CT scan, a treatment isocenter correction was derived to realign
the CTV with the original treatment plan. The correction was determined by
projecting the PTV and treatment CTV contours in three orthogonal planes to
measure distances between the contours. The planned coordinates for SBF set-up
at the treatment unit were then updated to establish the correction (shift) in the
treatment isocenter. Details of the treatment procedures have been described by
Méndez Romero et al. [91] and Wunderink et al. [151].
4.2.4 Calculated dose distributions
For each treatment CT, two treatments were simulated by calculating their dose
distributions: one treatment using the planned body frame set-up (Tp), and
one treatment using the corrected set-up (Tc), as delivered in clinical practice.
The beam configuration with respect to the treatment isocenter was copied from
the treatment plan and was identical in both treatment configurations; for the
corrected set-up, the position of the treatment isocenter was displaced according
to the measured tumor displacement. The two configurations Tp and Tc, and
the planning configuration, P, are schematically summarized in Figure 4.1. All
calculations were performed with the planning system also used for plan design.
(a) (c)(b)
ISO
beam
TV
OAR
liver
P
TV
OAR
ISO
liver
beam
                  Tc
beam
TV
OAR
liver
Tp
ISO
Figure 4.1: Schematic explanation of treatment configurations Tp and Tc (a) Planning
CT scan with a single beam. (b) Treatment scan with the isocenter according to planning
(Tp set-up), the beam partially misses the target, and (c) the same treatment scan, but
with a corrected isocenter and corresponding beam set-up (Tc set-up). Abbreviations: TV
= target volume, OAR = organ at risk, ISO = treatment isocenter.
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4.2.5 TV dose assessments and comparisons
To avoid effects of tumor delineation uncertainties, the TV in each treatment CT
was a copy of the PTV in the corresponding planning CT. For corrected set-ups,
PTVs were positioned in the treatment scans by applying a shift in accordance
with the displaced treatment isocenter (previous paragraph). As a result, for each
corrected set-up, all beam projections encompassed the PTV as in the planning
situation (see Fig. 4.1). Observed differences in target doses between a corrected
set-up and planning are then attributed to anatomical differences in the healthy
tissues surrounding the target (radiological path length differences), and to (small)
uncertainties in the applied procedures.
Target dose distributions were evaluated using TV coverages (percentage of
the TV within the 12.5 Gy isodose volume), and calculated generalized equivalent
uniform dose values (gEUD) with volume parameters a = -5 and a = -10 [36, 57,
99, 124]. Because of the high similarity of conclusions to be drawn from the a = -5
and a = -10 analyses, results are only shown for a = -5. For patients with more
than one lesion (Table 4.1), the analyses were performed for the composite TV.
4.2.6 OAR dose assessments and comparisons
For each simulated dose distribution, the following OAR dose parameters, (as also
used for plan design, see above), were evaluated: liver D33%, liver D50%, bowel,
duodenum, stomach and esophagus D5cc, spinal cord Dmax, kidneys D33%, and
heart D5cc. For the parameter assessments, OARs were additionally contoured in
all treatment CT scans. Despite the limited span of some treatment CT scans,
for the serial OARs, the relevant regions (exposed to the high doses) were always
included. In most treatment CT scans the caudal aspect of the kidneys was
not completely included, requiring the following procedure to establish the dose
parameters for these parallel organs. After registering the kidneys in the planning
and a treatment scan, the kidneys in the treatment scan were completed by adding
missing contours from the planning scan. Because the missing contours were to be
placed outside the original scanned volume, the treatment CT was first extended
with additional slices that were copies of the most caudal slice. In a similar way,
additional slices were added to the volume boundaries if required in the treatment
simulation to obtain representative radiological path lengths.
For all analyses, OAR dose parameters were converted into equivalent 2 Gy
fraction doses (EQD2), using:
EQD2 = D
d+ (α/β)
2 + (α/β) (4.1)
where EQD2 is the dose in 2 Gy fractions that is biologically equivalent to a
total dose D given with a fraction size of d gray [101, 116]. For liver we applied
an α/β value of 3.0 Gy; for stomach, duodenum and esophagus 3.5 Gy; for spinal
cord 2.0 Gy; for heart 2.5 Gy, and for kidneys 2.5 Gy [116]. The OAR constraint
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doses used for planning and converted to EQD2 are presented in Table 4.2. In
the remainder of this paper, OAR doses refer to EQD2 values.
4.2.7 Statistics
For the descriptive statistics, established dose parameters for P, Tp and Tc were
handled as separate measurements to give an overview of the actual data. To
test the difference of the dose parameters or the chance of falsely rejecting the
null hypothesis, “no difference” (p-value), the linear mixed model was used, and
correlation was assumed between the observations. The linear mixed model
was selected because it can properly account for correlation between repeated
measurements. The level of statistical significance was considered α = 0.05 for
all tests. Statistical analyses were performed using SPSS software, version 16.0
(SPSS Inc., Chicago, IL, USA).
4.3 Results
4.3.1 Target volume
Distributions of measured tumor displacements in the 42 treatment fractions
relative to planning were 2.1 mm, 4.0 mm, and 1.5 mm (1 SD), for the lateral,
superior-inferior, and anterior-posterior directions, respectively. Figure 4.2a shows
for all treatment fractions the length of the three-dimensional set-up error and
differences in target coverage with planning if no corrections would have occurred
(Tp-P), and for the actual treatment with set-up corrections (Tc-P). Distances
between corresponding Tc-P and Tp-P data points in Figure 4.2a represent
improvements in TV coverage resulting from the performed CT-guided tumor set-
up corrections. The planned mean target coverage for the 42 fractions was 97.2%.
Without set-up corrections this would have decreased by 6.8% to 90.4%. With
the clinically applied CT guidance, the mean coverage was 95.5%, a reduction of
1.7% compared to planning (Figs. 4.3a and 4.4a). Patients 3, 11, and 14 had
mean tumor set-up errors in the three fractions of 7.9 mm, 5.5 mm, and 5.0 mm,
respectively. Without corrections this would have resulted in mean target coverage
losses of 21.1%, 14.9%, and 12.0%, respectively. Due to applied corrections, the
reductions were limited to 2.9%, 4.4%, and 2.2%. All 42 set-up corrections, but
1 resulted in improved target coverage. The difference between Tc and Tp for
this exception was only -0.2 Gy. Ninety-five percent of treatment fractions had
a realized coverage after correction slightly lower than or equal to the planned
coverage (p = 0.001, Table 4.3).
Without corrections, 45% of fractions would have had a TV coverage lower
than 95%. With the applied corrections this was reduced to 24% (Fig. 4.5a). In
the absence of corrections, 31% of fractions would have suffered from a coverage
reduction relative to planning of 10% or more. With corrections, coverage
reductions larger than 10% could be fully avoided.
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Figure 4.2: Deviations in (a) target volume coverage and (b) generalized equivalent
uniform dose gEUD(-5) from planning before (Tp-P, ◦) and after (Tc-P, +) tumor set-
up corrections.
Table 4.3: Probability (p) values resulting from a linear mixed model, comparing dose
distribution parameters in the simulated actual treatments (with set-up corrections) with
corresponding planned parameters (Tc vs. P), and comparing differences between set-up
correction and no correction (Tc vs. Tp).
organ at risk  dose parameter Tc vs. Tp (p) Tc vs. P (p) 
duodenum D5CC 0.478 0.087 
heart D5CC 0.313 0.464 
kidneys D33% 0.630 0.788 
liver D33% 0.952 0.023* 
liver D50% 0.781 0.015* 
esophagus D5CC 1.000 0.769 
spinal cord Dmax 0.090 0.377 
stomach D5CC 0.157 0.480 
target volume coverage  0.002* 0.001* 
* p < 0.05 
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Figure 4.2b shows for individual fractions, drops in gEUD(-5) that would
have resulted from treatment with uncorrected tumor set-up errors (Tp-P), and
reductions in these gEUD(-5) losses with the applied set-up corrections (compare
with Fig. 4.2a). The mean planned fraction gEUD(-5) was 15.6 Gy (10-90%
percentile range: 13.1-17.0 Gy). Without corrections, the mean gEUD(-5) for
treatment would have been reduced by 15.5% relative to planning (10% and 90%
percentile values: -59% and -2%); 52% of fractions would have suffered from a
calculated gEUD loss of 5% or more. Performed corrections limited the gEUD
reductions to an average of - 2.3% (10% and 90% percentile values: -4% and 0%),
with only 10% of fractions having a gEUD loss (slightly) larger than 5%.
4.3.2 Organs at risk
OAR dose distribution parameters for planning (P) and the noncorrected (Tp)
and corrected (Tc) treatment simulations are summarized in Figure 4.3b. Figure
4.4b contains Tc-P and Tc-Tp summaries. p-values are presented in Table 4.3
(see also Discussion). Mean increases in OAR doses during treatment, relative
to planning, (positive mean values for Tc-P in Fig. 4.4b) were all below 0.3 Gy.
However, notwithstanding applied corrections, for some treatment fractions there
were substantial deviations from planning. For example, in Fraction 1, Patient
1 had a duodenum D5cc of 12.5 Gy, whereas the planning showed 1.3 Gy; in
Fraction 1, Patient 6 had a heart dose of 22.7 Gy, whereas the planning indicated
12.1 Gy; and Patient 4 had a stomach dose of 15.4 Gy in Fraction 3, compared
with a planned dose of 8.8 Gy. On the other hand, there were also important
decreases in realized OAR doses relative to planning. For example, Patient 1 had
a planned stomach dose of 29.9 Gy, whereas doses of 6.8 Gy, 7.0 Gy and 6.4 Gy
were calculated for the three treatment scans (with corrected tumor set-up errors
of 4 mm, 10 mm and 0 mm, respectively).
For the various OARs, the numbers of fractions with constraint adherence and
constraint violation in the planning (P) and treatment simulations (Tc and Tp)
are presented in Figure 4.5b. It confirms that the impact of set-up corrections on
OARs was not as consistent as for the TV (compare Tc and Tp in Fig. 4.5b). For
7 patients, all OARs were planned within the constraints. From these patients, 1
had constraint violations in both the Tc and Tp treatment simulations. From the
7 patients with constraint violations in the planning, 1 patient was fully within
the constraints in Tc, although above constraints in Tp.
The Tc-Tp data in Figure 4.4b show that for all OAR dose distribution
parameters the mean impact of correction was between -0.4 Gy and +0.3 Gy.
However, also here there were important deviations in individual patient fractions,
both positive and negative. For example, because of the applied tumor set-up
correction, the duodenum dose of patient 1 in Fraction 1 went down from 17.5 Gy
to 12.5 Gy (still far above the planned value of 1.3 Gy; see above), and in Fraction
2 it decreased from 9.6 Gy to 3.3 Gy; for Patient 6, tumor set-up correction in
Fraction 2 resulted in an increase in heart dose from 15.8 to 19.2 Gy, compared to
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Figure 4.3: Summarized planning and treatment dose distribution parameters.
Summaries for planning (P), corrected treatment simulations (Tc), and noncorrected
treatment simulations (Tp) for (a) the target volume, and (b) organs at risk.
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no correction. Both the residual deviations in OAR dose distribution parameters
from planning after tumor set-up corrections (Tc-P, Fig. 4.6a), and the impact
of CT guidance on parameter deviations (Tc-Tp, Fig. 4.6b) are independent of
the magnitude of the corrected tumor set-up error. The latter finding is in strong
contrast with observations for the TV (compare with Figs. 4.2 and 4.6).
4.4 Discussion
Set-up corrections were of major importance for adequate TV irradiation,
especially in fractions with detected large tumor set-up errors (Figs. 4.2a, 4.2b,
4.4a, and 4.5a). However, 95% of treatment fractions had a realized coverage after
correction slightly lower than or equal to the planned coverage (p = 0.001, mean
deviation -1.7%). In addition realized gEUD values were on average lower than
planned (-2.3%). With the high planned target coverages (97.2% on average),
for most points in the target edge, the planned dose is higher than or equal
to the prescribed 12.5 Gy, and an increase here in dose relative to planning
does not impact the TV coverage parameter. For these points, the parameter
is only sensitive to negative dose deviations that may yield a drop in coverage.
An increase in coverage compared to planning can only occur with enhanced
treatment doses in the low percentage of points with a planned dose lower than
12.5 Gy. As a consequence, deviations of treatment dose distributions relative to
planning are most likely to result in a TV coverage reduction, as was also observed
in practice (above). By its nature, gEUD(-5) is most sensitive to dose reductions
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Figure 4.6: Differences between realized organ-at-risk dose distribution parameters
(applying corrections) and (a) planned parameters (Tc-P), and (b) parameters that would
have occurred without corrections (Tc-Tp).
in the TV, yielding lower values. Consequently, when positive and negative target
dose deviations are equally distributed during treatments, treatment gEUD(-5)
values are mostly lower than planned. This might explain the observed mean
gEUD(-5) loss of 2.3%.
As explained in Methods and Materials, differences from planning in the
calculated realized target dose distributions cannot be attributed to tumor
delineation variations. On the other hand, radiological path length differences
between the planning and treatment CT scans may explain the differences.
Additionally, we have found that the procedures for positioning beams around
the TV in treatment CT scans may introduce errors of up to 1 mm, resulting
in some extra dosimetrical uncertainty. Hence, the observed mean differences in
TV coverage and gEUD(-5) between planning and treatment of -1.7% and -2.3%,
respectively, are upper limits for the mean impact of radiological path length
variations on these parameters, originating from day-to-day, non-rigid patient
anatomy variations or rotations. Obviously, the impact of radiological path length
variations on TV dose delivery was much smaller than the impact of set-up errors,
if not corrected (Figs. 4.2a and 4.2b).
As presented in Results, for all OAR dose distribution parameters, the mean
difference between correction (Tc) and nocorrection (Tp) was within -0.4 Gy and
+0.3 Gy. For the Liver D33% and D50%, the mean differences between actual
treatment and planning (Tc-P) were -0.6 Gy and -0.3 Gy, respectively, and during
treatment these parameters were significantly lower than planned (Table 4.3). No
explanation has been found for this benefit.
Reporting on clinically observed toxicity was not specifically the aim of this
study. Results of 11 of the 14 patients have been previously reported [91]. In
the other 3 patients, we did not find any toxicity of Grade 3, 4 or 5. Although
occasionally high doses above OAR constraints were delivered, in none of the 14
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patients, severe toxicity, such as perforation, cardiac insufficiency or neurological
symptoms, observed. Many OAR dose-volume histograms showed a tail towards
the high doses, suggesting that only a small volume was irradiated with high dose.
Locations of hot spots within OARs may also change every treatment day owing
to day-to-day variations in OARs’ positions and shapes.
The PTV margins in our clinical protocol for SBRT of liver patients presume
treatment with daily CT guidance [151], Chapter 3. In this study we have found
that the applied procedure is instrumental to ensure adequate TV dose delivery.
Obviously the tight stereotactic dose distributions do not, in general tolerate
TV displacements. Without set-up corrections, PTV margins should have been
enlarged to minimize the risk of underdosing the tumor.
On average, OAR dose distribution parameters were also close to planning,
but the spread was much bigger than for the TV (compare Figs. 4.2 and
4.6a). OAR parameters could both be higher and lower than planned. In
strong contrast with the TV, the mean impact of set-up corrections on OAR dose
distribution parameters was virtually zero. Corrections could both positively and
negatively strongly impact the OAR parameters, with comparable frequencies
and magnitudes. Moreover, the dosimetric impact of corrections was independent
from the magnitude of the set-up error (Fig. 4.6b). Obviously, set-up corrections
are needed to ensure target coverage, and may fail to reduce OAR doses higher
than planned, or may even enhance these doses, owing to day-to-day anatomy
deformations and/or rotations.
In this study, we did not account for dose variations caused by (residual)
respiratory organ motion in the SBF. However, the expected impact of respiratory
effects is very limited as reported by Wu et al. [144], because the breathing motion
was reduced to ≤5 mm by means of abdominal compression. With a single-
slice, spiral CT scanner, breathing motion may result in imaging artifacts, as
discussed in a previous article [151], and may therefore contribute to set-up error
measurements based on CT. To reduce imaging artifacts, we acquire respiratory-
correlated CT scans in our current liver SBRT practice. From this, we conclude
that the magnitudes of daily set-up errors found in this study are realistic and
inherent to an SBRT treatment in an SBF.
With the 14 patients in the study we were able to convincingly demonstrate
that daily set-up verification and correction can prevent severe TV underdosage
in some of the patients and that these set-up corrections have a mixed impact on
doses in OAR. To more precisely assess frequency distributions, this study should
be extended with more patients.
Several approaches could potentially result in safer dose delivery, with better
controlled-sparing of OARs. For treatment planning, OAR planning volumes
could be designed, using the information on organ changes sampled from
previously treated patients. International Commission on Radiation Units and
Measurements Report 62 [68] stressed the fact that movement and changes
in shape and/or size of OARs, should be considered together with the set-
up uncertainties. It was advised to add a margin to compensate for these
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variations and uncertainties, which led to the concept of the OAR planning
volume. However, neither dose criteria nor suggestions to calculate these margins
for the different types of OARs were supplied. A few groups have attempted
to give a margin recipe, but limitations have been found, especially for parallel
OARs [89, 119]. A second solution could be a change in the current image-
guidance procedure by explicitly including OARs in the on-line image analyses.
As a first step, before dose delivery, one could first establish the required tumor
set-up correction, followed by a dose calculation for the treatment CT scan, taking
into account the set-up correction. Accurate and fast evaluation of the simulated
treatment dose distribution would however require segmented OARs in the
treatment scan. Because manual delineation would be too time consuming, some
sort of autosegmentation would be needed. In case of unacceptable OAR doses,
one could ideally replan on-line to adapt the planning to the patient anatomy of
the day, (e.g. using a system for automated beam angle and weight optimization)
[34]. Until such a system for fast, on-line replanning is clinically available,
occurrence of observed unacceptable OAR doses in the simulated treatment dose
distribution could be a reason not to treat on the particular day. Optimal dose
delivery could be achieved with an adaptive treatment strategy, based on added
fraction doses, assessed with a reliable non-rigid image registration technique [15].
Ideally, non-rigid registration should be part of an on-line procedure, but also off-
line application could improve dose delivery. In the latter, prior to each fraction,
a new treatment plan could be designed, taking into account the added dose
distributions delivered in the previous fractions.
4.5 Conclusions
With the tight dose distributions applied in liver SBRT, daily tumor set-up
correction is required to ensure coverage of the TV according to planning. OAR
dose distribution parameters were on average close to planning, but showed a
large variability in observed deviations. In contrast with the target, and caused
by day-to-day anatomical variations, the mean impact set-up corrections on
OAR dose distributions was virtually zero, with large occasional positive and
negative deviations. Moreover, for OARs, the dosimetric impact of corrections
was independent from the magnitude of the set-up error. Especially for dose-
escalation protocols, development of adaptive treatment techniques and daily
(on-line) replanning is warranted.
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Reduction of Respiratory Liver Tumor Motion by Abdominal
Compression in Stereotactic Body Frame, Analyzed by
Tracking Fiducial Markers Implanted in Liver
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Abstract
Purpose: To investigate in a three-dimensional framework the effectiveness and
reproducibility of reducing the respiratory motion of liver tumors using abdominal
compression in a stereotactic body frame.
Methods and Materials: A total of 12 patients with liver tumors, who were
treated with stereotactic body radiotherapy, were included in this study. These
patients had three gold fiducial markers implanted in the healthy liver tissue
surrounding the tumor. Fluoroscopic videos were acquired on the planning day
and before each treatment fraction to visualize the motion of the fiducial markers
during free breathing and varying levels of abdominal compression. Software was
developed to track the fiducial markers and measure their excursions.
Results: Abdominal compression reduced the patient group median excursion
by 62% in the cranial-caudal and 38% in the anterior-posterior direction with
respect to the median free-breathing excursions. In the left-right direction, the
median excursion increased 15% (maximal increase 1.6 mm). The median residual
excursion was 4.1 mm in the cranial-caudal, 2.4 mm in the anteroposterior,
and 1.8 mm in the left-right direction. The mean excursions were reduced by
compression to <5 mm in all patients and all directions, with two exceptions
(cranial-caudal excursion reduction of 20.5 mm to 7.4 mm and of 21.1 mm to
5.9 mm). The residual excursions reproduced well during the treatment course,
and the cranial-caudal excursions measured on the treatment days were never
significantly (α = 0.05) greater than on the planning days. Fine tuning the
compression did not considerably change the excursion on the treatment days.
Conclusions: Abdominal compression effectively reduced liver tumor motion,
yielding small and reproducible excursions in three dimensions. The compression
level established at planning could have been safely used on the treatment days.
Reduction of respiratory motion by abdominal compression
5.1 Introduction
Stereotactic body radiotherapy (SBRT) for liver tumors (hepatocellular carcinoma
and metastases) was pioneered by Lax et al. [82] at the Karolinska Hospital in
Sweden. Their first report was published in 1994 [82]. Since then, more centers
have entered the field, showing remarkable local control rates [66, 145]. Parallel
developments have taken place in the United States [25, 110]. Since October
2002, patients at the Erasmus Medical Center have been treated with SBRT
using a commercially available stereotactic body frame (SBF) with abdominal
compression (Elekta Instrument AB, Stockholm, Sweden). The clinical results
were published in 2006 [91] and confirmed high local control rates with acceptable
toxicity.
Because very high radiation doses are delivered in only a few fractions, tumor
positioning is of major importance in SBRT. Respiration invokes continuous
motion of the liver, resulting in uncertainty in the tumor position. In a free-
breathing patient, respiration-induced liver motion is typically >5 mm, levels
for which, according to the American Association of Physicists in Medicine Task
Group 76 report, some form of motion management is advisable [74]. Moreover,
in a recent study, we demonstrated the effect of respiratory motion on the
accuracy of a computed tomography (CT)-guided treatment procedure [151].
In this procedure, the frame setup in the treatment unit is derived from the
tumor localization on a contrast-enhanced CT scan obtained just before dose
delivery. Particularly when a single-slice CT scanner is used, respiratory motion
can cause artifacts on the CT scans. Because of these artifacts, the tumor center,
as visible on a CT scan, can deviate from the actual mean tumor center position.
Consequently, for high precision RT, the residual respiratory tumor motion must
be small and the motion range known.
The SBF immobilizes the patient and provides a way of reducing organ
respiratory motion. The organ motion is limited by applying screw-controlled
pressure on the patient’s upper abdomen, a method called forced shallow
breathing [74]. Few quantitative results have been published on the effect of
abdominal compression on respiratory liver tumor motion. To date, most studies
have only assessed cranial-caudal (CC) diaphragm motion as a surrogate for tumor
motion [60, 82]. To our knowledge, neither the dependence of the motion reduction
on the level of compression, nor the day-to-day reproducibility, has ever been
studied in detail.
The purpose of our study was to measure the effect of abdominal compression
on the respiratory motion of liver targets in the three principal directions, the
relation between the level of abdominal compression and motion reduction,
the reproducibility of the excursion in daily treatment for a defined level of
abdominal compression, and the reproducibility of the excursion after a temporary
compression release. Patients had three gold fiducial markers implanted in the
vicinity of the tumor. By acquiring both frontal and lateral fluoroscopic videos,
we could accurately measure the fiducial motion in three dimensions. The motion
53
Chapter 5.
was measured during free breathing and with the patients subjected to varying
levels of abdominal compression in the planning and treatment sessions. We
additionally investigated the value of directly measuring the force acting on the
patients’ abdomen, as an alternative to the standard compression measure (i.e.,
the screw position). For this, the SBF abdominal press plate was redesigned to
allow inclusion of a force transducer.
5.2 Methods and Materials
5.2.1 Patients and treatment
This study included patients undergoing SBRT at our institution between
November 2004 and November 2006. The patients complied with the criteria
described by Mendez Romero et al.in [91] and had gold fiducial markers (diameter
1 mm, length 5 mm) implanted in the liver. The markers were implanted
percutaneously under ultrasound guidance in the liver tissue surrounding the
tumor at least 1 week before the treatment preparation day. The markers were
usually not implanted if anticoagulants had been administered or in the case of
anxiety (1 patient). Of the 15 patients who complied with the criteria, 3 were
eventually excluded from SBRT because of disease-specific conditions. All patients
could tolerate abdominal compression. The 12 included patients (10 men and 2
women) were treated for hepatocellular carcinoma in 2 and liver metastases in 10
patients (Table 5.1).
The patients were treated in an Elekta SBF (the characteristics of which have
been described by Negoro et al. [98]) using a large, screw-controlled, abdominal
compression plate. A change in screw position in millimeters is a direct measure
of the corresponding change in the space for the patient between the anterior
compression plate and the posterior wall of the SBF. Treatment was given during
1 week in three fractions of 12.5 Gy, prescribed to the 65% isodose surrounding
the planning target volume. At a maximum of 2 weeks before the first treatment
fraction, preparation for treatment took place on the planning day. This included
fluoroscopy examinations on a conventional simulator and planning CT scans.
On each treatment day, fluoroscopy and CT scanning were scheduled just before
dose delivery. The position of the tumor on that particular day was defined on a
contrast-enhanced CT scan and was used to update the setup coordinates of the
SBF in the treatment unit. Details of the treatment and procedures have been
previously reported [91] and [151].
5.2.2 Fluoroscopy
Equipment
Fluoroscopic videos were acquired by recording the video signal from the image
intensifier of a conventional simulator (Simulix, Nucletron B.V., Veenendaal, The
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Table 5.1: Patient characteristics
 
 
patient gender markers fluoroscopy sessions F (N) ΔF (N) 
1 m 2 4 33-86 10-36 
2* m 3 5 40-74 12-55 
3* f 3 4 74-116 14-33 
4* m 3 4 28-63 5-19 
5 m 3 4 39-60 11-31 
6† m 3 4 < 38 - 
7 m 3 4 119-174 23-41 
8* m 3 4 38-47 3-19 
9† m 3 4 < 38 - 
10 m 3 4 157-187 5-18 
11* f 3 5 44-88 9-17 
12† m 3 4 < 38 - 
Abbreviations: F = base force, ΔF = respiration induced force (At sea level the force acting on  
1 kg of mass is approximately 9.8 N)  
* Force could not be measured for screw positions retracted 8mm from treatment position.  
† Minimum force was <38 N for most measurements. 
 
Netherlands). The video signal was recorded at a frame rate of ≈12 frames/s on
a computer’s hard disk, using a frame grabber with 8-bit digitization (HaSoTec
GmbH, Rostock, Germany). Using typical focal settings, the resolution achieved
at the simulator’s isocenter level was 0.3 mm/pixel. The pixel positions in
the images were converted to space coordinates (relative to the isocenter) using
transformation models that corrected for S and cushion-shape distortions in the
imaging system. The models were calibrated using a phantom, which resulted in
a localization correction inaccuracy less than the reported resolution.
For this study, we developed a new abdominal compression plate for the SBF
that contained a force transducer to monitor the force exerted by the screw on
the plate owing to the reactive pressure from the patient’s abdomen (Fig. 5.1).
The plate’s design closely matched that of the original plate and was entirely
interchangeable with it. The signal from the transducer was stored with the
fluoroscopic video frames. The transducer’s readout was calibrated by known
forces. With the specific design of force sensing plate during the study, it was not
possible to measure forces <38 N.
Measurements and clinical procedure
The fluoroscopy sessions were scheduled on the planning and treatment days. The
patient was placed in the SBF and positioned on the simulator table in such a way
that the implanted markers were close to the simulator’s isocenter. Fluoroscopic
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compression plate
cable grip
washer
force transducer
compression screw (original)
Figure 5.1: Compression plate redesigned to include force transducer
videos were acquired during continuous X-ray beam-on periods, each covering
at least four complete breathing cycles (typically ≈15 s). A software tool was
developed in-house, using MATLAB (MathWorks, Natick, MA), to assess, on
line, the CC motion of the implanted markers from a video. Using this tool, the
video was played, and an adjustable measuring box was projected to surround the
depicted markers. The accuracy achieved with this on-line method of assessing
the markers’ excursions was less than that achieved with the method used in the
retrospective analyses (see section 5.2.3).
A standard fluoroscopy session comprised (in chronologic order):
1. A frontal and lateral video taken during free breathing (i.e., without
abdominal compression).
2. Specific to the planning day: a series of frontal videos were taken with
increasing compression to determine the screw position appropriate for
treatment. To let the patient get accustomed to the compression, it was
increased slowly, which typically took 15 minutes If the top-top CC motion
of each marker was clearly less than the desired 5 mm, or if the compression
became too painful before reaching this level, compression was not increased
further.
3. A frontal video taken with the compression screw in the treatment position.
4. Frontal videos were taken with the screw retracted 4 and 8 mm with respect
to the treatment position. The offsets of -4 and -8 mm were chosen as a
result of experiments with volunteers, who reported that these offsets from
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maximal tolerable compression had substantial effects on their breathing
comfort. These positions were not intended for treatment.
5. Frontal and lateral videos were then taken after the screw position for
treatment had been re-established.
Based on the findings of the on-line measurement of CC marker excursion
on treatment days, we occasionally selected a screw position during treatment
that was slightly greater (1-3 mm) than the planned screw position. This was
done only if the CC marker excursion measured that day was greater than the
measurement established on the planning day (i.e., usually 5 mm). Together with
the planned screw position, these adjusted positions formed the feasible screw
positions.
5.2.3 Retrospective analyses of fluoroscopy videos
A method was developed to accurately assess, in retrospect, the motion of the
fiducial markers visualized in a fluoroscopic video. The automatic localization
of the markers in each frame, called marker tracking, was implemented using
MATLAB. A marker extraction kernel was developed to detect the locations of
the markers in each video frame. The kernel was based on work by Nederveen
et al. [97]. In each video, marker tracking was initiated by manually indicating
the approximate positions of all markers in a single frame. The initial positions
were then used by the program to automatically determine the marker positions
in all the frames. Marker tracking with this algorithm was independent of
personal judgment. The tracking performance could be verified by showing
the marker positions that were determined in the video frames. In each video
frame, we determined the location of the geometric center of mass of the markers,
yielding a two-dimensional motion track of the marker group. Each component,
or dimension, of such a track described the motion along one principle axis of
the image plane (projected track). The CC and left-right (LR) tracks resulted
from frontal videos and the CC and anterior-posterior (AP) tracks from lateral
videos. Marker tracks were corrected with a scaling factor, determined by the
estimated average position of the marker group relative to the isocenter plane
(depth correction). The correction was estimated using marker tracks from two
corresponding orthogonal videos.
Each projected track was converted into a frequency distribution for the
projected marker positions. Such a discrete frequency distribution shows the
frequency with which a marker is observed at a certain position along the
corresponding principle axis. Before generation of the frequency distribution,
positions at the beginning and end of the projected track were removed, leaving
a truncated track that included complete breathing cycles only. The interval of
projected positions was determined such that it included 95% of all observations,
with one-half of the remaining observations (2.5%) observed to the left and the
other one-half (2.5%) observed to the right of this interval. The length of this
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interval was defined as the excursion (R) in the direction of the principle axis.
From each video, two excursions resulted (frontal: RLR, RCC ; and lateral: RAP ,
RCC). An analysis showed that this method of measuring excursion provided
better intrapatient reproducibility in the presence of irregular motion compared
to measures related to a track’s extremes (peaks and valleys).
A similar approach was used to process the signal from the force transducer
recorded with the video, resulting in a 95% interval of measured force. The lower
bound of this interval was designated the base force (F ). The difference between
the lower and upper bound of the interval was the result of the pressure difference
between inhalation and exhalation. It was designated respiration-induced force
(∆F ). An overview of the base force and respiration-induced force observed at
feasible screw positions is provided in Table 5.1. An example of all measurements
performed for a single patient is shown in Fig. 5.2.
5.2.4 Statistical analysis
Effectiveness of abdominal compression in three principal directions
For each patient, excursions measured during free breathing were compared with
the excursions measured with the feasible screw positions. Excursions observed on
the planning and treatment days were analyzed in the three principal directions by
calculating their means and the corresponding 95% confidence intervals according
to the t distribution. In the CC and LR directions, the measurements with screw
positions that slightly deviated from the planned position (see above) were first
corrected using a linear extrapolation to the planned position, according to the
estimated slope derived by regression analysis (see section 5.2.4). The resulting
values were unbiased excursion estimates at the planned screw position. In the AP
direction, the original measurements were used, because no regression coefficients
were available to correct the excursions.
Relation between abdominal compression and motion reduction
In current clinical practice, the screw position (S) is used as a measure of
abdominal compression. A positive change in the screw position S decreases the
distance between the anterior compression plate and the posterior wall of the SBF.
The relation between the screw position (S) and the residual respiratory marker
excursion (R) was investigated in each patient by regression analysis (according
to Model 5.1, see section 5.2.4). All measurements resulting from the planning
and treatment days, with the patient subjected to abdominal compression, were
combined in this analysis. Because laterally exposed videos, necessary to derive
the AP excursions, were not acquired at screw positions -4 mm and -8 mm, the
analysis was limited to the CC and LR directions.
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Figure 5.2: Excursions observed in Patient 10. (a-c) Excursion R as function of
screw position S: (a) cranial-caudal, (b) left-right, and (c) anteroposterior. Units
along horizontal axes are relative to planned screw position. FB = free breathing. (d-f)
Excursion R as function of measured force F : (d) cranial-caudal, (e) left-right, and (f)
anteroposterior. Intervals defined by minimal force measured at expiration (base force
F ) and maximal force (F + ∆F ) at inspiration, with ∆F indicating respiration-induced
force. Gray lines represent regression lines.
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Force in relation to motion reduction
Conventionally, the screw position S is used as the reference for defining the
level of compression. We investigated the applicability of the base force F as
an alternative reference. The dependence of excursion R on F was modeled by
linear regression in Model 5.3, similar to the regression of R and S in Model
5.1. Because respiration induces a varying force (∆F ), its presence might directly
affect the excursion R. To examine this influence, we entered ∆F as an additional
explanatory variable (Models 5.2 and 5.4).
R = C1 + α1S + ε1 (5.1)
R = C2 + α2S + γ2∆F + ε2 (5.2)
R = C3 + β3F + ε3 (5.3)
R = C4 + β4F + γ4∆F + ε4 (5.4)
In these models, αi, βi, and γi are regression coefficients that determine the
effect of variations in S, F , and ∆F on R; Ci is a constant term, and εi a
stochastic error variable with a mean of 0. The coefficients αi, βi, γi, and Ci were
estimated for each patient using the ordinary least squares method. To decide
on the best overall model for the patient group, for each model i, the estimated
residual variances of the patients (the square of standard deviation [SD] in εˆi)
were combined in a weighted quadratic sum. The weights were proportional to
the degrees of freedom in the estimations of individual residual error variances.
Thus, for each model i, a combined residual variance resulted. They were mutually
compared in F-tests to find possible differences in the models’ predictive qualities.
Reproducibility of excursion in treatment
We investigated the day-to-day excursion reproducibility associated with the
planned treatment screw position for each patient individually. The mean
excursion was calculated from the measurements on the planned screw position
during the planning day. It was compared with the mean excursion calculated
from the treatment day measurements related to that screw position. For the
latter, we included measurements from videos at feasible screw positions that
could be extrapolated to the planned position. For each patient, a t-test for two
population means was used to test for differences in the two means in the presence
of variations among the individual measurements. The test takes into account the
different number of observations used to calculate the means. Because laterally
exposed videos, necessary to derive the AP excursions, were not acquired at screw
positions -4 mm and -8 mm, the comparison could only be performed for the CC
and LR directions.
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The spread in excursion measurements on free breathing and at the planned
screw position was determined for each patient in each principle direction. For
this purpose, the observations made on the planning and treatment days were
combined. SDs were calculated from the free-breathing excursions and from
the excursions measured at, or extrapolated to, the planned screw position. We
verified that combining measurements from the treatment and planning days was
justified, with F-tests performed for each patient, comparing the squared SDs on
the planning and treatment days.
Reproducibility of excursion after temporary reduction of compression
The reproducibility of the CC and LR excursions before and after a temporary
reduction of abdominal compression was analyzed. During each fluoroscopy
session, the screw, originally in a feasible position, was temporary retracted
by 4 mm, and then another 4 mm, after which the original position was re-
established. Frontal videos were acquired before the compression release and
after the re-establishment. The excursion measurements corresponding to these
videos were collected pair-wise from all fluoroscopy sessions for all patients. The
measurements were combined in a paired sample t-test to test the hypothesis that
an average nonzero difference in excursion existed.
5.3 Results
A significance level of α = 0.05 was used for hypothesis testing.
5.3.1 Effectiveness of abdominal compression in three principal
directions
Table 5.2 lists the detailed data for each patient on the free-breathing excursions,
excursions for the planned screw position (CC and LR), and excursions for feasible
screw positions (AP). The data in Table 5.2 were used to generate Fig. 5.3, which
contains the mean excursions with the 95% confidence intervals for each patient.
In agreement with the published data [15, 77, 78, 135], the largest free-breathing
excursion was always observed in the CC direction. This motion component could,
however, be most effectively reduced by compression (Fig. 5.3a). The percentage
of CC excursion reduction was 44-72% (median 62%), depending on the patient.
In 10 of 12 patients, the measured average CC excursion with compression was
<5 mm (Fig. 5.3a). In 2 patients, the average CC free-breathing excursion was
reduced from 20.5 mm to 7.4 mm and from 21.1 mm to 5.9 mm. Excursion
reduction in the AP direction was also established for all patients (range, 11-
58%; median, 38%; Fig. 5.3c). In each patient, the mean observed excursion with
compression was <5 mm. In the LR direction (Fig. 5.3b), the excursion reductions
were 24-73% in 4 patients and excursion increases were 8-124% in 8 patients. A
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15% median increase was observed. The maximal increase in LR excursion was
1.6 mm, and all excursions with abdominal compression were always <5 mm.
The median and maximal value for the mean excursions in the study group was
4.1 mm and 7.4 mm in the CC, 1.8 mm and 2.8 mm in the LR, and 2.4 mm and
4.9 mm in the AP direction.
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Figure 5.3: Free breathing (FB) vs. abdominal compression. (a-c) Each patient
represented by single point. Location along horizontal axis determined by mean excursion
measured on FB during all fluoroscopy sessions. (a,b) For cranial-caudal and left-right
directions, location of data point along vertical axis represents mean excursion measured
on, or extrapolated to, planned screw position of all sessions. (c) For anteroposterior
direction, this location indicates mean of excursions measured on feasible screw positions.
Line segments show 95% confidence intervals. Dashed line at 45o indicates zero effect of
compression.
5.3.2 Relation between abdominal compression and motion
reduction
Regression coefficients describing the dependence of the excursion R in the CC
direction on the screw position S ranged from -0.07 to -0.28 (median -0.11; Table
5.3). These data show that near the level of treatment compression, as a rule
of thumb, one can assume that a 1 cm adjustment of the screw, toward the
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posterior wall of the SBF, will result in a 1 mm decrease in target excursion in
the CC direction. Of the estimated coefficients in the LR direction, only three
were significantly different from 0 (p < 0.05). Daily adjustments of the planned
screw positions were, at a maximum, 3 mm. Consequently, the corrections that
were applied in some analyses, which involved the extrapolation of excursions
measured at feasible screw positions to planned screw positions, were very small.
Table 5.3: Regression coefficients describing dependence of excursion on screw position
 
 
patient no. CC direction  LR direction 
1αˆ  L U n  1αˆ  L U n 
1 -0.14 -0.42 0.14 14  0.00 -0.11 0.11 14 
2 -0.14 -0.33 -0.05 21  -0.04 -0.05 -0.01 16 
3 -0.28 -0.38 -0.18 27  -0.13 -0.26 -0.01 20 
4 -0.23 -0.34 -0.12 25  0.00 -0.04 0.05 19 
5 -0.20 -0.32 -0.09 27  0.02 -0.02 0.07 23 
6 -0.16 -0.27 -0.04 24  -0.02 -0.06 0.02 21 
7 -0.15 -0.30 0.01 21  0.00 -0.07 0.07 18 
8 -0.04 -0.12 0.05 20  0.01 -0.05 0.07 16 
9 -0.10 -0.28 0.07 26  -0.01 -0.12 0.11 21 
10 -0.19 -0.33 -0.05 21  0.01 -0.02 0.03 17 
11 -0.21 -0.28 -0.14 30  0.05 0.00 0.11 25 
12 -0.07 -0.13 0.00 24  0.04 0.02 0.06 20 
Abbreviations: 1αˆ  = estimated regression coefficient representing ΔR/ΔS (i.e., unitless; see  
Model 5.1 in text), L = lower bound of 95% confidence interval for 1αˆ , U = upper bound of  
95% confidence interval for 1αˆ , n = number of observations used for regression analysis. 
 
5.3.3 Force in relation to motion reduction
Force measurements in 9 patients (Table 5.1) were used to compare Models 5.1-
5.4 (see section 5.2.4). The overall SD (in millimeters), describing the predictive
quality of Models 5.1-5.4 was 0.87, 0.76, 0.95, and 0.84 mm, respectively. The
smaller this SD, the better the predictive quality. Equations that took into
account the respiration-induced force (Models 5.2 and 5.4) resulted in the smallest
estimated residual error variance. Model 5.2 performed significantly better than
did Model 5.1 (p = 0.047) and Model 5.3 (p = 0.003) and also resulted in a lower
estimated residual error variance than Model 5.4; however, the difference was no
longer significant (p = 0.121). Comparing Model 5.4 with Models 5.1 and 5.3 did
not provide any significant difference (p = 0.314 and p = 0.056, respectively).
Predictions based on screw position (Model 5.1) resulted in smaller estimated
residual error variances than did predictions based on base force only (Model
5.3), although the difference was not statistically significant (p = 0.131). At the
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level of the individual patient, differences in estimated residual error variances
between the candidate models were not always conspicuous. This was the reason
for the relatively small differences in the patient group residual error variance
estimates among the models.
5.3.4 Reproducibility of excursion in treatment
The differences in excursion measurements on the planned screw position (par-
tially extrapolated) between the planning and treatment days were characterized
by their median, minimal, and maximal values: -0.3 mm, -1.8 mm, and 0.7 mm
for the CC and 0.0 mm, -0.9 mm, and 1.0 mm in the LR direction (negative values
indicate smaller excursion on treatment days than during planning), respectively.
In only 1 patient (Patient 8) was a significant difference found in the CC direction
(p = 0.01). In Patient 8, the mean of the treatment-day CC excursions was,
on average, 0.7 mm less than the mean of the planning day measurements.
Significant differences for LR excursions were found in Patient 1, with excursions
on treatment days, on average, 0.5 mm larger than during planning (p = 0.01),
and in Patient 7, with treatment excursions 0.9 mm less than during planning
(p = 0.001). No significant differences were found between the SDs of excursions
measured on the planning day and treatment days, according to the F-tests.
The spread in excursion measurements is reflected by the SDs reported in
Table 5.2. The median, minimal, and maximal SD with compression was 0.7 mm,
0.5 mm, and 1.4 mm for the CC direction, 0.2 mm, 0.1 mm, and 0.8 mm for the
LR direction, and 0.6 mm, 0.2 mm, and 0.8 mm for the AP direction, respectively.
In the CC direction, the spread observed in the free-breathing measurements was
significantly larger than the spread in the measurements at the planned screw
positions (p < 0.001, combined F-test). With compression, the SDs were reduced
by a maximum of 2.4 mm (median 0.4 mm). In some cases, a considerable
reduction in spread was also observed in the AP direction.
5.3.5 Reproducibility of excursion after temporary reduction of
compression
No evidence was found for systematic differences in respiratory excursion resulting
from a temporary reduction of abdominal compression. The mean of the
differences that were calculated from the excursions before the reduction and
after re-establishment of the compression was not significantly different from 0
(CC, p = 0.57; LR, p = 0.70). The spread in observed differences was a SD of
0.98 mm for the CC direction and 0.56 mm for the LR direction.
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5.4 Discussion
The results of this study have shown that abdominal compression in an SBF is
an effective method of managing respiratory motion in patients with liver tumors.
The median free-breathing excursions we observed in our patient group was
9.0 mm in the CC, 1.2 mm in the LR, and 4.1 mm in the AP direction. Residual
excursions became substantially <5 mm in all directions by applying abdominal
compression, except for in 2 patients in whom a slightly larger motion toward the
CC direction was observed. Although compression did reduce tumor excursion in
the CC and AP directions in all patients, in 8 patients LR tumor motion increased
with compression (patient median excursion went up from 1.2 mm to 1.7 mm, with
a maximal excursion increase of 1.6 mm). However, the maximal mean residual
LR excursion observed was only 3.6 mm, which still makes LR motion, in general,
the smallest component of motion.
To date, liver tumor motion in the SBF has never been measured accurately.
CC motion was commonly assessed using fluoroscopy, measuring the excursion of
the diaphragm cone as a surrogate [60, 82]. Motion in radial directions has been
assessed with a technique, designated “dynamic CT,” which involves acquiring
CT scans in a fixed CT couch position [146]. These studies assessed neither the
reproducibility nor the effects of compression on excursions. Moreover, it has been
shown that the relationship between diaphragm motion and tumor motion during
normal breathing is poor [27, 135]. Accurate derivation of the radial extent of
residual respiratory tumor motion using dynamic CT could be hampered by the
occurrence of imaging artifacts related to the larger respiratory motion in cranial-
caudal direction. Negoro et al. [98] used fluoroscopy to study the CC motion of
lung tumors in 11 patients during free breathing and maximal tolerable abdominal
compression in an SBF. The free-breathing excursions were comparable to those
in our group. With compression, the motion increased in 1 patient, in another
patient no change was observed, and in 9 patients, the excursions were reduced to
2-11 mm (mean 7 mm). Abdominal compression was apparently not as effective
in reducing the motion of lung tumors as it was for liver tumors.
In our study, gold fiducial markers were implanted in the vicinity of the tumor,
and both frontal and lateral fluoroscopy videos were acquired. This allowed
us to measure motion in three dimensions with submillimeter precision. Such
measurements are, however, snapshots of a dynamic breathing process having
random short and long-term variations. Apart from the measurements themselves,
the reproducibility, which we reported using SDs, is also of concern. Although
intrapatient variation was addressed in this way, evidence on the interpatient
variations was limited by the small group size of 12 patients. Another limitation
of our study was that fiducial markers were used as a surrogate for the tumor
to measure motion. Although fiducial markers were placed in the vicinity of the
tumor, the center of mass of the fiducial markers might not have exactly coincided
with the tumor. Despite this discrepancy, the fiducial markers’ center of mass does
represent a part of the liver tissue (even in the presence of small deformations [15]),
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which can equally well be used to analyze motion reduction and reproducibility.
In a clinical setting, however, the relationship between tumor and fiducial motion
should preferably be estimated (e.g., respiration correlated scanning) or a safety
margin should be included.
In the regression analysis on screw position and the degree of excursion,
we found a relationship between the level of abdominal compression and the
reduction in CC motion. However, major screw adjustments resulted only in
relatively small changes in excursion (e.g., 1 cm adjustment typically effectuated
a 1 mm excursion change). Although, in retrospect, we were able to measure
the limited effect of small adjustments, in clinical practice, screw positions were
often fine tuned on the treatment days (maximum, 3 mm adjustment). This can
be explained by the limited measurement precision of the on-line motion analysis
at that time. Excursion was measured as top-top motion, rather than a 95%
incidence interval (as applied in the retrospective analyses), yielding relatively
large intermeasurement variations. Moreover, breathing variation induces a
random component in the measurements, rendering subtle treatment decisions
on the basis of a single measurement of four breathing cycles problematic. In
retrospect, using all available excursion measurements and performing regression
analyses, we concluded that the small screw adjustments performed, had a
negligible effect on treatment accuracy and are obsolete.
Using linear regression analysis, we demonstrated that the residual tumor
excursion was not better explained by the baseforce, F , than it was explained
by the screw position, S. However, excursion was significantly better explained
by including the variable ∆F (breathing-induced force). Although the base force
F can be changed by adjusting the position of the screw, the breathing-induced
force ∆F cannot be tuned using the screw. Only the patient can possibly regulate
this. We concluded that the screw position can best be used as a reference point
for patient set-up. Force monitoring could be used to verify the reproducibility
of breathing activity and tumor motion.
In this study, we observed excellent day-to-day reproducibility of residual
tumor excursion from planning to treatment (1-2 week interval). This implies
that during planning an appropriate screw level can be established and then be
safely applied during the treatment sessions, without additional verification. To
establish appropriate planning target volume margins, it is important though, to
accurately assess the residual motion during planning [151]. The reproducibility
of excursion measurements is affected by random short and long-term breathing
variations, as the SDs reported show. Although the variations were generally
small, it is advisable to acquire multiple videos on the day of planning to
accurately estimate, for each patient, the mean excursion, as well as its variation.
To this end, we have treated >30 patients with SBRT at our institution.
Patients eligible for SBRT always tolerated abdominal compression. Patients
with anxiety problems sometimes required medication to accept treatment, and
the extra bladder pressure experienced by another patient required a catheter.
Predefined exclusion criteria for the support of abdominal compression were
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never used. We advocate the use of compression in SBRT, because apart
from suppressing motion, it might also stabilize the patient in the SBF. To
avoid discomfort during a treatment procedure, we have partially released the
compression between sessions (e.g., between fluoroscopy, CT, and the treatment
unit). In this study, we found no evidence of changing respiratory motion after
such a temporary reduction of abdominal compression. Other treatment methods
have been successfully used to immobilize the tumor (e.g., active breathing
coordination [38] and forms of gating [78]) that have showed high intrafraction
reproducibility. However, in the study by Eccles et al. [38], 38% of their
patients could not be treated using active breathing control because of intolerance,
poor reproducibility, and communication problems. Gating and robotic tumor
tracking require advanced technology that is not yet widely available. Moreover,
the duration of dose delivery often increases substantially, when using such
technology. The simplicity and the general tolerance to compression make
SBRT with abdominal compression an attractive option compared to alternative
treatment methods.
We are currently working on improving daily tumor set-up in the treatment
unit by on-line fluoroscopic imaging of the fiducial markers and on improving the
tumor definition using respiration-correlated CT scanning. We hypothesized that
the margin reduction involved would have considerable therapeutic advantages
[95].
5.5 Conclusions
In patients with liver tumors treated in an SBF, abdominal compression was
used effectively to achieve small and reproducible tumor excursions in three
dimensions. The screw position that was assessed on the treatment planning
day could have been used on subsequent treatment days without the need for
additional verification. Respiratory motion was relatively insensitive to fine-
tuning the level of treatment compression.
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Integration of a Force Transducer in the Abdominal
Compression Plate of the Stereotactic Body Frame for
Monitoring Respiration
Inventor: W. Wunderink.
Patent filed by Elekta AB, Stockholm, Sweden
Patent number: US 2010 0094153 A1, published on April 15th, 2010.
Abstract
A respiration sensor comprises a frame that is adapted to extend from a first point
of contact on one side of a patient to a second point of contact on an opposing side
of the patient, including a force sensor in the first point of contact. The second
point of contact can comprise a patient support, which will usually support the
patient in a generally horizontal state. The frame is preferably as shown in U.S.
Pat. No. 5,681,326 with an arch extending over an area adapted to receive a
patient. The first point of contact can include a plate which abuts the patient.
The sensor is ideally located between the plate and the remainder of the frame.
Force sensing abdominal compression plate
6.1 Background art
Respiration monitoring is useful during a range of treatments, including radio-
therapy. As radiotherapy involves directing harmful beams of radiation toward
a tumour, it is important to minimise the dose that is applied to healthy tissue.
Collimators are used to shape the beam appropriately, and the beam direction
is varied over time, and these can assist in delivering the maximum dose to a
tumour area and a minimum dose to healthy tissue.
These measures require the location of the tumour to be known. Generally,
this is established through prior investigation, but tumours near to the lungs
present difficulty in that they move with the surrounding tissue as the respiration
cycle progresses. Generally, the tumour will only be at the expected location at
like points in the respiration cycle.
Respiration monitoring is also important in imaging applications. Computed
Tomography (CT) scanners can produce very good quality three dimensional
representations from a series of two-dimensional images, but assume that the
patient has not moved or changed between the successive images. Respiration
obviously breaches this assumption and therefore causes artefacts or degradation
in the 3D representation.
To date, this has been dealt with either by prompting the respiration cycle with
indicators that direct the patient when to breathe, or by detecting the cycle. Our
earlier application WO2004/066211 described an algorithm that could detect the
respiration phase from cone beam CT images and select the appropriate images
for processing. Most prior art used to detect the respiration cycle relies on the
detecting the motion that results from respiration.
6.2 Summary of the invention
This invention seeks to simultaneously minimise or even eliminate the respiratory
motion while detecting the respiratory cycle.
The present invention therefore provides a respiration sensor, comprising a
frame that is adapted to extend from a first point of contact on one side of a
patient to a second point of contact on an opposing side of the patient, including
a force sensor in the first point of contact.
The second point of contact can comprise a patient support, which will usually
support the patient in a generally horizontal state. Thus, the frame can extend
around the patient in the for of a support beneath the patient and a first point
of contact above the patient.
The frame is preferably non-yielding and radiolucent thereby to avoid
interfering with the radiological investigation taking place. The frame cab further
comprise a radiolucent fixing means arranged inside the frame and on which the
patient’s body is intended to rest, said fixing means comprising a flexible casing
which contains a yieldable substance, the fixing means being adapted to permit
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the patient to be partly sunk into the fixing means and oriented in a desired
position at a first stage, and the yieldable substance of the fixing means being
transformable into a non-yielding state to fix the patient in the desired position
at a second stage. Such a frame is shown in U.S. Pat. No. 5,681,326 which is
herein incorporated by reference in its entirety.
The frame can include an arch extending over an area adapted to receive a
patient. An arch is advantageous in that it is able to connect to the frame on
both sides of the patient and thereby offer a more rigid substrate from which to
measure forces exerted by the patient.
The first point of contact can include a plate which abuts the patient. A plate
will offer a greater surface area and therefore inflict less discomfort on the patient
The plate can be attached to the frame via an adjustable means, for example, to
cater for different sizes of patient. A screw thread offers suitable adjustability.
The sensor is ideally located between the adjustable means and the plate. The
adjustable means can be attached to the frame at the arch, thereby enabling it
to be placed directly over the patient’s abdomen. This will ensure that, in use, it
is placed purely in compression rather than being subjected to bending moments.
Again, this assists in ensuring the rigidity of the overall structure.
6.3 Detailed description of the embodiments
Fig. 6.1 shows a stereotactical body frame 1 as can be used in the present
invention. This comprises an elongate, non-yielding frame 2 which is made of
a material that does not cause any artefacts (disturbances) in the images, i.e., a
material which is translucent to X-rays and other radioactive radiation. A fixing
means 3 is adapted to be inserted in the frame 2 which is open at the top and at the
ends, said fixing means comprising a flexible casing that is impermeable to fluid
and hermetically encloses a yielding substance, not shown. On this fixing means,
the patient is caused to take the desired position for diagnostics or treatment,
the patient partially sinking into the yieldable fixing means, and a large contact
surface against the patient is obtained, see Fig. 6.2. Subsequently, the fixing
means 3 is given a non-yielding state so as to fix the patient in the desired position.
This can be achieved by the casing of the fixing means holding a plurality of small
bodies, for example so-called Frigolit beads or the like, which are fixed in their
respective positions when a negative pressure is produced in the impermeable
casing. It is also possible to fill the casing with a fluid which can be caused to
solidify so as to keep its enforced shape. Thus, the casing can be filled with
prepolymerised polyurethane foam which, when the patient has been oriented in
the desired position, is caused to finally polymerise and thus form a non-yielding,
fixing compound. By means of a first indicating device 4 fixedly arranged on
the frame 2 in the longitudinal direction thereof, and a second indicating device
5 arranged on an arch 6 which is displaceable on the frame in the longitudinal
direction thereof, the patient can be oriented in the fixing means for treatment of
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an area which has previously been located by means of computerised tomography,
X-rays etc.
1
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4
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Figure 6.1: A patient prior to treatment in a body frame.
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Figure 6.2: Vertical section through the frame of Fig. 6.1.
The frame 2 is preferably formed with fixing holes (not shown) into which
the fixing means can penetrate at its first, yielding stage, and/or fixing lugs 7
penetrating into the fixing means so as to fix this at its second, non-yielding
stage.
Finally, the frame 2 comprises one or more orienting means 8 along each
longitudinal side of the frame. The orienting means 8 which preferably is
releasably attached to the inside of the frame, consists of a radiolucent support
with three arrays of lines preventing radiation, which are made of, e.g., wire,
strips or thin sections of copper for diagnostic X-ray, angiography, DSA and CT
examinations or gas-, liquid- or substance-filled tubes for diagnostic PET and
MRI examinations. The first array 10 comprises a number of lines of different
lengths extending in parallel from one open end of the frame, said lines preferably
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being parallel also with the bottom of the frame, as shown in Fig. 6.1. The
second array 11 comprises parallel lines extending at an angle to the first array
10 and extending from the first array along each longitudinal side of the frame.
The second array 11 is terminated at a third array 12 adjacent the upper edge of
the longitudinal side. The third array 12 comprises one or more unbroken lines
which preferably are parallel with the lines of the first array. See also Fig. 6.2
which schematically illustrates a vertical section of the orienting means 8. In this
Figure, the frame 2 is indicated by full lines and the upper surface of the fixing
means 3 by dashed lines.
The frame 2 is supported by a bed unit which allows the patient to be moved
while fixed in the frame.
The diagnostic equipment produces an image section, for example an MRI
or CT sectional image, and the orientation of this section is indicated by the
orienting means 8. By counting the number of lines in the first array 10, a base
value is obtained. The distance between the uppermost unbroken line in the first
array and the point in which the image section cuts one of the inclined lines in
the second array is measured and yields a supplementary value, see Fig. 6.2.
Since the distance between the two upper horizontal marks 11 and 12 is known,
this distance can be used as a reference for calculating the vertical coordinate
in the image sectional plane. Similarly, the horizontal coordinate in the image
plane can be calculated by the distance between 11 and 12 on the two sides of
the frame being known. By means of these values, the orientation of the image
section can be determined with great accuracy. It should be noted that the image
section need not be oriented at right angles to the longitudinal axis of the frame
2, but may be oriented at an optional angle, as shown in Fig. 6.2 in which
each point of intersection between the image section and the associated line in
the second array 11 is positioned on different levels. This Figure schematically
illustrates a sectional image of the patient in which the target area or treatment
area 13 appears. In diagnostic use, the orienting accuracy of the stereotactical
system has been about 1 mm, and in repeated treatment using the stereotactical
instrument the orienting accuracy has been about 3 mm in the transverse plane
and about 6 mm in the longitudinal plane. These values were obtained for target
areas close to the diaphragm and were to a certain extent affected by the patient’s
breathing. In order to reduce the effect of the breathing movements, an abdominal
compression plate (14) has been used on such occasions.
The stereotactical coordinates are adjusted on the scales 4 and 5 in the treat-
ment room by means of prior-art wall-mounted lasers, mounted-and set in con-
ventional manner, which define the system of coordinates for the room/treatment
unit. Guided by the values which are obtained in the locating of the target point,
i.e. the tissue area To be treated, and which are transferred to the stereotactical
instrument, the coordinates are obtained which are necessary to be able to set
a radiation source, starting from the frame, such that the beam therefrom is
directed to the treatment site or target point.
Fig. 6.3 shows the type of image that is available through the use of such
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a frame. Even with an abdominal compression plate 14 in place (visible in
the image), there are visible artefacts 16, 18 in the image that result from the
patient’s respiration cycle. Thus, although the body frame offers great advantages
in supporting the patient, especially during second or subsequent visits, there is
clearly scope for improvement.
14
16
18
Figure 6.3: sagital CT-slice of the patient of Fig. 6.1.
Fig. 6.4 shows a force sensor 20. As their name implies, force sensing resistors
use the electrical property of resistance to measure the force (or pressure) applied
to them. A force sensing resistor is made up of two parts, a resistive material
22 carried on a film and a set of interdigitating contacts 24, 26 also carried on a
film. Each respective contact 24, 26 is connected to one of the two lead-out wires
20a, 20b. This is apparent in Fig. 6.4, but Figs. 6.5a and 6.5b shows a simplified
pattern in more detail. The resistive material serves to make an electrical path
between the two sets of conductors on the other film. When a force is applied
to this sensor, a better connection is made between the contacts, and hence the
conductivity is increased. Over a wide range of forces, it turns out that the
conductivity is approximately a linear function of force as shown in Fig. 6.6, the
resistance of a typical sensor as a function of force.
20
22
24
26
20b
20a
Figure 6.4: Sensor according to the present invention.
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(a) (b)
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Figure 6.5: Schematics of such a sensor. (a) schematic illustration from above and (b)
schematic exploded illustration.
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Figure 6.6: Response of such a sensor to a force exerted thereon.
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Figs. 7 and 8 show abdominal compression plates 28, 30 suitable for use in
the present invention. Generally, these are held in place via a threaded shaft (not
shown) that passes through a threaded aperture in the arch 5 or a like structure
in the body frame, and which seats in a blind recess on 32 on a washer 34. That
washer 34 fits in a corresponding recess 36, 38 in the compression plates 28, 30.
Thus, once the patient is in position in the body frame, the arch 5 (or other
structure) is erected, the shaft is threaded into its hole in the arch 5 (or other
structure), and the compression plate 28 or 30 with washer 34 is placed in position
on the patient. The shaft is then rotated to drive it downwards into the recess
32, pressing the plate 28 or 30 into the patient’s abdomen. This assists in holding
the patient in place and in (to an extent) limiting respiratory movement of the
patient’s organs. Washer 32 assists in limiting the transfer of rotational forces
from the shaft to the compression plate 28, 30.
32
34
36
28
40
44
Figure 6.7: Fitting location for the sensor of Fig. 6.4.
38
34 32 46
42
30
Figure 6.8: Alternative to Fig. 6.7.
Figs. 7 and 8 show a channel 40, 42 in each of the compression plates 28, 30
leading from the recess 36, 38 to an edge of the plate 28, 30. At the edge of the
plate 28, 30, the channels 40, 42 end with a cable grip 44, 46. In the plate 28 of
Fig. 6.7, the channel 40 leads away from the recess 36 diagonally with respect to
the patient whereas in the plate 30 of Fig. 6.8, the channel 42 leads away from
77
Chapter 6.
the recess 38 longitudinally with respect to the patient. The choice is largely a
matter of convenience and comfort for the patient.
These channels 40, 42 allow a force sensing resistor 20 to be placed in the
compression plate 28, 30. The active area of the resistor 20 can then be sandwiched
between the plate 28, 30 and the washer 32, within the recess 36, 38. To obtain
reliable operation, it assists to place a flexible material (preferably one that shows
few hysteretic effects after a release of pressure) in between the washer 32 and the
resistor 20, in the channel 40, 42 of plate 28, 30. We prefer to fill the channel 40,
42 with silicone and use a 2 mm soft rubber layer on top, which partially makes
contact with the plate 28, 30, and partially with the resistor 20. In this way, part
of the pressure exerted by washer 32 can be directed straight to the plate, thereby
preventing the sensor from saturating at the slightest force on the washer. The
lead-out connections 20a, 20b attached to the resistor 20 can be placed in the
channel 40, 42 and are secured by the cable grip 44, 46.
Fig. 6.9 shows the processing of the information received from the force sensing
resistor 20. The lead-out wires 20a, 20b are connected to conductors 48. 50 within
a cable leading to a driver/amplifier unit 52 which supplies a current to the resistor
20, detects the voltage drop, and amplifies this to a useful signal level. That signal
is passed via a cable 54 to a connection unit 56 which also receives imaging data
from the CT scanner 58 via a sensor port 60 and connecting cable 62.
64
66
56 54 52
48
50 
58
6062
Figure 6.9: Data processing apparatus.
The imaging data and the respiratory signal data from the resistor 20 are
both then fed to a computing means 64, the respiratory signal data passing via
an analogue to digital converter 66. The respiratory signal data can then be used
to select samples from the imaging data that correspond to like-phase points in
the respiratory cycle. These selected images can be used to construct a three
dimensional tomography via known computing methods.
In another example in which the Siemens Sensation Open CT-scanner is used,
employing the Anzai sensor-port system, the signal entering the connection unit
56 (via 54) is duplicated within unit 56. The signal is directed via 62 to sensor
port 60 and can also be received by 66. The sensor port provides the respiration
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signal to the CT-scanner computer, where it is stored together with the imaging
data. In other words, in this example unit 56 is a simple rewiring device without
any active components, and could simply be replaced by two separate cables. For
CT applications, the computer 64 is only used for monitoring the signal, to adjust
the right offset and gain on the amplifier unit 52. In a kV fluoroscopy application,
the computer 64 is used to store the respiration signal, together with kV-images
provided to this computer.
Alternatively, the respiratory signal data can be analysed in real time and used
to gate the CT scanner 58, thereby creating images that are phase-coordinated.
This will have the advantage that the patient will be exposed to less radiation,
but the disadvantage that only one point in the phase can be imaged. Offline
selection of the images after exposure allows substantially any required phase to
be chosen.
Fig. 6.10 shows a digital x-ray fluoroscopic image 68 of gold markers implanted
into a patient. Each marker such as that referenced 70 can be seen to leave a line
in the time-averaged image showing the movement of that local area if tissue
during respiration. Fig. 6.11 shows an upper line 72 that is the instantaneous
location of one such marker with time. A lower line 74 is the monitored force
reported by the force sensing resistor 20. It can be seen that the two lines show
a variation that exhibits a periodic variation that has the same phase; therefore
it can be concluded that the resistor 20 accurately reports breathing phase.
68
70
Figure 6.10: Motion in a patient detected during respiration.
It will of course be understood that many variations may be made to the
above-described embodiment without departing from the scope of the present
invention.
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Figure 6.11: Detected motion together with the force sensed according to the present
invention.
6.4 Claims
1. A respiration sensor, comprising a frame that is adapted to extend from a
first point of contact on one side of a patient to a means permitting a second
point of contact on an opposing side of the patient, including a force sensor
in the first point of contact.
2. The respiration sensor according to claim 1 in which the means permitting
a second point of contact comprises a part of the frame adapted to abut the
patient.
3. The respiration sensor according to claim 1 in which the means permitting
a second point of contact comprises a connector for fitting the sensor to a
patient support.
4. The respiration sensor according to claim 1 in which the means permitting
a second point of contact comprises at least part of a patient support of
which the remainder of the respiration sensor is an integral part.
5. The respiration sensor according to claim 4 in which the patient support
supports the patient in a generally horizontal state.
6. The respiration sensor according to claim 1 in which the frame is non-
yielding and radiolucent.
7. The respiration sensor according to claim 1 in which the frame further
comprises a radiolucent fixing means arranged inside the frame and on which
the patient’s body is intended to rest, said fixing means comprising a flexible
casing which contains a yieldable substance, the fixing means being adapted
to permit the patient to be partly sunk into the fixing means and oriented in
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a desired position at a first stage, and the yieldable substance of the fixing
means being transformable into a non-yielding state to fix the patient in the
desired position at a second stage.
8. The respiration sensor according to claim 1 in which the frame includes an
arch extending over an area adapted to receive a patient.
9. The respiration sensor according to claim 1 in which the first point of contact
includes a plate which abuts the patient.
10. The respiration sensor according to claim 9 in which the plate is attached
to the frame via an adjustable means.
11. The respiration sensor according to claim 10 in which the adjustable means
is a screw thread.
12. The respiration sensor according to claim 10 in which the sensor is located
between the adjustable means and the plate.
13. The respiration sensor according to claim 16 in which the adjustable means
is attached to the frame at the arch.
14. (canceled)
15. The respiration sensor according to claim 11 in which the sensor is located
between the adjustable means and the plate.
16. The respiration sensor according to claim 8 in which the plate is attached
to the frame via an adjustable means.
17. The respiration sensor according to claim 8 in which the adjustable means
is a screw thread.
18. The respiration sensor according to claim 17 in which the adjustable means
is attached to the frame at the arch.
19. The respiration sensor according to claim 8 in which the sensor is located
between the adjustable means and the plate.
20. The respiration sensor according to claim 19 in which the adjustable means
is attached to the frame at the arch.
81

Chapter 7
Potentials and Limitations of Guiding Liver Stereotactic
Body Radiation Therapy Set-Up on Liver-implanted Fiducial
Markers
W. Wunderink, A. Méndez Romero, Y. Seppenwoolde, J.C.J. de Boer,
P.C. Levendag and B.J.M. Heijmen.
Published in the International Journal of Radiation Oncology, Biology and
Physics. Volume 77, issue 5. Pages: 1573-1583.in August 2010
Abstract
Purpose: We investigated the potentials and limitations of guiding liver stereo-
tactic body radiation therapy (SBRT) set-up on liver-implanted fiducial markers.
Methods and Materials: Twelve patients undergoing compression-supported
SBRT in a stereotactic body frame received fluoroscopy at treatment preparation
and before each treatment fraction. In fluoroscopic videos we localized the markers
and diaphragm tip at expiration and the spine (measurements on free breathing
and abdominal compression). Day-to-day displacements, rotations (markers
only), and deformations were determined. Marker guidance was compared to
conventional set-up strategies in treatment set-up simulations.
Results: For compression, day-to-day motion of markers with respect to their
centers of mass (COM) was σ = 1 mm (random error SD), Σ = 0.6 mm (systematic
error SD), and <2.1 mm (maximum). Consequently, assuming that markers were
closely surrounding spherical tumors, marker COM-guided set-up would have
required safety margins of ≈2 mm. Using marker COM as the gold standard,
other set-up methods (using no correction, spine registration, and diaphragm tip
cranial-caudal registration) resulted in set-up errors of 1.4 mm < σ < 2.8 mm,
2.6 mm < Σ < 5.1 mm, and 6.3 mm < max < 12.4 mm. Day-to-day intermarker
motion of <16.7%, 2.2% median, and rotations between 3.5o and 7.2o were
observed. For markers not surrounding the tumor, e.g., 5 cm between respective
COMs, these changes could effect residual tumor set-up errors up to 8.4 mm,
1.1 mm median (deformations), and 3.1 mm to 6.3 mm (rotations). Compression
did not systematically contribute to deformations and rotations, since similar
results were observed for free breathing.
Conclusions: If markers can be implanted near and around the tumor, residual
set-up errors by marker guidance are small compared to those of conventional set-
up methods, allowing high-precision tumor radiation set-up. However, substantial
errors may result if markers are not implanted precisely, requiring further research
to obtain adequate safety margins.
Potentials and limitations of marker guidance
7.1 Introduction
Stereotactic body radiation therapy (SBRT) is used increasingly for treating
tumors in the liver, a development that is supported by high local control rates
with acceptable toxicity [53]. Still, major therapeutic advantages are to be gained
by improving dose distributions [95] and tumor radiation set-up [52, 54, 55, 151].
The geometrical uncertainties caused by tumor motion require substantial safety
margins in most treatment strategies [52, 54, 151]. However, if margins were
reduced, dose could be escalated while healthy tissues could be spared better [95].
Only proper management of tumor motion would allow us to do so.
Tumor motion involves short and long-term displacements. The short-
term motion due to respiration can be controlled effectively by commercially
available systems, like active breathing coordination [38], forced shallow breathing
(abdominal compression) [58, 149], and tumor tracking technologies [79, 87].
Long-term motion, on the other hand, like intrafraction drifts and day-to-day
motion, cannot be controlled easily and may lead to a partial underdose to the
tumor and to an overdose to critical structures [93]. Moreover, in hypofractionated
SBRT, the corrective effect of averaging dose by delivery in multiple fractions is
uncertain.
To manage treatment delivery in the presence of long-term motions, image-
guided radiotherapy methods are used. Using computed tomography (CT),
anatomical structures can be imaged before dose delivery. The equipment is often
installed in the treatment room to optimize reproducibility during dose delivery
(e.g., cone beam CT [55], in-room CT [52]). The requirements for accurately
localizing the tumor position are often hard to combine (e.g., high image quality,
the use of contrast agent, measures to control breathing motion, and short interval
between image guidance and dose delivery) [52, 55]. Moreover, it has been shown
that the tumor can drift away in a matter of minutes (up to ≈5 mm) [52, 137],
thereby impairing reproducibility.
An alternative for CT imaging is in-room portal kV/MV imaging to visualize
surrogates for tumor position like implanted fiducial markers. After being
explored by Kitamura et al. [79], other treatments have evolved that rely fully
on surrogates for tumor position e.g., using conventional equipment [5], and a
robotic LINAC (Cyberknife) [87]. Since images can be acquired just in advance
of or even during treatment, delay between imaging and dose delivery can be
minimized. Additionally, positional drifts and breathing motion can be accurately
measured. All procedures, however, implicitly assume that the geometry in the
planning scan, which establishes the relative position of the markers to the tumor,
is reproduced on the treatment day (i.e., rigid-body geometry). During treatment,
beams are positioned relative to the markers by translation to reproduce the
planning situation. If fiducial markers cannot be placed near and around the
tumor, deformations or rotations presented in the marker groups may indicate
unknown displacements in the distant liver tissue containing the tumor. Marker
guidance could then jeopardize target coverage.
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Little is known about the reliability of using fiducial markers for image
guidance in liver tumor patients. The daily reproducibility of the marker
positions, its consequences for the uncertainty in tumor localization, and the
specific benefit in terms of reducing set-up errors relative to other strategies have
not yet been widely explored. Such evidence is required if marker guidance is
considered for a routine treatment practice.
In this study, we investigated the potential reduction in residual set-up errors
by comparing marker guidance with conventional set-up methods (uncorrected
frame-based set-up, bony anatomy registration, and diaphragm tip cranial-caudal
[CC] registration) for compression-supported SBRT by hypothesizing that fiducial
markers were closely surrounding the tumor tissue. Second, we investigated the
limitations of marker guidance for those situations in which fiducial markers
cannot be precisely placed by measuring daily deformations and rotations in
the marker groups (abdominal compression and free breathing measurements)
and by evaluating their potential impact on geographical misses. The positions
of fiducial markers were measured in kV fluoroscopic videos acquired on the
treatment preparation (planning) day and on each treatment day in a group of
12 consecutively treated patients.
7.2 Methods and Materials
7.2.1 Patients and treatment
Twelve patients who received SBRT for liver tumors (hepatocellular carcinoma
and metastases) were included in this study. The treatment was supported by
abdominal compression using a stereotactic body frame (SBF, Elekta Instrument
AB, Stockholm, Sweden). Generally, three fiducial markers (gold seeds, 5 mm
long and 1 mm in diameter) were implanted percutaneously in liver tissue under
ultrasound or CT guidance at ≥1 week before acquiring the planning CT scan.
Markers were implanted outside the tumor to avoid tumor cell spread. Previously,
we reported on the reduction of breathing motion by abdominal compression for
the same patient group [149]. That report also included further treatment details.
The same patient numbers were used to link treatment details.
7.2.2 Fluoroscopy
Fluoroscopic digital videos were acquired with a conventional simulator (Simulix,
Nucletron B.V., Veenendaal, The Netherlands) on the planning day (the day on
which treatment planning CT scans were acquired) and before each treatment
fraction was delivered. The time between the first treatment fraction and the
planning day was typically 2 weeks.
On the planning day, the patient position in the SBF and the SBF position
relative to the simulator were established. The patient position was marked by
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placing skin marks (tattoos) on the chest and legs at the spots indicated by the
SBF’s positioning lasers. The SBF position in the simulator room was selected
such that the fiducial markers were near the simulator’s isocenter. Room lasers
were used to record the SBF position in stereotactic coordinates and to convert
retrospectively the stereotactic coordinates of the treatment plan isocenter into
the coordinate space of the simulator’s isocenter. On the following treatment days,
the patient position in the SBF and the SBF position relative to the simulator
were reproduced.
Videos were acquired for treatment compression level and free breathing
(without compression) that contained the trajectory of markers during at least
four cycles of respiration. Patients were asked to breathe regularly and to
avoid deep inhalations and exhalations, as during treatment. Frontal and lateral
exposures were recorded consecutively.
The influence of a temporary release of compression (occasionally applied
after CT scanning to increase patient comfort) was measured in a pair of frontal
videos. These videos were acquired at treatment compression level, one before
compression was released and one after compression was reestablished. To release
compression, we retracted the screw by 8 mm, which had a substantial impact on
the patient’s breathing comfort.
7.2.3 Measuring positions of fiducial markers, bony anatomy
and diaphragm
An application was developed using MATLAB software (MathWorks, Natick, MA,
USA) to automatically detect fiducial marker positions in each video frame [149].
It provides the marker positions in two-dimensional (2D) coordinates, which have
their origin on the simulator’s isocenter. The size of pixels in a video frame
limited the spatial resolution of measurement to ≈0.3 mm at isocenter level.
In each video, we typically identified four to five frames that corresponded to
end-expiration (where markers appeared most cranial during a respiratory cycle).
End-expiration was most suitable for observing day-to-day changes, as it provided
the most reproducible marker positions during respiratory cycles. The mean
exhalation position of each marker was calculated from the set of frames. Finally,
3D exhalation positions were derived by combining pairs of 2D coordinates from
frontal and lateral videos while accounting for beam geometry.
The impact of a compression release was measured in frontal videos. Original
marker coordinates (isocenter plane) were multiplied with a scaling factor to
calculate their off-plane coordinates. The scaling factor was determined from the
average anteroposterior (AP) marker position in a lateral video that was acquired
at another moment during the same session, using the same compression level.
The CC position of the tip of the diaphragm dome was identified in lateral
videos (identification in frontal videos was cumbersome due to saturated pixels in
the region of interest). The mean exhalation position was determined from the
selection of most cranial positions per breathing cycle. Vertebral bodies (bony
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anatomy) were identified in both frontal and lateral videos. From each video an
average image was created by averaging the gray values per pixel over all frames.
Landmarks were then used to identify the vertebral bodies located close to the
liver in these images. Positions were scaled for the isocenter offset, using the
method described above to correct 2D marker positions.
7.2.4 Definitions
Figure 7.1 shows the definitions used to describe day-to-day changes in position
and orientation of marker groups and of individual markers. For each patient,
markers were numbered from the most cranial toward the most caudal. Unless
stated otherwise, measurements reported are relative to those of the planning day
configuration.
transformation
translation and rotation
g + h + k x 100% = transformation residual
b + e + f
a - b = inter-marker motion (1,3)
m
m - n = marker-to-COM motion (1)c = marker group displacement (P,T)
p1
tCOM
pCOM
t1
p2 , t2
p3 , t3
a
b
c
b
e
f
h
g
k
pCOM , t'COM                                 
t'2
p2
p3
t'1
t'3
p1
n
Figure 7.1: Two-dimensional example of marker group displacement, intermarker
motion, marker-to-COM motion, and transformation residual. Shown is a fiducial
marker group and corresponding COM at planning (p1, p2, p3, pCOM , circles and solid
line) and treatment (t1, t2, t3, tCOM , pluses and dashed line), before (left) and after
(right) transformation (a prime mark [ ′ ] identifies transformed marker positions). Left
panel, a simple deformation from planning to treatment is illustrated by moving marker 1
(p1 toward t1). Right panel, the transformation minimized the distances (g, h, k) between
corresponding pairs (p1, t′1), (p2, t′2), and (p3, t′3).
Let P = {pi|i = 1, 2, 3} and T = {ti|i = 1, 2, 3} be the sets of planning
and treatment marker positions, respectively. The intermarker motion between a
pair of markers, and from planning to treatment, is
inter-marker motion = d(ti, tj)− d(pi, dj) (7.1)
where i 6= j, and d is the distance. Intermarker motion was also expressed as a
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fraction of the original distance between markers on the planning day, as follows:
proportional inter-marker motion = d(ti, tj)− d(pi, dj)
d(pi, pj)
· 100% (7.2)
The marker-to-COMmotion of individual markers, from planning to treatment
is, as follows:
marker-to-COM motion(i) = d(ti, tCOM )− d(pi, pCOM ) (7.3)
where tCOM and pCOM are the COM positions of the marker group on treatment
and planning.
The day-to-day displacements and rotations of a marker group were deter-
mined using a rigid transformation (ITK software library [www.itk.org]). The
transformation (global translation and rotation of a treatment marker group
towards the planning group) minimized the distances between corresponding
markers (example shown in Fig. 7.1). The translation results in overlapping
COM, as follows:
marker group displacement(P, T ) = tCOM − pCOM (7.4)
The rotation of this transformation is centered on the COM. The rotation
matrix resulting from the transformation was converted into the primary rotations
Ψ, Φ and θ, along three fixed Cartesian axes in the order X, Y, Z (left-right
[LR], CC, and AP, or pitch, roll, and yaw) in the right-handed coordinate
system, complying with the International Electrotechnical Commission (IEC)
standard EN61217 (www.iec.ch). For this purpose we implemented the algorithm
described in [63]. Internal daily changes in the marker group preclude a perfect
fit between registered markers in transformation. To describe the goodness of fit
by transformation, the transformation residual was introduced by:
transformation residual =
∑3
i=1 d(t′i, pi)∑2
i=1
∑3
j=i+1 d(pi, pj)
· 100% (7.5)
which describes the sum of residual distances between the transformed
treatment marker position t′i and its corresponding planning position pi as
a fraction of the sum of intermarker distances on planning. Note that a
transformation residual of 0 indicates a perfect overlap of registered markers.
For convenience, all fractions were presented as percentages, although results of
>100% are theoretically possible.
7.2.5 Data analyses
First, we hypothesized a situation where the observed markers closely surrounded
the tumor tissue to study the potentials of marker guidance under ideal circum-
stances. A marker-guided treatment that tracks day-to-day tumor displacements
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by COM displacements of a surrounding marker group (Eq. 7.4) was investigated.
When marker-to-tissue migration is excluded, internal motion of a marker group
infers tumor deformation, which may impair tumor coverage in the marker-
guided treatment. To estimate safety margins that, when uniformly applied,
would compensate for coverage errors, we assessed the maximum marker-to-COM
motion (Eq. 7.3) per session. The impact of abdominal compression on internal
motion was analyzed by comparing intermarker motion (Eq. 7.1) measured on
free breathing and compression for each marker pair in each patient, using a paired
sample t-test.
The errors introduced by marker-to-COM motion were compared with the set-
up errors of conventional treatment set-up strategies. For the latter, we simulated
conventional set-up strategies and measured the day-to-day marker group COM
displacements with respect to the planning session. Considering markers as ideal
surrogates, these displacements equal the set-up errors that marker guidance
would inherently cancel. In the no-correction strategy, the SBF was positioned
according to the treatment plan, and the crude marker group displacement(P, T)
was assessed. We simulated online corrective strategies using CC registration
of the diaphragm tip and 3D registration of bony anatomy, between treatment
and planning. The displacements were determined by registering the structures’
landmarks put in the treatment and corresponding planning images. The
diaphragm and bony displacements were subtracted from the crude marker group
displacements to obtain the residual set-up errors.
Displacements were summarized by calculating the random (σ) and systematic
(Σ) errors (standard deviations) for the patient group in each direction. The
mean displacements per patient and the overall patient group mean (M) were
calculated. The systematic error SD (Σ) was estimated by correcting the standard
deviation of the mean displacements per patient for small-sample bias [120].
Rotations of marker groups were treated similarly. Additionally, the norm of
the 3D displacement vector was determined as well as its random and systematic
components (since the norm of each displacement is always positive, statistics are
not comparable to those of a single direction).
Displacements and rotations resulting from a temporary abdominal compres-
sion release were determined by transformation of a marker groups’ positions
before the compression release and after its reestablishment. Using frontal videos,
we analyzed CC and LR displacements and rotations around the AP axis. The
random and systematic error components were calculated relative to the position
and orientation before compression release.
The impact of guiding tumor radiation set-up based on markers implanted
at a distance from the tumor was investigated by measuring deformations and
rotations in marker groups and by deducing tumor set-up errors that might
result (see section 7.4). The analysis was performed on a patient-by-patient
basis to present systematic components and to distinguish between the causes of
transformation-determined rotations. Global or ‘real’ rotations were distinguished
from ‘apparent’ rotations that resulted from deformations within a marker group.
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The transformation residual (Eq. 7.5) was calculated to analyze the goodness
of fit by rotation. Proportional intermarker motion (Eq.7.2) was calculated to
analyze deformation in a marker group independent of the actual distance between
markers.
MATLAB’s Statistics Toolbox software (MathWorks, Natick, MA, USA) was
used for hypothesis testing. An α significance level of 0.05 was selected.
7.3 Results
Table 7.1 provides details per patient, like the distance between markers and the
distance of the marker group COM to the treatment isocenter. Since the treatment
isocenter was always located in the tumor (for single lesion treatments), the latter
indicates the distance between the real tumor location and the implanted markers.
Furthermore, an overview of the structures and markers observable during the
video recording sessions is provided to check availability of data.
7.3.1 The motion of markers within a marker group
Figure 7.2 shows the absolute values of maximum marker-to-COM motion,
observed for each patient over the treatment course, given in a cumulative
frequency distribution. The patient group random and systematic components
of maximum marker-to-COM motion were σ = 1.0 mm and Σ = 0.6 mm for
compression and σ = 0.9 mm and Σ = 0.4 mm for free breathing. In the ideal case
that the markers would have closely surrounded a spherical tumor, a 2.1 mm safety
margin would have compensated for the observed deformation in all patients.
Intermarker motion is plotted pairwise for compression and free breathing in
Fig. 7.3, showing data for all patients, marker pairs, and sessions. No systematic
differences in intermarker motion between compression and free breathing were
found (paired t-test, p = 0.26). Outlying scores were observed in patient 4,
showing that compression systematically increased the distance between markers
1 and 3 during treatment sessions.
7.3.2 Day-to-day displacements
The patient group sample statistics for displacements are listed in Table 7.2. The
residual displacements of marker groups (the set-up errors if markers were ideal
surrogates) resulting from the simulation of conventional set-up strategies are
shown in Fig. 7.4. For each set-up strategy, all available data (Table 7.1) are
entered.
Figure 7.5 shows the crude marker group COM, diaphragm, and bony anatomy
displacements measured concurrently in the fluoroscopic videos. Correlation
between bony and marker displacements was generally poor: CC r2 = 0.40;
LR r2 of <0.01; AP r2 = 0.01. Correlation between diaphragm and marker
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Figure 7.2: Marker-to-COM motion. Shown is the maximum marker-to-COM motion
in absolute values observed in each treatment session for all patients for compression
and free breathing measurements (see example shown in Fig. 7.1).
6
4
2
0
-2
-4
-6
-6       -4      -2       0       2        4       6 
free-breathingshrinkage extension
com
pression
extension
shrinkage
inter-marker motion (mm)
in
te
r-
m
ar
ke
r 
m
ot
io
n 
(m
m
)
Figure 7.3: Intermarker motion: free breathing versus abdominal compression. Shown
for all patients and treatment sessions is the intermarker motion (example shown in Fig.
7.1) of marker pairs measured on abdominal compression and free breathing during the
same session. Line at 45o indicates zero difference. Circles mark outlying observations
of marker pair (1,3) of patient 4.
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Table 7.2: Systematic and random variations of fiducial marker group, diaphragm tip,
and bony anatomy*
surrogate σ  shift (mm)  M shift (mm)  Σ  shift (mm) 
 CC LR AP norm  CC LR AP norm  CC LR AP norm 
marker group               
  no correction 2.8 1.7 2.0 2.4  -1.9 -0.5 -0.5 6.3  4.2† 2.6† 3.0 2.0 
  diaphragm tip reg. 1.2     -2.2     3.0†    
  bony reg. 2.2 3.2‡ 1.4 2.8  -2.6 0.7 -0.3 6.7  2.9 4.1 4.1† 2.0 
diaphragm tip 2.6§     0.6     5.1†    
bony 2.5 2.7 1.2 2.0  0.7 -1.2 -0.5 5.9  4.2†  2.1† 2.2 
 σ  rotations (°)  M rotations (°)  Σ  rotations (°) 
 Φ  Ψ  θ    Φ  Ψ  θ    Φ  Ψ  θ   
marker group 1.2 0.9 1.5   0.1 -0.7 0.8   1.6 3.7* 2.4*  
Abbreviations: CC = cranial-caudal, LR = left-right, AP = anterior-posterior, σ  = 
random error, Σ  = systematic error, M = mean over the treatment session means 
(m), reg. = registration.  
* Observations were measured as deviations from the planning session during  
 abdominal compression. Rotations were calculated in the order: Ψ , Φ , θ . 
† p < 0.05, F-test, null-hypothesis (H0): Σ=σ .  
‡ p < 0.05, F-test, H0: σ bony reg. = σ no correction.  
§ p > 0.05, F-test, H0: σ diaphragm tip reg. = σ no correction. 
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Figure 7.4: Residual displacement of marker group COM (absolute value relative to
the planning position) resulting from simulation of conventional set-up methods.
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CC displacements was r2 = 0.76. Using regression analysis, we tested the
null hypothesis that the diaphragm/bony displacements equal the marker dis-
placements (slope = 1). Only in the CC direction were the hypotheses not
rejected (diaphragm displacement, p = 0.20 CC; bony displacement, p = 0.10 CC,
p < 0.001 LR, p = 0.03 AP), indicating that CC registration of bony anatomy
or the diaphragm would, on average, have reduced set-up errors in comparison
with an uncorrected set-up, as Fig. 7.4 confirms. Bony registration resuted in
a significanty greater random component of set-up errors in the LR direction
(F-test p = 0.001) than that of the uncorrected set-up. No other significant
differences were found between the protocols’ set-up errors in either the random
or the systematic components (Table 7.2).
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7.3.3 Changes resulting from a temporary release in abdominal
compression
The displacement of marker groups due to a temporary release are summarized
in Fig. 7.6. The sample statistics are entered in Table 7.3. The largest rotation
observed was θ = 4.9o.
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Figure 7.6: Marker group COM displacements (absolute values) resulting from a
temporary compression release.
Table 7.3: Systematic and random variations of fiducial marker groups due to a
temporary abdominal compression release
 σ   M  Σ  
shifts (mm) / rotation (°) CC LR θ   CC LR θ   CC LR θ  
marker group 1.5 0.8 1.4  0.3 -0.1 0.4  0.4 0.0 0.5 
Abbreviations as in Table 7.2 
 
7.3.4 Day-to-day marker group rotations and proportional
intermarker motion
Figures 7.7 and 7.8 show per patient the day-to-day rotations of marker groups,
the proportional intermarker motion, and the transformation residual measured
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over the course of the treatment. No graphs were entered for patients 1 and 9,
since no 3D rotation could be calculated using two markers (Table 7.1).
7.4 Discussion
The potential of guiding liver tumor radiation set-up based on fiducial markers lies
in the achievable set-up precision and the short delay between determining set-
up corrections and delivering dose. If markers would have closely surrounded
spherical tumors, safety margins of ≈2 mm would have compensated for the
observed errors of deformation in a marker-guided tumor set-up procedure
(marker-to-COM motion of σ = 0.9 mm and Σ = 0.4 mm). Moreover, no
other set-up method simulated (uncorrected frame-based set-up, bony anatomy
and diaphragm tip CC registration) achieved comparable residual set-up errors
for this patient group (1.4 mm < σ < 2.8 mm; 2.6 mm < Σ < 5.1 mm;
6.3 mm < max < 12.4 mm, using marker COM as the gold standard).
The management of long-term tumor motion presents one of the major
problems in liver SBRT and has been the topic of various investigations
[38, 52, 54, 55, 151]. In a treatment setting comparable to ours, Hansen et
al. [54] measured day-to-day tumor displacements in daily CT scans. The SDs
of random errors were 3.6 mm CC, 2.4 mm LR, 2.6 mm AP for uncorrected
set-up, and 3.3 mm, CC, 2.3 mm LR, 2.5 mm AP for using bony anatomy
as a surrogate. Our results are in agreement with those findings, as errors
distribute similarly over directions (compare with Table 7.2). The slightly
larger magnitudes they presented may be explained by measurement errors
introduced by using CT (see below). Furthermore, we found that bony anatomy
registration resulted in significantly greater random errors in the LR direction
than the uncorrected set-up. Nevertheless, we support their assertion that the
widely used 5 mm axial/10 mm CC margins generally result in poor tumor
coverage in spine-based and uncorrected frame-based set-up approaches (Fig. 7.4).
We additionally showed that even diaphragm registration occasionally provided
inaccurate CC set-up measures, despite the average reduction in CC errors
compared to uncorrected set-up. In two patients who had markers implanted
≈10 cm from the diaphragm tip, this registration resulted in set-up errors (using
marker COM as the gold standard) of between 3.5 mm and 9.4 mm. Diaphragm-
based methods [52, 55] should therefore be approached with care. Surprisingly, we
found larger systematic than random displacements (5 out of 8 significant [Table
7.2]). Apparently anatomical changes are more prominent between planning and
treatment than between treatment days, and complementing a non-image-guided
method with at least a verification CT on the first treatment day is recommended.
It was recently shown that tumor motion can also occur over shorter periods,
impairing the reliability of image-guided procedures. In compression-supported
SBRT, Guckenberger et al. [52] found drifts of 3.7 ± 2.2 mm during treatment
delivery. In a magnetic resonance imaging (MRI)-based study, von Siebenthal et
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Figure 7.7: Day-to-day marker group rotations, proportional intermarker motion and
transformation residual measured on abdominal compression and free breathing relative
to planning. Patients 2 to 6 are shown. An example is shown in Fig. 7.1.
99
Chapter 7.
Patient:
−20
−15
−10
−5
0
5
10
15
20
di
st
an
ce
 c
ha
ng
e 
 (
%
)
−10
−8
−6
−4
−2
0
2
4
6
8
10
ro
ta
tio
n 
 (
°)
−20
−15
−10
−5
0
5
10
15
20
di
st
an
ce
 c
ha
ng
e 
 (
%
)
−10
−8
−6
−4
−2
0
2
4
6
8
10
ro
ta
tio
n 
 (
°)
treatment 
session: 
ab
do
m
in
al
 c
om
pr
es
sio
n
fre
e 
br
ea
th
in
g
marker pair (1,2)           marker pair (2,3)           marker pair (3,1)           transformation residual
distance change
pitch, Ψ roll, φ yaw, θ
rotation
1 2 3
7
1 2 3
8
1 2 3
10 11
1 2 3 4
 
1 2 3
12
Figure 7.8: As shown in Fig. 7.7, patients 7 to 12
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al. [137] observed drifts of 2.5 to 5.5 mm over a 10 minute period, increasing
from 3.9 to 15.3 mm over 30 minutes. We found substantial displacements and
rotations due to a temporary release, which were only slightly smaller than day-to-
day changes (Table 7.3). Besides the recommendation not to temporarily release
compression, results show the importance of marker guidance in reducing time
lags between determining set-up corrections and delivering dose.
Limitations for marker guidance arise when markers cannot be ideally
implanted. To avoid the spread of tumor cells, markers are not implanted
inside but near and preferably surrounding the tumor. However, many factors
may hinder ideal implantation: tumor location (e.g., near portal veins or liver
boundary), needle insertion directions, visibility on ultrasound or CT, and the
presence of multiple tumors (6 out of 12 patients in our study). The patients
in this study received radiotherapy because the location of the tumors did not
permit other treatments, explaining the large distances between the treatment
isocenter (indicating the tumor position) and the marker group COM (between
36.7 mm and 103.0 mm [Table 7.1]). Under these circumstances, a marker-guided
and translation-based set-up is accurate only if the liver acts like a rigid and
nonrotating body.
Our study, however, shows that the magnitudes of day-to-day deformations
and rotations of marker groups varied considerably among patients (Fig. 7.7
and 7.8). On compression, we measured relatively small rotations (<2.4o) and
transformation residuals (<2.2%) for patients 2, 8, and 10, over the complete
treatment course. For these patients, translation-based marker guidance would
probably have provided accurate tumor radiation set-up. For patients 3, 5, and 11,
on the other hand, substantial rotations around the marker group COM (between
3.5o and 7.2o, second session) were necessary to establish a similar fit, most likely
caused by a tissue rotation that spanned at least the region of the marker group.
Assuming, for example, a 5 cm separation between the tumor and the marker
group COM, these rotations would, in the absence of deformation, result in tumor
displacements of 3.1 mm to 6.3 mm, as was calculated using the law of cosines.
Such displacements induce tumor set-up errors in translation-based marker
guidance, unless rotations are explicitly accounted for. Even when accounting for
rotations, set-up can be misguided, as intermarker motion sometimes resulted in
substantial apparent rotations, while actually the fit was poor due to deformation
(patients 4 and 6, transformation residuals of >7.6% and >5.5%, rotations of
>4.5o and >8.2o, respectively). To summarize, calculated rotations may originate
from tissue rotations as well as from local deformations (an example is given in
Fig. 7.1), which cannot be clearly distinguished. Consequently, the possibilities
of correcting set-up for rotations are limited. Also, deformation by itself can
misguide the set-up if it changed the distance between the markers and the tumor.
Overall shrinkage and enlargement of the marker groups were observed for patients
12 (session 2 and 3) and patients 5 and 7. Proportional intermarker motion for
all patients was <16.7% and 2.2% median. Over a 5 cm distance of uniformly
stretching or shrinking tissue, for example, these deformations could lead to errors
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of <8.4 mm and 1.1 mm median. Therefore, at a COM–tumor distance of only
5 cm, set-up errors caused by rotations and deformations could become as large as
errors in conventional set-up approaches. Problems are not unique to compression-
supported SBRT, as we found that compression did not systematically contribute
to intermarker motion (Fig. 7.3), and similar rotation and deformations were
observed for free breathing (Fig. 7.7 and 7.8). Therefore, other marker-guided
treatments, like those on a robotic LINAC (Cyberknife), are also affected [87]. If
markers cannot be precisely placed, marker-guided treatments require additional
image guidance or otherwise extra safety margins.
By using markers to study day-to-day motion, we avoided most measurement
errors involved in CT-based studies, such as reconstruction artifacts due to
residual organ motion, delineation uncertainty, and the impossibility of char-
acterizing dynamic respiration by a momentary acquisition (even for breath
hold). By averaging exhale positions (>4 breathing cycles during continuous
breathing), accurate measures were acquired. Similar to CT studies, the day-
to-day displacements measured are affected by inaccuracies in SBF alignments
(SD ≈ 0.7 mm). Another limitation of this study is that maker-to-tissue
migration could not be distinguished from deformation, as no breathhold CT scans
were available. Marker-to-tissue migration may partially explain the systematic
intermarker motion we observed.
To exploit the benefits of a marker guidance as a routine practice, a tumor
margin recipe should be derived that compensates residual set-up errors of marker
guidance and tumor drifts. This would require an analysis of the variability
between tumor and marker positions in a larger group of patients, which could for
example be measured using a set of breathhold CT/MRI scans. The advantages
of using markers in combination with a treatment cone beam/in-room CT may
be explored to improve marker guidance and dose to organs at risk.
7.5 Conclusions
If markers can be implanted near and around the tumor, residual set-up errors
by marker guidance are small compared to those of conventional set-up methods.
A high-precision tumor set-up can be established shortly before dose delivery,
which minimizes the impact of tumor drifts. If markers cannot be implanted
surrounding the tumor, marker guidance may induce set-up errors comparable
to or greater than those of conventional set-up methods, as substantial rotations
and deformations in marker groups were observed. SBRT treatments without
abdominal compression (e.g., using robotic linac, breath hold, or gating) are
equally affected, as abdominal compression did not systematically contribute
to deformations and rotations. Before tumor set-up can be safely guided on
marker positions, additional evidence is required for the geometric relationship
between marker and tumor positions, which will allow the design of adequate
safety margins.
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Treatment Precision of Image-Guided Liver SBRT Using
Implanted Fiducial Markers Depends on Marker-Tumour
Distance
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Abstract
Purpose: To assess the accuracy of day-to-day predictions of liver tumour
position using implanted gold markers as surrogates and to compare with other
set-up strategies.
Patients and Methods: Twenty patients undergoing Stereotactic Body Ra-
diation Therapy with abdominal compression for primary or metastatic liver
cancer were analyzed. We retrospectively determined the 3D correlation between
gold marker positions and tumour in contrast-enhanced CT-scans acquired at
treatment preparation and before each treatment session. Prediction of tumour
position was based on individual markers as well as marker groups and compared
to the real position of the tumour. Marker-guidance was compared to other set-
up strategies/surrogates i.e. no correction, vertebrae and 3D diaphragm-based
set-up.
Results: The distance between gold markers and the center of the tumour varied
between 5 and 96 mm. Marker-guidance was superior to guiding treatment using
other surrogates, although both the random and systematic components of the
prediction error SD depended on the tumour-marker distance. For a marker-
tumour distance of 4 cm, we observed σ=1.3 mm and Σ=1.6 mm. The 3D position
of the diaphragm dome was the second best predictor.
Conclusions: The tumour position can be predicted accurately using implanted
markers, but marker-guided set-up accuracy decreases with increasing distance
between implanted markers and the tumour.
Accuracy of marker guidance
8.1 Introduction
Image guided radiotherapy techniques often rely on implanted fiducial markers,
assuming that the position of these markers is representative for the position
of the tumour from the preparation phase to the completion of the treatment.
Little is known about the day-to-day stability of the correlation between positions
of fiducial markers and the tumour volume in liver tissue, as the tumour is
neither visible on fluoroscopic/EPID (Electronic Portal Imaging Device) images,
nor on (cone-beam) CT-scans acquired without contrast [44]. This complicates
verification of the marker-tumour relation in liver, as opposed to e.g. a solid
tumour in the lung, for which the marker-tumour relation can be checked using
fluoroscopic images or EPID.
Preferentially, fiducial markers are placed around the tumour, but implanta-
tion should not induce tumour cell spread [19, 84] or bleeding by perforation of
major vessels. Moreover, some tumours can only be approached from a limited
number of directions, mainly frontal-lateral. Therefore markers in liver can not
always be placed close to the tumour.
Deformations or rotations may induce changes in marker groups, that do
not necessarily correlate with displacements in distant liver tissue containing
tumour [150], Chapter 7. Furthermore, it was shown motion may depend on
location in the liver [137, 136]. Especially for markers far away from the tumour,
reduced correlation is more likely, possibly jeopardizing treatment set-up accuracy
if image guided techniques rely on a stable correlation between fiducials and
tumour. According to the authors’ knowledge, the inter-fraction variability of the
correlation between implanted markers and liver tumour position, and the impact
of the distance between markers and tumour have not been investigated before. In
SBRT, where sharp dose gradients and high doses per fraction are achievable with
current planning techniques [35], even small geometric errors in a single fraction
can be dosimetrically relevant [25, 93] and therefore a good correlation between
tumour position and the surrogate that is used for image guidance is important.
In our current practice, the tumour position is determined before each
fraction using contrast enhanced exhale breath-hold CT-scans. This rather time
consuming procedure increases the risk of tumour movement between scanning
and dose delivery. We therefore investigate methods for speeding up the image
guidance procedure, with marker guidance being one of the options. Moreover,
to date some other treatment techniques already fully rely on the use of fiducial
markers as surrogates (e.g. those with a robotic tracking unit, CyberKnife), while
the accuracy of markers as surrogates is not sufficiently investigated yet.
We investigated the correlation between fiducial marker positions and the
position of the tumour by analyzing contrast enhanced exhale repeat CT-scans of
20 patients, acquired in exhale breath-hold at treatment preparation and before
each treatment session. Tumour set-up errors were simulated for a marker-guided
treatment. For comparison, residual set-up errors were likewise calculated for
conventional set-up methods using stereotactic frame-based set-up using fixed
105
Chapter 8.
coordinates (= no correction), bony anatomy registration and 3D diaphragm dome
registration.
8.2 Methods and materials
8.2.1 Patients
Twenty patients, treated by stereotactic body radiotherapy (SBRT) for hepatocel-
lular carcinoma or metastasis [91] using a stereotactic body frame with abdominal
compression (SBF; Elekta Instrument AB, Stockholm, Sweden) were included
in this study (Table 8.1). Generally, three fiducial markers (gold seeds, 5 mm
long and 1 mm diameter) were implanted percutaneously in liver tissue under
ultrasound or CT-guidance, ≥1 week before acquiring the planning CT-scan.
Table 8.1: Patient information. Dose prescription is at 65% isodose level for patients
before 2009 and at 67% for recently treated patients. In the case of presence of 5 markers,
2 were placed during previous surgical treatments for other reasons than tumour area
localization.
pt gender age 
(y) 
tumour type liver 
segment 
prescribed 
dose 
distance marker-tumor  
per marker (cm) 
1 f 68 colorectal metastasis 8 3x15 2.5, 4.7 
2 f 72 colorectal metastasis 8 3x12.5 6.1, 6.6, 7.5 
3 f 48 hepatocellular carcinoma 4 3x15 1.9, 3.6 
4 m 79 colorectal metastasis 5 3x12.5 3.0, 3.0 
5 m 63 colorectal metastasis 8 3x12.5 3.9, 4.3 
6 f 78 colorectal metastasis 8 3x15 3.1, 3.4, 3.5 
7 f 71 colorectal metastasis 8 3x12.5 0.5, 4, 4.3, 4.6, 5 
8 f 75 hepatocellular carcinoma 1 6x8 3.5 
9 f 62 colorectal metastasis 8 3x16.75 3.9 
10 m 69 colorectal metastasis 7 6x8 0.5, 0.5, 8.8, 9.0, 6.9 
11 m 61 colorectal metastasis 8 3x12.5 7.6, 8.8 
12 m 67 colorectal metastasis 5 3x12.5 2.1, 2.2, 5.2 
13 f 65 colorectal metastasis 1 3x15 2.0, 3.8, 4.5 
14 f 70 colorectal metastasis 8 3x12.5 1.1, 2.1, 7 
15 m 65 colorectal metastasis 7-8 3x16.75 1.4, 2.2, 4.5 
16 m 71 colorectal metastasis 8 3x12.5 3.8, 5.7, 6.1 
17 m 64 colorectal metastasis 7-8 3x16.75 1.9, 2.2, 2.2, 4.4, 4.9 
18 f 35 colorectal metastasis 2-3 3x16.75 1.9, 3.1, 3.4 
19 m 75 colorectal metastasis 5 3x12.5 0.6, 2.7 
20 f 79 cholangiocarcinoma 8-4a 6x7.5 3.9, 4.0, 5.9 
Abbreviation: pt = patient number. 
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8.2.2 Current procedure
In our current clinical procedure, implanted markers are only used to establish
an adequate compression level in a pre-treatment fluoroscopy session as described
by [149]. Individualized margins are determined, based on the residual marker
excursions in three directions. There is no need for fluoroscopy prior to each
treatment fraction, as the day-to-day respiratory tumour motion reproduces to a
high extent [149, 17].
For each patient, the tumour position for treatment planning was determined
by a contrast-enhanced exhale breath-hold CT-scan that was matched to the
planning-CT (also exhale breath-hold) so that the radiation oncologist could
delineate the tumour on the fused scans. The interval between the first treatment
fraction and planning-CT was one to two weeks. Just prior to each treatment
fraction, a new contrast-enhanced exhale breath-hold CT-scan was acquired and
registered to the planning-CT scan with the SBF as a reference. The actual daily
position of the tumour, in the SBF was then established in a second registration
performed by the treating physician. A third registration was performed to
establish the shift of a vertebral bodies close to the tumour. The new frame
co-ordinates for correctly positioning the tumour in the linac isocenter were then
calculated and used for patient set-up of that day.
8.2.3 The stability of day-to-day marker-tumour correlation
For all patients, the tumours visualized in the repeat-CT scans acquired
before dose delivery were manually matched (3D grey-value to contour match,
translations only) to the planning-CT (Figure 8.1), using FocalSim (Version 4.3.3,
CMS Software Inc., Maryland Heights, USA), representing the ground truth
for tumour position in this analysis. Similar procedures were then applied for
various surrogates using gray value matching, i.e. 1) each individual marker, 2)
vertebral bodies close to the tumour, 3) the frame (by using the radio-opaque
line indicators) and 4) the diaphragm dome. The difference between the match
vector of each surrogate and the match vector of the tumour for that day was
calculated. For a perfect surrogate, the difference between the match vectors
should be (0, 0, 0). Otherwise, the difference indicates the tumour set-up error
vector for image guidance based on that particular surrogate with components in
LR, SI and AP directions. 3D marker-tumour and diaphragm-tumour distances
were measured in the planning-CT to investigate distance dependency of set-up
errors.
Tumour positions were also predicted by using combinations of all implanted
markers in a patient. In the first approach, shifts (translations) of the marker
the center of mass (COM) were investigated. Secondly, global translational
and rotational marker group transformations were derived by minimizing the
distances between corresponding treatment- and planning marker positions.
The resulting transformation was then applied to the planning tumour center
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frame mismatch
in AP direction
tumor matched
to delineation
vertebrae mismatch
in AP direction
lateral image
axial image
marker
marker mismatch
in CC and AP direction
++
Figure 8.1: A planning CT (gray scale) and a fraction CT (superimposed) after
registration of the tumour. Dashed arrow in lateral image: tumour-marker distance,
dotted arrow: tumour-diaphragm distance (measured in 3D). Example of mismatches of
the stereotactic body frame, vertebra and implanted marker after tumour registration are
indicated.
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position to predict the treatment tumour position. For all treatment sessions
the transformation residual was calculated to determine the goodness-of-fit of
the marker transformation [150], Chapter 7. This value can be used to detect
cases of marker migration of gross deformation. The equation was extended
for an arbitrary number of markers. If pi is the position (frame-coordinates) of
marker i in a planning-CT, and if the corresponding position ti in a frame-matched
treatment CT-scan results in position t′i after transformation, the transformation
residual is
transformation residual =
(
K
2
) K∑
i=1
∣∣∣−−→t′ipi∣∣∣
K
K−1∑
i=1
K∑
j=i+1
|−−→pipj |
· 100%, (8.1)
where K is the number of markers in a patient. A large transformation residual
indicates a poor fit, (i.e. if marker configuration changed due to migration or
tissue deformation) obscuring rotations, whereas a value 0 indicates a perfect
overlap between all corresponding markers in a marker group.
8.2.4 Tumour registration uncertainty
The registration of a tumour visualized in the treatment CT scan and its
delineation in the planning CT scan, is limited in precision, owing to delineation
inaccuracies and limitations to the enhancement of tumour visualization in
the treatment CT scans. Consequently, the displacements derived from this
registration (the ground truth for all performed analyses) are slightly uncertain.
We investigated this uncertainty in the assumed ground truth. First, the positions
of each marker in the treatment scans were predicted based on registrations of
other markers in the same patient (performing one registration per each available
other marker). As markers were clearly visible in CT scans, this registration
could be performed very accurately, and errors in these predictions were primarily
contributed by day-to-day deformations and rotations in the liver tissue. Second,
we compared these prediction errors with those obtained from with predicting a
tumor position from a marker position. The difference in predictive quality is
the uncertainty in the tumor registration. More specifically, the variance of the
marker-marker prediction errors was subtracted from the variance of the marker-
tumor prediction error (as a function of distance, see section 8.2.5) to obtain the
estimate of the variance of tumor registration uncertainty.
8.2.5 Data analysis
For all surrogates, residual tumour set-up error vectors were reported using
their (signed) directional components (LR, SI, AP), and their lengths (norms).
Standard deviations (SDs) of random (σ) and systematic (Σ) errors were
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calculated from the directional error components, and from the set-up error
vectors. The methods that are mentioned briefly in the paragraph below are
described in more detail in Chapter 9.
From the literature [31, 121] it is known that the distribution variance of
random and systematic set-up errors calculated from data of a treatment with a
specific number of fractions (the effective values, σ2eff and Σ2eff) differ from the
variance of the population distribution from which they were sampled, σ2 and
Σ2). Consequentially, the effective values of σ and Σ as usually reported in the
literature are not valid for treatments of a similar patient population with an
alternative number of fractions. In this study, we reported the population SDs (σ
and Σ), which were calculated from the effective values σ2eff and Σ2eff, (in Chapter
9 we presented the estimators for the effective values). The variance of effective
random errors for patients p were converted according to:
σˆ2p =
F
(F − 1) σˆ
2
eff,p forp = 1, . . . , P (8.2)
with F the number of fractions, see Chapter 9. By averaging the individual
estimates, we obtained the overall estimate of the random error population
variance,
σˆ2 = 1
P
P∑
p=1
σˆ2p. (8.3)
The variance of systematic errors was calculated according to
Σˆ2 = Σˆ2eff −
σˆ2
F
. (8.4)
In Chapter 9 we developed a method to estimate the relation between variances
of set-up errors and an exogenous variable, to correlate the distance (r) between
the surrogate (marker or diaphragm) and the tumour to the treatment set-up
accuracy. The variance estimates of random and systematic errors were described
according to the linear models,
σˆ2(r) = αˆ+ βˆr (8.5)
and
Σ(r)2 = γˆ · σˆ2(r). (8.6)
The hypothesis β = 0 (no distance dependency) was tested for significance in
a Breusch-Pagan parametric test (equation 9.34, Chapter 9). Differences between
different set-up strategies were tested using a two tailed paired t-test. Matlab’s
Statistics Toolbox (MathWorks, Natick, MA, USA) was used for hypothesis
testing. Statistical significance was assumed if p ≤ 0.05.
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8.3 Results
The distance between gold markers and tumour centers varied between 5 and
96 mm. Errors in predicted tumour position resulting from set-up corrections
based on single markers are plotted in Figure 8.2. Marker-guided set-up accuracy
decreases significantly (p < 0.001, Table 8.2) with increasing distance between
implanted marker and tumour. For the diaphragm dome as a predictor, we did
not observe a significant correlation (p = 0.62) with the distance to the tumour
(Figure 8.2, Table 8.2).
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Figure 8.2: Binned averaged residual set-up error vector lengths (a, b) and σeff (c,
d). Prediction of tumour position based on individual marker positions (a, b, solid
line), prediction of marker position based on every other marker (a, b, dashed line)
and prediction of tumour position based on diaphragm position (c, d), all as a function
of distance r between the structures. For the markers, a clear distance dependency is
present, while for the diaphragm there is no distance dependency. Error bars represent
1SD of the average in each bin.
In Figure 8.3, systematic and random components of the set-up error SDs are
plotted for different set-up strategies, for markers, as a function of marker-tumour
distance (r). For a marker-tumour distance <8 cm, the systematic error of marker
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Table 8.2: Estimated parameters of models Equations 8.5 and 8.6, describing distance
dependent random and systematic set-up error variances. 3D parameters represent
direction-invariant set-up errors.
 
 
est. parameter tumor-marker marker-marker tumor-COM tumor-diaphragm 
αˆ      
  CC 0.0    
  LR 0.4    
  AP 0.5    
  3D 0.3 0.1 0.5 2.1 
βˆ      
  CC 0.048    
    p-value <0.0001    
  LR 0.034    
    p-value 0.0001    
  AP 0.029    
    p-value 0.0002    
  3D 0.036 0.033 0.05 0.012 
    p-value <0.00001 <0.0001 0.03 0.62 
γˆ      
  CC 1.7    
  LR 1.4    
  AP 1.8    
  3D 1.5 0.9 1.1 1.6 
Abbreviations: est. = estimated, COM = center of mass of the marker group. 
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guided set-up proved to be smaller (in AP and CC) than all other set-up strategies
(Figure 8.4, Table 8.3).
Table 8.3: Significance of one set-up correction strategy compared to others, tested
using a two tailed paired t-test. Best predictor listed in the first column.
set-up strategy 1 set-up strategy 2 p-value 
individual markers frame (no correction) << 0.0001 
individual markers vertebrae << 0.0001 
individual markers diaphragm 0.0050 
vertebrae frame (no correction) 0.0050 
diaphragm frame (no correction) 0.0005 
diaphragm vertebrae 0.0170 
most proximal marker most distal marker 0.0002 
most proximal marker marker group COM, translations only 0.1000 
marker group COM translations only most distal marker 0.0300 
marker group COM translations & rotations marker group COM, translations only 0.6700 
 
The estimated coefficients αˆ, βˆ, γˆ of Eq. 8.2 and 8.3 and the significance
levels of β are given in Table 8.2. There was no significant difference between the
set-up error variances in the 3 directions and therefore the 3 distances could be
combined to obtain more reliable direction-invariant estimations of set-up errors
SDs (Table 8.4), for which we used the method developed in Chapter 9.
Distance dependency was also present in tumour position prediction using the
marker group COMs (Table 8.3). The distance between the marker group COM
and tumour varied between 16 and 82 mm. Tumour position prediction by the
marker group COM resulted in a slightly worse, though not statistically significant
different, prediction error compared to the marker that was positioned nearest
to the tumour. The most distal marker provided a significantly less accurate
prediction (Figure 8.5).
The set-up errors of the two methods described in methods section 2.3 (based
on COM-translation only, and on a transformation including both transformation
and rotation) were pair-wise compared. Inclusion of rotation did not necessarily
improved set-up accuracy. Also no obvious rule of thumb could be derived for
marker patterns with and without a large transformation residual (Figure 8.6).
Overall, prediction of a marker position from another marker position, was
more accurate than prediction of a tumor position from a marker position,
showing a residual uncertainty in tumor registration. The errors showed a nearly
equal trend as a function of distance (Figure 8.2, Table 8.2). A subtraction
of the respective variances, and averaged over a distance range from 2 cm to
10 cm, provided σ = 0.6 mm, Σ = 1.3 mm. These errors can be explained
by limited tumor registration accuracy, but possibly also by differences in liver
density/deformability between normal liver and tumour tissue. If a part of this
difference is indeed related to uncertainties in tumour delineation and matching,
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and SI direction for different surrogates. For the marker based tumour prediction the
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Table 8.4: Values for σ and Σ. The estimated SDs of marker-tumor and marker-marker
predictions are shown for the individual directions and as the 3D direction-invariant
estimate for increasing distance.
 σ  (mm)  Σ  (mm) 
 CC LR AP 3D  CC LR AP 3D 
tumor prediction based on          
  frame (no correction) 2.2 2.2 1.8  3.0 1.4 3.6 
  bony 2.1 1.6 1.4  2.3 1.5 2.9 
  diaphragm 1.6 1.6 1.5  2.3 1.2 2.1 
  marker          
    d = 20 1.1 1.0 1.0 1.0 1.2 1.3 1.3 1.2 
    d = 40 1.3 1.4 1.3 1.3 1.6 1.8 1.7 1.6 
    d = 60 1.6 1.7 1.5 1.6 1.8 2.2 2.0 1.9 
    d = 80 1.8 2.0 1.7 1.8 2.1 2.5 2.2 2.2 
    d = 100 2.0 2.2 1.8 2.0 2.3 2.8 2.4 2.4 
marker prediction based on          
  marker          
    d = 20 1.1 1.0 0.7 0.9 0.5 0.3 1.1 0.8 
    d = 40 1.3 1.4 1.0 1.2 0.6 0.4 1.6 1.1 
    d = 60 1.4 1.7 1.2 1.4 0.7 0.5 1.9 1.3 
    d = 80 1.6 2.0 1.4 1.7 0.8 0.6 2.2 1.5 
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Figure 8.4: Comparison between marker and diaphragm based tumour position
prediction showing the length of set-up error vectors. The diameter of the circles is
proportional to the distance between tumour and marker. Especially for the markers
close to the tumour (smaller circles), the marker prediction is better than diaphragm
prediction.
the real systematic and random set-up error components for using markers as
tumour surrogates could actually be smaller than reported here (Figure 8.3
between grey and black lines).
8.4 Discussion
This is the first study evaluating in detail the inter-fraction accuracy of liver
tumour position prediction by implanted markers as a function of marker-tumour
distance, by analyzing repeat contrast-enhanced CT-scans acquired in a voluntary
exhale breath-hold. We included 20 patients which were evaluated for 3-6 fractions
over the course of radiotherapy.
For implanted markers in liver tissue, both systematic and random components
of the tumour position prediction error variances depended on the tumour-marker
distance. A phenomenon that was noted but not quantified by [87] for patients
with multiple lung lesions.
Despite distance dependency, for a marker-tumour distance <8 cm, the
prediction of tumour position using implanted markers was better than that using
any of the other set-up strategies (no correction, bony anatomy or diaphragm
dome).
In our patient population, marker configurations were always located at one
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Figure 8.5: Comparison of tumor prediction using the nearest and most distal marker
of patients with more than one marker. Shown is the length of set-up error vectors. In
(a) the size of the circle represents the distance between tumor and nearest marker. The
closer the nearest marker is to the tumor (smallest circles), the better the prediction of
this marker. In (b) the circle’s size represents the distance between the nearest and most
distal marker. Especially for the markers that are far apart (larger cicles) the nearest
marker is a better predictor.
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Figure 8.6: Set-up error vector length for prediction of the tumour position using
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translations only (y-axis). The radius of a circle around a data point indicates the
transformation residual (Equation 8.1) as a result of transformation; a smaller circle
indicates less deformation. Data points above the 45-degree line indicate that inclusion of
rotation improved set-up accuracy. Only patients with 3 or more markers were included.
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side of the tumour due to the central location of the tumours in the liver (Figure
8.7): in none of our cases the markers were placed surrounding the tumour. This
means that in theory, because of the distance dependency of the prediction error,
prediction based on marker-group COM is generally worse than that based on
the marker nearest to the tumour. In practice, marker-group COM prediction
showed an almost equal accuracy compared with that of the nearest marker,
indicating that despite the distance dependency, random errors in individual
marker positions were cancelled out with the use of more markers in the prediction.
Including marker group rotations in the tumour position prediction did not
always improve prediction of the tumour position; for marker groups with small
transformation residuals, one would only expect improvement if liver tissue rotates
rigidly. For those cases where it did not, tissue deformation at a larger scale
could have been present. For abovementioned reasons, it is important to try to
implant the markers in close proximity of the tumour. If markers can be implanted
surrounding the tumour, COM based set-up including rotations is a good strategy.
(b)(a)
 
r nearest 
tumor
tumor
r nearest 1
m
1m
2m
2m
3m
3m
r COM  
r COM  
Figure 8.7: (a) Typical marker implant positions relative to the tumour for the studied
liver patients; all markers are at one side of the tumour and dnearest < dCOM . (b) Ideal
implant positions surrounding the tumour with dCOM < dnearest.
To ensure that marker migration or major deformation do not obscure the
match during treatment, the transformation residual (compared to the planning)
should be calculated; if the transformation residual is too large, one can decide
which markers to ignore, re-establish the marker-tumour relation for that day, or
only use the markers that are nearest to the tumour. Checking for outliers using
the transformation residual is required for good practice marker-guidance.
All measurements in this study were done under abdominal compression.
Arguably, this may had influenced the day-to-day liver deformability and limit the
applicability of the study. Wunderink et al. [150], Chapter 7, however, showed
that inter-marker distance variation is similar with and without compression.
Therefore, the results of the current study of equal importance for other marker-
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guided treatment procedures (e.g., liver patients treated with Cyberknife’s
SynchronyTM Respiratory Tracking System, the use of surrogate markers in
beams’ eye view EPID images to track the tumour [6, 5]. All these techniques fully
rely on the reproducibility of the marker-tumour configuration established in the
planning CT scan, as usually no re-imaging before each fraction is performed. An
appropriate margin depending on the marker-tumour distance is recommended
for these treatment modalities.
Some publications report on whole liver position prediction by anatomical
structures (bony anatomy, superficial markings) and present in general residual
errors of 1.5-5 mm SD [18, 139, 58, 2, 38, 153]. Other studies. [3], and [79] describe
the positions of implanted markers in rrelation to the liver itself, but tumour
position was not determined. Lu et al. [87] discussed preliminary data of some
liver patients in which the tumour volume was visualized. They observed larger
deformation of liver tissue due to breathing than for lung tissue. Guckenberger
et al. [52] made in-room contrast-enhanced CT-scans for four liver patients and
compared tumour position with liver contours. They found 5 mm errors in the
SI direction, which they attributed to scan technique artifacts. Both studies did
not report quantitative inter-fraction data.
8.4.1 Conclusions
Marker-guided set-up accuracy decreases with increasing distance between im-
planted marker and tumour. However, implanted markers are superior for
predicting the tumour position compared to other surrogates if implanted
reasonably (<4 cm) close to the tumour. The 3D position of the diaphragm
dome is the second best predictor, showing no distance dependency.
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Abstract
The radiotherapy set-up error paradigm is used for reporting the geographical
accuracy of external beam radiotherapy treatments, by expressing it in terms
of systematic and random error components. The standard deviations (SDs) of
these errors are the key to the design of geometric safety margins for tumour
irradiation. When the estimation of these SDs is based on small data sets (e.g.,
small number of fractions and/or patients), the resulting estimates tend to be
unreliable. For this reason we introduced a method to combine the SDs estimated
in different directions, resulting in a direction-invariant SD estimator. We showed
that under certain conditions, using a direction-invariant estimated SD to design
isotropic margins is more reliable than using direction-specific estimated SDs to
design non-isotropic margins. The paradigm was further extended to model the
influence of an exogenous variable on the variance of set-up errors. A linear
model was applied to estimate the relation between the variance of random errors
and an exogenous variable, and the corresponding estimator for the variance of
systematic errors was derived. Originally, it was developed to model the effect of
the tumour-surrogate distance on the accuracy of a surrogate-guided treatment
set-up procedure. The patient specific value of the exogenous variable can be used
to predict the patient’s individual set-up error SDs, and with that, the CTV-PTV
margin. All methods were validated using computer simulation experiments.
Extension of the set-up error paradigm
9.1 Introduction
The radiotherapy set-up error paradigm for the calculation of systematic and
random error components became the standard for reporting the geographical
accuracy of external beam radiotherapy treatments. The standard deviations
(SDs) of the set-up errors are the key to the design of geometric safety margins
for tumour irradiation [51, 62, 120, 131]. The paradigm classifies set-up errors
into two categories, systematic (treatment preparation) and random (treatment
execution) errors, as introduced by [8], and further explored by [31, 118, 132].
When a patient is positioned on the treatment couch, the tumour should be
aligned with the treatment beams, as defined by the treatment plan. Any offset
from the intended tumour position is considered a treatment set-up error. To
minimize set-up errors in practice, specific image-guided procedures are designed.
Proper CTV-PTV margins for such treatment procedures, can retrospectively be
determined by measuring set-up errors for a limited number of patients, often
using additional imaging (e.g., extra treatment CT-scans). Ideally, variances
of set-up errors are measured and reported in all directions (cranial-caudal,
anterior-posterior and left-right), reflecting the possibly different variability
among directions, and then used for the design of non-isotropic margins. However,
a small data set usually results in insignificant differences between set-up errors
in different directions. Therefore, sometimes the length of the error vectors are
reported, as the errors are assumed to be direction-invariant [39, 150]. The vector
length, however, is not suitable to be used in margin recipes, as for these recipes
SDs of normally distributed errors are required and a vector length cannot be
normally distributed. This paper presents a solution for calculating direction-
invariant set-up error SDs from measured set-up error vectors, by combining the
components into a single estimator. The direction-invariant SDs can be used
for designing isotropic margins if indeed the differences between set-up errors in
different directions are insignificant.
Set-up errors may depend on patient characteristics, expressed in terms of
exogenous variables. For example, if the treatment set-up is guided using a
tumour surrogate, the distance between the surrogate and tumour may determine
how accurate the tumour can actually be targeted. Other exogenous influences
which may impact the set-up accuracy are the patient’s weight, anxiety score, age,
filling/size of organs, location of the tumour, breathing amplitude etc. [64, 143].
Margin prescription could be improved if the relation between the exogenous
variable and set-up error variances would be known. In that case, set-up error
variances could be predicted for the individual patient, based on the patient’s
specific value of the exogenous variable. Ignoring the influence of exogenous
variables leads to an over- or underestimation of set-up errors for certain patients.
In this paper we used a linear model to estimate the relation between the
variance of random errors and an exogenous variable, taking into account the
heteroscedastic error structure [71]. The estimator for the variance of systematic
errors was derived, using the inferred dependence between the exogenous variable
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and the variance of random errors
All model extensions were designed such that they reduce to the formulas of
the existing paradigm once one-dimensional errors are used, or in absence of a
relation between the exogenous variable and the error variances. The methods
developed in this paper were applied in chapter 8. This paper also establishes
a theoretical basis for the paradigm for calculating systematic and random error
variances, and may therefore also serve as an introduction into the topic.
9.2 Methods and materials
9.2.1 Introduction
In sections 9.2.2 to 9.2.6 we present the existing paradigm for calculating set-up
errors. We introduce the statistical model on which this paradigm is based as it
will serve to extend the estimation methods, and validate these with computer
simulations (section 9.2.10). In section 9.2.7 we present a method to combine the
components of set-up error vectors into a single estimator, to calculate direction-
invariant set-up error variances. In sections 9.2.8 to 9.2.9 we present a method
to model the influence of an exogenous variable on set-up error variances. In
section 9.2.10 the computer simulations are described used to validate the method
extensions, introduced in sections 9.2.7 to 9.2.9.
Mathematical concepts and their notations are adopted from the standard
theory of statistics, see e.g., [96].
9.2.2 The set-up error paradigm
The set-up error paradigm describes targeting inaccuracy of a radiotherapy
treatment during dose delivery. The inaccuracy is expressed in terms of errors,
where an error is defined as the shift of a target (e.g., tumour) relative to
a reference (e.g., beam geometry), occurring in the period between treatment
preparation (acquiring planning CT-scan) and treatment delivery. The paradigm
defines systematic and random error components, to distinguish between the
errors’ different origines: the treatment preparation and execution phases. For an
introduction into the topic and its applicability, we refer to [120].
The paradigm was originally developed to describe errors measured in one
dimension [8, 31, 118]. We describe the more general three dimensional model.
Moreover, unlike most reports on this topic, we make a clear distinction between
the population probability distributions and sample (below denoted effective)
probability distributions, and between true parameter values and estimated
parameter values, see Figure 9.1. A sample of observations (e.g., errors for one
patient treated in F fractions) are assumed to be sampled from the underlying
population (of possible errors for all patients P → ∞ and all fractions F →
∞). The parameters characterizing the sample and population distributions are
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unknown true parameters (right column Figure 9.1), and can only be estimated
using the sample of observations (left upper pane Figure 9.1). The expected set-
up errors of future patients (treated using a finite number of fractions F ) are best
described by the true parameters of effective error distributions (right upper pane,
Figure 9.1). The design of safety margins would ideally be based on these values.
The distinction between estimated and true parameters is required to analyze the
reliability of estimators and margins.
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Figure 9.1: The relationship of true (unknown) and estimated (^), standard deviations
of effective and population set-up errors, for treating P patients, with F fractions per
patient.
The set-up error paradigm is based on a model, which describes the distribu-
tions of systematic and random errors (right lower pane Figure 9.1). Therefore,
we first define systematic and random population errors to introduce the model
assumptions in section 9.2.3. Second, in section 9.2.4, we define the effective
systematic and random errors, required to describe the sample distributions.
In sections 9.2.5-9.2.6 the estimators of the parameters characterizing these
distributions are introduced.
9.2.3 Model assumptions, definition of population errors
Consider a patient, sampled from the patient population, undergoing a fraction-
ated treatment. Let f indicate the f th treatment fraction for f > 0, and the
treatment planning for f = 0. Let tf = 〈tx, ty, tz〉f be a vector originating from
the reference and pointing to the target. Then the error of fraction f is defined
as
ef
def= tf − t0. (9.1)
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The target’s position tf varies randomly from fraction to fraction. We
assume that the elements of tf are stochastic variables with normal distributions.
Consequently, the components ef are normally distributed, and we state
ef ∼N(µ,Φ) for f > 0, (9.2)
with µ = 〈µx, µy, µz〉 def= 〈E[exf ], E[eyf ], E[ezf ]〉 and Φ the covariance matrix.
The diagonal of Φ are the variances σ˙ def=
〈
σ2x, σ
2
y, σ
2
z
〉
. The mean, µ = E[tf ]−t0,
is denoted systematic error (or population systematic error) as it describes the
target’s mean shift from planning during a treatment. The shift of an error vector
relative to its treatment mean,
δf
def= ef − µ, (9.3)
is called a random error (or population random error), indicating the random
uncertainty in target positioning among treatment fractions. Consequently, the
mean of random errors is E[δf ] = 0 and its variances are var[δf ] = var[ef −µ] =
σ˙+ 0 =
〈
σ2x, σ
2
y, σ
2
z
〉
The variances σ˙ are therefore called random error variances.
Figure 9.2, provides an illustration of various concepts in two dimensions.
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Figure 9.2: Example of the set-up error concept in 2 dimensions for (a) patients 1, 2
and 3 and (b) a detail of patient 1. Gray shaded regions illustrate the error distributions,
with dashed circles at 1 standard deviation from the mean.
For a single patient p, tp,0 is a constant, as it indicates the target position
at planning. If several patients p receive treatment, for each patient we have a
different tp,0, and so a different µp. However, we assume that the covariance
matrix of the distributions of ep,f = tp,f − tp,0 are equal for all patients, namely
Φ. In a patient population the systematic error µp is a stochastic variable varying
from patient to patient and assumed to be normally distributed
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µp∼N(M,Ψ), (9.4)
where the population mean systematic error M = 〈Mx,My,Mz〉, and Ψ
the covariance matrix. The diagonal of Ψ are the systematic error variances
Σ˙
def=
〈
Σ2x,Σ2y,Σ2z
〉
. Note that, we did not assume that tp,0 and tp,f (f > 0) were
equally distributed, allowing for a distinction between random and systematic
errors, that is, systematic changes between planning and treatment.
9.2.4 Definition of effective errors
The random and systematic error variances, Φ and Ψ, and means µ and M,
are unknown parameters characterizing population distributions. To get to know
them, it would require an infinite number of patients and fractions. As any
treatment has only a finite number of fractions F , the realized average mp in
the sample of errors for patient p differs from µp, and is denoted the effective
systematic error
mp
def= 1
F
F∑
f=1
ep,f . (9.5)
Likewise, the random error δp,f , has its counterpart in the effective random
error dp,f , which is the error measured relative to the realized average of the
treatment
dp,f
def= ep,f −mp. (9.6)
The variances of the distributions of the effective errors σ2i eff and Σ2i eff , with
i ∈ {x, y, z}, can be expressed in terms of the population variances σ2i and Σ2i ,
i ∈ {x, y, z}. In section 9.5, it is shown that:
σ2i eff =
(
1− 1
F
)
σ2i for i ∈ {x, y, z}, (9.7)
and
Σ2i eff = Σ2i +
1
F
σ2i for i ∈ {x, y, z}. (9.8)
9.2.5 Estimation of variances of effective set-up errors
Estimated parameters are distinguished from true parameter values with a
circumflex, or hat, ^. For notational simplicity we provide the estimators for
the one-dimensional case (fixed i), and we will omit the index i. In section 9.2.7
we will return to multi-dimensional notation.
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The estimator for the variance of effective random errors for patient p is given
by:
σˆ2eff, p =
1
F
F∑
f=1
d2p,f , (9.9)
which is the average sum of squares of the effective random errors. The square root
of equation 9.9, or σˆeff, p, is an unbiased estimate of the true standard deviation
σeff, p of the effective random errors dp,f (horizontal upper arrow in Figure 9.1).
Equation 9.9 can be considered a biased estimator of the standard deviation σp
of population random errors δp,f (arrow from left upper pane to right lower pane
in Figure 9.1). When F in equation 9.9 is replaced by F − 1 degrees of freedom
this results in an unbiased estimate of the standard deviation σp. Note that the
sample-average mp, given by equation 9.5, is an unbiased estimator of µp, so
mp = µˆp. The estimator for the variance of the effective systematic errors of a
patient group is given by
Σˆ2eff =
1
P
P∑
p=1
(mp −M)2. (9.10)
Equation 9.10 assumes thatM is known, and consequently P (instead of P−1)
degrees of freedom are used in this estimation. If M is unknown, the unbiased
estimator for the variance of the effective systematic errors of a patient group is
Σˆ2eff =
1
P − 1
P∑
p=1
(mp − Mˆ)2, (9.11)
with
Mˆ = 1
P
P∑
p=1
mp. (9.12)
Only if, according to a t-test, Mˆ is significantly different from zero, equation
9.11 should be used. In that case, the treatment set-up procedure should be
designed to compensate for the estimated patient group systematic error Mˆ .
Otherwise, M = 0 is substituted in estimator 10, which we will assume in the
remainder of this chapter.
9.2.6 Estimation of variance of population set-up errors
Equations 9.7 and 9.8 are also used to convert the estimators for the variances of
effective errors into estimators for variances of population errors. For each patient
p that is treated with F fractions we obtain,
σˆ2p =
F
(F − 1) σˆ
2
eff, p . (9.13)
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If a group of P patients were treated with F fractions, we obtain an
overall group estimate of the random error population variance by averaging the
individual estimates,
σˆ2 = 1
P
P∑
p=1
σˆ2p. (9.14)
If however the number of fractions varies from patient to patient (Fp for patient
p), the standard averaging in equation 9.14 has to be replaced by a weighted
averaging, using the number of fractions Fp as weights.
The estimator for the variance of population systematic errors is
Σˆ2 = Σˆ2eff −
σˆ2
F
. (9.15)
Again, for different Fp, equation 9.10 or 9.11 has to be replaced by its weighted
equivalent because var(mp) depends on Fp.
9.2.7 Combining set-up error vector components into a single
estimator
If errors are measured in more than one direction (e.g., cranial-caudal, anterior-
posterior and left-right) we sometimes observe no significant difference in the
error variances for these directions (e.g., a scatter plot of errors would result in a
spherical cloud). In that case, the variation in errors could be described by one
single direction-invariant error variance. This direction-invariant variance would
be suitable for designing uniform tumour safety margins. In this section we present
a method to combine the components of set-up error vectors into a single estimator
for estimating the direction-invariant error variances. The direction-invariant
estimator is more efficient than the estimators for the individual directions, as
twice or triple the number of observations can be used. Consequently, a more
accurate margin is obtained by using the combined estimator for uniform margins,
in comparison to deriving different margins for each direction.
We consider error vectors ef only for those directions in which their error
variances are equal and non-correlated. For example: if σ2x = σ2y = σ2z = σ2, then
we consider ef = 〈ex, ey, ez〉, σ = 〈σx, σy, σz〉, and the dimension D = 3, but if
for example only σ2x = σ2z = σ2 , we consider ef = 〈ex, ez〉, σ = 〈σx, σz〉, and
D = 2. The variance σ2 is denoted the direction-invariant variance of random
errors.
To estimate σ2 we use the property that the squared norm of the vector
σ = 〈σ1, ..., σD〉 is |σ|2
def= σ12 + ...+ σD2. Therefore, if σ2i = σ2 for i = 1, ..., D
we can then write |σ|2 = σ2 + ...+ σ2 = D · σ2, or,
σ2 = 1
D
|σ|2. (9.16)
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From equation 9.9, it follows that
|σˆeff,p|2 = 1
F
F∑
f=1
|dp,f |2 = 1
F
F∑
f=1
|ep,f −mp|2, (9.17)
with
mp =
1
F
F∑
f=1
ep,f . (9.18)
Consequently, using the property in equation 9.16, the direction-invariant
variance of effective random errors, estimated from D dimensions for a patient p
becomes,
σˆ2eff,p =
1
F · D
F∑
f=1
|ep,f −mp|2. (9.19)
By using equations 9.13 and 9.14, the estimates for patients p = 1, ..., P from
equation 9.19 (scalar results) are converted into the overall estimate of the variance
of random errors. Likewise, from equation 9.10 it follows that the estimator of
the effective systematic error variance is,
Σˆ2eff =
1
P ·D
P∑
p=1
|mp −M|2. (9.20)
This result is converted into a population variance using equation 9.15. Note
that the equations above reduce to the standard equations for the D = 1.
9.2.8 Modelling the impact of an exogenous variable on the
variance of random set-up errors
If set-up errors are correlated with an exogenous variable x, that is e = f(x), or
simply e(x), all other variables in the earlier presented models, are also correlated
with x. Note that the exogenous variable x (a vector) should not be confused
with the symbol x, used before as subscript to indicate a directional component.
We investigate the relation between the variance of population random errors and
an exogenous variable x by using the linear model,
σ˙(x) = α+ β x, (9.21)
where α and β are the model’s parameters and σ˙ def=
〈
σ2x, σ
2
y, σ
2
z
〉
. It is assumed
that variances of random errors can be described by a single α and β for all
directions i withD = 3 (comparable to the direction invariant estimator presented
above in equation 9.19). If this cannot be assumed, the estimator provided below
should be used for a combination of D = 2 and D = 1, or for all directions
130
Extension of the set-up error paradigm
seperately. To maintain compatibility with the original paradigm, we chose
to linearly relate the variance σ˙ instead of the standard deviation σ to the
exogenous variable. Then estimation of the model parameter α closely resembles
the averaging of variances of equation 9.14, especially in absence of an exogenous
influence (β = 0).
The parameters α and β of the model in equation 9.21 must be estimated using
observations ˆ˙σp and xp. for all patients p. Substitution of these observations in
equation 9.21, results in χ2− distributed residuals, and therefore the standard
conditions for linear regression are not fulfilled. Still we apply the linear regression
model, but use a more general estimation method originally developed for models
with a heteroscedastic model error structure, as presented in [71]. We tailored
the methods for the estimation of parameters α and β, and refer to the reference
for its derivation and a more general description of the framework. What follows
is a recipe to find the estimator for the coefficients α and β in equation 9.21, by
relating corresponding observations of random errors ep −mp and xp.
For each direction i, observed effective random errors are transformed into
corrected squared population random errors FF−1 (ei,p,f−mi,p)2, were we used the
property equation 9.7 (as var[ep − mp] = σ2eff,p = F−1F σ2p). For all patients p,
fractions f , and dimensions i, these are grouped into a single vector s˙T(superscript
T indicates a transposed vector or matrix),
s˙T = F
F − 1
〈
(ex,1,1−mx,1)2, . . . , (ey,p,f −my,p)2, . . . , (ez,P,F−mz,P )2
〉
, (9.22)
where f = 1, . . . , F ; p = 1, . . . , P and i ∈ {x, y, z}.
So the length of the column vector s˙ is: P · F · D. Using the same order, we
group the corresponding observations on the exogenous variable x in XT, with
the addition of a column of ones:
XT =
[
1 . . . 1 . . . 1
xx,1,1 . . . xy,p,f . . . xz,P,F
]
, (9.23)
where f = 1, . . . , F ; p = 1, . . . , P and i ∈ {x, y, z}. So the size ofX is: P·F·D×2.
Note that it can usually be assumed that xi,p,f = xp∀f and ∀i, and equation 9.22
has many equal elements. This is because for one patient, usually only one value
for the exogenous variable is applicable to all fractions and dimensions. When
using the observations in vector s˙ and the matrix X to estimate the coefficients
α and β of equation 9.21, its regression model in matrix notation is
s˙ = Xθ + ε, (9.24a)
where
θT = 〈α, β〉 . (9.24b)
and ε is a vector of random model errors with mean zero.
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In [71] several unbiased estimators are proposed for the parameter vector for
the model in equations 9.24a and 9.24b. We found that the ‘minimum norm
quadratic unbiased estimator’ (MINQUE) is the most robust for small samples in
the presence of small perturbations which are present in real treatment data. The
alternative estimators were included in the program code, which is available for
download as additional material to this issue. The MINQUE estimator is given
by
θˆ = (XTH˙X)−1XTs˙, (9.25a)
where H˙ is the matrix
H = I−X(XTX)−1XT, (9.25b)
with each of its elements squared. I is the identity matrix. For each patient p,
the result of the estimation is the model
ˆ˙σp = αˆ+ βˆ xp. (9.26)
If not all patients received the same number of fractions, in equation 9.22, FF−1 is
replaced by the product of each element and its corresponding FpFp−1 .
Testing the significance of βˆ
Evidently, the impact of an exogenous variable on set-up error variances should
only be modelled if its influence is significant, otherwise the estimation methods of
the previous sections should be used. In other words, it should be tested whether
parameter estimate βˆ is significantly different from zero. In [71] the Breusch-
Pagan parametric test for heteroscedasticity is described. The test statistic for
our specific model reduces to
g = βˆ
2
2q ˆˆσ4
, (9.27a)
where q is equal to the matrix (XTX)−1 with its first row and column deleted,
and
ˆˆσ2 = 1
FPD
sT · s, (9.27b)
is the average of the elements of vector s˙. The test statistic g has an approximate
χ2(1)-distribution. The null-hypothesis, H0: β = 0, is rejected if the probability
(p-value) that g is greater or equal than the calculated g∗, is less than the selected
significance level ψ, or Pr{g ≥ g∗} < ψ (e.g., ψ = 0.05). The p-value of this test
results from one minus the outcome of the substitution of g∗ in the cumulative
χ2(1)-distribution.
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9.2.9 Modelling the impact of an exogenous variable on the
variance of systematic set-up errors
We continue deriving the estimator for the variance of the population systematic
errors as a function of x, ˆ˙Σ(x). The resulting estimator is given by equation 9.35a
and 9.35b. We now present the steps that lead to this result.
In the standard paradigm presented in section 9.2.5, the estimation of a
variance of effective systematic errors (equation 9.10) includes observations mp.
As mentioned above, if e(x) depends on x, and so will m(x) and the variance
of m(x). For a patient p, we observe mp only in combination with a specific
xp for that patient, but one would like to have an estimator for the variance of
population systematic errors as a function of an arbitrary x. Consequently, we
have to combine all observations mp(xp) to find an estimate of mp(x) for any
x. Equation 9.20 provides the direction-invariant estimator for the variance of
the population systematic errors. As this equation can also be used to estimate
the variance for single directions separately (using D = 1), for generality we use
the direction-invariant estimator. Consequently, the influence of the exogenous
variable x is also direction-invariant and it is replaced by x. For a specific xp , it
follows from equation 9.20
Σˆ2eff(xp) =
1
D
|mp(xp)−M|2, (9.28)
which includes specific observation for patient p, mp(xp) only.
According to Equation 9.15,
Σˆ2(x) = Σˆ2eff(x)−
σˆ2(x)
F
(9.29)
.
The vector of estimated variance of effective systematic errors is
ˆ˙Σeff(x) = V aˆr[mp(x)] =
1
F
V aˆr[ep(x)] =
1
F
ˆ˙σ(x), (9.30)
see section 9.5. Therefore using equation 9.16, the estimated direction-invariant
variance of systematic errors is
Σ2eff(x) =
1
D
∣∣∣ ˆ˙Σeff(x)∣∣∣ = 1
D · F σˆ
2(x). (9.31)
Likewise we find for the estimator at xp,
Σˆ2eff(xp) =
1
D
∣∣∣ ˆ˙Σeff(x)∣∣∣ = 1
D · F σˆ
2(xp) =
1
D · F (αˆ+ βˆ xp), (9.32)
using equation 9.26. From equations 9.31 and 9.32 it follows that:
Σˆ2eff(x)
Σˆ2eff(xp)
= σˆ
2(x)
αˆ+ βˆ xp
. (9.33)
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Finally, by using this result, we find the estimator for Σˆ2eff(x), by averaging over
all observations p = 1, ..., P ,
Σˆ2eff(x) =
σˆ2(x)
P
P∑
p=1
Σˆ2eff(xp)
αˆ+ βˆ xp
= σˆ
2(x)
P ·D
P∑
p=1
|mp(xp)−M|2
αˆ+ βˆ xp
, (9.34)
in which equation 9.28 was substituted. By substituting equation 9.34 in 9.15, we
obtain the estimate of the population systematic error variance as a function of
x,
Σˆ2(x) = γˆ · σˆ2(x), (9.35a)
with,
γˆ = 1
P ·D
P∑
p=1
|mp(xp)−M|2
αˆ+ βˆ xp
− 1
F
. (9.35b)
Note that γˆ is fully expressed in terms of observationsmp(xp), xp, and the earlier
derived parameter estimates αˆ and βˆ. Again, if not all patients receive the same
number of fractions, equation 9.35b should be replaced by a weighted average
using Fp as weights.
We summarize the steps to calculate the estimated variances of random
and systematic population errors as a function of an exogenous variable x in
D = 3 directions i ∈ {x, y, z}. First, we estimate parameters αˆ and βˆ using the
observed squared random errors FF−1 (ei,p,f−mi,p)2, and the corresponding values
of xp, using the MINQUE estimator of equations 9.25a and 9.25b. Then, the
significance of the parameter estimate βˆ is checked, using the statistic of equations
9.27a and 9.27b. Assuming βˆ is significantly different from zero, the direction-
invariant estimated variance of population random errors σˆ2(x) as a function
of x, is provided by equation 9.26. Second, γˆ is calculated using observations
mp(xp), xp, and parameter estimates αˆ and βˆ in equation 9.35b, providing the
direction-invariant estimator of the variance population systematic errors Σˆ2(x)
as a function of x, equation 9.35a.
9.2.10 Computer simulation to verify the method extensions
A Matlab (MathWorks, Natick, MA, USA) computer program was developed to
demonstrate the estimation of parameters, using the methods described above.
The program will be available for download at the publisher’s website or on request
to the author.
First, the program simulates treatment set up-errors for a specified large
number of patients with a specified number of fractions, characterized by the
parameters α, β, γ, defining the true random and systematic errors distributions.
To generate these errors the Matlab pseudo-random number generators for
uniform and normal distributions, were used. We will refer to this process as
sampling errors from distributions.
134
Extension of the set-up error paradigm
Second, the program estimates the values of α, β and γ from the generated
set-up errors, and returns the estimated values αˆ, βˆ, γˆ as output. The parameter
estimation described in sections 9.2.7 is used if β = 0 is selected, and otherwise
the method of sections 9.2.8 and 9.2.9. From αˆ, βˆ, γˆ , the standard deviations
σˆ(x) and Σˆ(x) can directly be calculated using equations 9.26 and 9.35a.
We describe the first step in further detail. For a treatment of patient p, a value
xp of the exogenous variable is sampled from a standard uniform distribution xp ∼
U(0, 1), so that 0 ≤ xp ≤ 1. The corresponding variance of population random
errors was calculated with σ2(xp) = α + β xp, and the variance of population
systematic errors with Σ2(xp) = γ σ2(xp), using values of α, β and γ provided as
input. Subsequently, for the D dimensions i, D population systematic errors of
patient p are sampled from a normal distribution (D is specified), characterized
with mean M = 0 and variance Σ2(xp), or
µ
i,p
∼ N(0,Σ2(xp)).
For each dimension i, the observation µ
i,p
was used to generate a sample of set-
up errors for F fractions drawn from the normal distribution, characterized with
mean µ
i,p
and variance σ2(xp), or ei,p ∼ N(µi,p , σ2(xp)).
9.3 Results
Errors were generated for a maximum of P = 1000 patients (the maximum was
restricted by the computer memory), and F = 3 fractions (a hypofractionated
treatment). The parameter sets α = 1, β = 3, γ = 4, and α = 1, β = 0, γ = 4,
were used to simulate treatment errors respectively with and without the influence
of an exogenous variable. Both parameter sets were selected to generate errors in
D = 1 and D = 3 dimensions. Results for α = 1, β = 0, γ = 4 were presented as
the estimated values σˆ and Σˆ (Fig. 9.3), calculated for an increasing number
of patients P (or simulations), according to the semi-exponential sequence:
P = 2, 3, 4, 6, 8, 11, 16, 22, 32, 45, 63, 89, 126, 178, 251, 355, 501, 708, 1000. Results
for α = 1, β = 3, γ = 4 were presented as the estimated values αˆ, βˆ, γˆ (Fig.
9.4), using the same set of P s. Convergence of an estimated value φˆ was reported
according to, conv(φˆ) = |φˆ−φ|φ · 100%.
9.4 Discussion
The radiotherapy set-up error paradigm for the calculation of systematic and
random set-up error components was extended to include the estimation of
direction-invariant variances, and to model the influence of the exogenous variable.
If variances measured in different directions showed no significant difference, the
direction-invariant estimator had the advantage of a faster convergence to the true
variance. The estimation method that we proposed for modelling the influence
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Figure 9.3: Estimation of population random (circles) and systematic (triangles) error
standard deviations (SDs) from computer generated set-up errors for a F = 3 fraction
treatment using an increasing number of patients P . Errors were generated using σ = 1,
Σ = 2, M = 0, solid and dashed lines. Estimation (a) using errors in one dimension
(D = 1), and convergence (b), conv(ŜD) = (|ŜD − SD|/SD) · 100%. Panels (c,d) as
(a,b) using error vector components (D = 3) combined into a single estimator.
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Figure 9.4: Estimation of parameters α (circles), β (triangles), γ (squares), relating
population random and systematic error variances to an exogenous variable xp, according
to σ2(xp) = α+β xp, and Σ2(xp) = γ σ2(xp), using an increasing number of patients P .
Set-up errors for a F = 3 fraction treatment were computer generated, using the models
given above, where xp ∼ U(0, 1), α = 1, β = 3, γ = 4 (resp. solid, dashed, and
dash-dotted lines) andM = 0. Estimation (a) using errors in one dimension (D = 1),
and convergence (b), conv(φˆ) = (|φˆ − φ|/φ) · 100%. Panels (c,d) as (a,b) using error
vector components (D = 3) combined into a single estimator.
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Figure 9.5: Observed combinations on the exogenous variable xp and effective random
errors dp from the experiment of Figure 9.4 (D = 1, F = 3) for 200 patients (dots),
and ± the true SD (solid line, σeff,p =
√
F−1
F
(α+ βxp)) and estimated SD (dashed line,
σˆeff,p =
√
F−1
F
(αˆ+ βˆxp)) of effective random errors.
of an exogenous variable on error variances, provided unbiased estimates of the
coefficients of the regression.
The estimator presented for combining the elements (in 2D or 3D) of a set-up
error vector, is used to calculate direction-invariant estimates of the random and
systematic variances of set-up errors. The direction-invariant variances describe
the average variation found in all considered directions. This measure is fully
compatible with the conventional error SDs measured in a single dimension, and
can be used to design isotropic CTV-PTV margins. If the variances of set-up
errors do not significantly differ among directions, these margins will be more
accurate than non-isotropic margins, especially useful for smaller patient groups
and/or a small number of fractions. To verify whether direction-invariant set-up
error estimates can safely be used for isotropic margins it is advisable to first
calculate the variances for each single dimension, after which they are mutually
compared in F-tests. Subsequently, the dimensions (two or three) can be selected
that are suitable for inclusion in the estimator. Although small differences between
variances in single dimensions are easily obscured in small data sets (F-tests
presenting large p-values), it is usually still appropriate to combine the data into
a single estimator. The bias introduced this way may still be small compared
to the gain achieved by reducing the residual variance in comparison to the
separate estimates for single dimensions. Computer simulations of 3 fraction
treatments showed that reasonably accurate (deviation from true value < 20%)
SD estimates are already obtained with groups of about 10 patients using the 3D
vector direction-invariant estimates, while 100 patients would be required if errors
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were measured in only 1 dimension, example in Figure 9.3.
The paradigm was further extended with the possibility to model the impact
of an exogenous factor on the set-up error variances. A linear model was applied
to estimate the relation between the variance of random errors and an exogenous
variable, and the corresponding estimator for the variance of systematic errors
was derived. The model can be used to predict the set-up error variance for
an individual patient using the patient’s specific value of the exogenous variable,
and thus allows for the selection of patient-individualized CTV-PTV margins.
Although only a single exogenous variable was linearly related to the random
error variance, methods could be generalized to include more variables and
parameters, allowing an analysis of variance (ANOVA) or covariance (ANCOVA).
The methods for a single exogenous variable were validated by computer treatment
simulations. Our initial experiments (not reported) showed that the MINQUE
estimator is robust when applied for real patient data, and the Breusch-Pagan
test showed good discriminative power for testing the significance of the regression
parameter. The computer simulations showed that more patients (> 50 for a 3
fraction treatment) were required to accurately estimate the model parameters,
in comparison with a standard model in absence of an exogenous influence.
However, the estimator has the favourable characteristic that the underestimation
of parameter α tends to go with the overestimation of β, and vice versa, resulting
in an overall error SDs estimation that still tends to be accurate. The methods
were successfully applied to model set-up error variances for a marker-guided
treatment procedure in chapter 8.
The distinction between effective and population errors and their variances is
essential in CTV-PTV margin calculations for treatments with a small number
of fractions (e.g., F < 20) [51]. We consider it useful to distinghuish true
variances from estimated variances not only for population errors but also for
effective errors. This is unconventional, as the variance estimators Σˆ2eff and
σˆ2eff(effective) are usually considered biased estimators of Σ2 and σ2 (population),
and equations 9.7 and 9.8 as the bias correctors [31, 118]. However, all treatments
are eventually characterized by effective variances (finite F ), and ideally true
variances of effective errors should be the input of margin formulas. It is therefore
useful to introduce true effective variances Σ2eff and σ2eff besides the estimators
Σˆ2eff and σˆ2eff. The latter are considered unbiased estimators of the former. Figure
9.1 shows a diagram to illustrate the relationships between estimated and true
error variances of population and effective errors.
Unfortunately, most reports on set-up errors make no distinction between
variances of effective and population errors and calculate the error variances
straightforwardly (without corrections) from the treatment data. In the best case
treatments were delivered using the same number of fractions, so that it concerns
estimates for effective values. Variances of effective errors are only applicable
to the specific treatment (specific F ), and not if a similar patient population
is treated with a different number of fractions. Although variances for effective
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errors can still be converted to population values, this is not the case if variances
were calculated for treatments with a mixed number of fractions. Therefore,
for any report on set-up errors, the variance of population errors should be the
preferred measure, as it is independent of the fraction number, and therefore
most general. The, population variances can then straightforwardly be converted
into effective variances (using equations 9.7 and 9.8), for any treatment design.
When calculating the variance of population systematic errors from its estimated
effective value it can in exceptional cases become negative due to residual noise.
Obviously, the true variance cannot become negative. Also it can be shown that
for unguided treatment procedures, the true variance of population systematic
errors can practically not become smaller than the true variance of population
random errors. It may then be reasonable to assume that variances of random
and systematic errors are equal.
9.5 Chapter appendix
For notational simplicity we provide the derivations for the one dimensional case
(fixed i).
9.5.1 Proof of equation 9.7
For all patients (we omitted the patient index p for simplicity) we have
σ2eff
def= var[ef −m] = var[ef ] + var[m]− 2cov[ef ,m]
= var[ef ] + var[
1
F
F∑
f=1
ef ]− 2cov[ef , 1
F
F∑
f=1
ef ], (9.36)
in which the covariance between e.g. x and y is defined by cov[x, y] = E[(x−
E[x])(y − E[y])]. Since cov[ej , ek] = 0 ∀j 6= k, equation 9.36 yields
σ2eff = var[ef ] +
F
F 2
var[ef ]− 2 F
F 2
var[ef ] =
(
1− 1
F
)
var[ef ] =
(
1− 1
F
)
σ2.
(9.37)
9.5.2 Proof of equation 9.8
For all patients p we have
Σ2eff
def= var[mp] = var[mp − µp + µp] = var[mp − µp] + var[µp] + 2cov[mp − µp, µp]
(9.38)
For a single patient, we consider the stochastic variable mp with E[mp] = µp.
Since, µp is a constant, and mp stochastic,
cov[mp − µp, µp] = 0, (9.39)
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and
var[mp − µp] = var[mp] =
1
F
var[ep,f ] =
1
F
σ2. (9.40)
for which we used the relation derived in section 9.5.1
As soon as we consider the patient population, µp is no longer a constant, but
a stochastic variable, with variance var(µp) = Σ2. Therefore, using equations 9.39
and 9.40 we obtain for equation 9.38:
Σ2eff =
1
F
σ2 + Σ2. (9.41)
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Discussion
The delivery of high doses of radiation in few fractions in SBRT has been
shown to be a successful approach to the treatment of liver tumors. High local
rates of control and limited toxicity have been reported [85], and the potential
for cure has been demonstrated [56, 53]. Since 2003, when we started providing
liver SBRT, a substantial part of our research has been directed at reducing CTV-
PTV margins, aiming at minimizing the dose to the healthy tissues, and allowing
more patients to be effectively treated. Encouraged by the low toxicity levels
observed in our protocol (Chapter 2), currently we escalate the tumor dose for
each treatment in such a way that doses in organs at risk stay just below tolerance
levels. Recent findings suggest that an increased prescription dose could improve
local control [107, 106]. With smaller margins more patients can receive higher
doses, and sparing of the normal liver can still be improved [95]. In this discussion,
treatment procedures described in the literature will be compared with SBF-based
procedures, including techniques for managing respiratory motion and methods
for image guidance. We also introduce our recently developed image-guidance
procedure, which optimally combines the use of contrast-enhanced CT-scans and
implanted fiducial markers, to obtain a very accurate treatment set-up procedure.
Finally, future developments that may further improve the quality of liver SBRT
will be discussed.
10.1 Reduction or compensation of respiratory
motion: a comparison of methods
During unrestricted breathing liver motion varies considerably between patients
(typical range 1.5-2.5 cm, Chapter 5 and [3, 23, 40, 58]). Any uncompensated
motion effectively blurs the planned dose distribution [105, 133]. Respiration
can also cause image artifacts in CT scans (Chapter 3). When this occurs in
the planning scan, the resulting uncertainties in position, size and shape of the
tumor are systematic in nature, and require large CTV-PTV margins. The use
some form of motion management if motion is >5 mm is advised [74]. Common
methods for managing respiratory motion in SBRT include motion reduction
by abdominal compression (this thesis), breath-hold supported by the Active
Breathing Coordinator (ABC, manufactured by Elekta AB), respiratory gating
(available on Varian and Brainlab linacs), and tumor tracking with the robotic
Cyberknife linac (Accuray).
Chapter 4 shows that if abdominal compression is applied, breathing excur-
sions could be reduced to levels below 5 mm, or occasionally just above. Other
studies were performed by Heinzerling et al. [58] using 4D-CT, and by Eccles et
al. [40] using MR scanning in cine mode. On average they found a larger residual
motion in cranial-caudal (CC) direction than in our study, i.e. 7.6 mm versus
9.4 mm. It seems unlikely that differences in measuring techniques can fully
explain these observations. This inter-institutional variation in residual motion
could also be related to differences in the level of abdominal compression that
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was applied. Moreover, from experience we know that our routine of training
patients to get accustomed to chest breathing instead of diaphragmatic breathing
is essential to establish a good reduction of liver motion. It is unknown if or how
patients in the other institutes were trained. Finally, part of the variation might
be related to differences in the location of the studied structures in the liver, as
excursion may depend on location in the liver [135].
Methods for managing respiratory motion can be compared by considering
residual motion in terms of errors. Van Herk et al. [133] showed that
unrestricted respiratory motion can be described using a Gaussian spatial
frequency distribution, and showed that the associated random error SD is
calculated by multiplying the amplitude of motion by a factor 0.358. We
confirmed the applicability of this finding to residual liver respiratory motion
during abdominal compression by investigating the motion tracks of implanted
markers [152]. The intra-fraction random error for the 5 mm residual excursion
range (reported above for abdominal compression), is given by σ = (5/2)×0.358 =
0.9 mm.
The effectiveness of other methods to limit the effective respiratory motion has
also been reported. Dawson et al. [24] investigated the reproducibility of breath-
holds obtained with the ABC system by imaging liver implanted fiducial markers.
The CC intra-fraction variation was characterized by 2.3 mm (1 SD), range: 1.2-
3.7 mm. In a more recent study, Eccles et al. [38] reported an intra-fraction SD of
0.5 mm (range 0.6-3.9 mm) in the CC diaphragm position. Smaller displacements
were found in the other directions. At Erasmus MC we also studied residual
tumor motion for respiratory tracking of lung tumors with the robotic Cyberknife
[111, 64]. Instability in the tumor-marker relation resulted in random error SDs
that ranged from 0.4-0.9 mm. Intra-fraction error SDs by mechanical delays of
the robot were described by a factor 0.1 of the total breathing excursion (e.g.,
σ = 2 mm for 20 mm breathing excursion). Respiratory gated liver treatment
employing the Varian RPM system, was investigated by Wagman et al. [138]. The
CC diaphragm motion was measured during the simulated beam-on time window.
The excursion (90% of the frequency distribution) was on average reduced from
22.7 mm (the full excursion) to 5.1 mm (±2.1 mm, 1SD) in the gate. Respiratory
gating was also investigated by Briere et al. [14] who measured residual motion
of fiducial markers implanted in the livers of five patients using portal images and
found an intra-fraction random error SD of σ = 1.0 mm.
We conclude that all the methods discussed above perform comparably
regarding the limiting of effective respiratory motion. The actual residual motion
is patient-dependent, and will generally result in intra-fraction random error SDs
in the range of σ = 1-2.5 mm. Although residual respiratory motion which has
been established during treatment preparation can be used to individualize CTV-
PTV margins, it should be realized that the contribution to the margin is small
compared to inter-fraction random and systematic errors. Recent work [152] on
liver motion tracks, confirmed this assertion that was originally made by van Herk
et al. [133]. Therefore, more important than limiting the respiratory motion is
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reducing inter-fraction errors. Since none of the methods discussed eliminates
day-to-day variations in the median tumor position, additional image guidance is
mandatory for accurate tumor targeting. The choice of a breathing management
solution should therefore not primarily be based on its capabilities of limiting the
effective respiratory motion, but rather on factors such as compatibility with a
linac or image guidance solution, or patient compliance.
In the experience of most of our patients, abdominal compression is uncom-
fortable but tolerable. In contrast, a study on ABC [38] showed that only 62% of
patients were able to comply with its use. ABC has the advantage of providing
a reproducible patient anatomy for CT scanning during a treatment day which
is useful for CT-based image guidance (see below). Abdominal compression in
an SBF provides the necessary patient stability for out-room image guidance
procedures (Chapter 3, [112]) and it has been shown to reduce tumor drifts
associated with unrestricted breathing. Drifts of 2.5-5.5 mm over a 10 minute
period were observed by von Siebenthal et al. [137], increasing to 3.9-15.3 mm
over 30 minutes. For compression-supported SBRT, Guckenberger et al. [52]
found drifts of 3.7 ± 2.2 mm during treatment delivery. Case et al. [18]
compared unrestricted breathing with abdominal compression and found shifts
between pre and post treatment CBCTs: σ = 2.2-3.0 mm, Σ = 1.0-1.4 mm for
unrestricted breathing, and σ = 1.4-1.8 mm and Σ = 0.6-1.2 mm for abdominal
compression. Recently we also studied tumor drifts during treatment supported
by abdominal compression in the SBF. Fluorocopic kV movies acquired before
and after treatment showed that during the delivery period (≈30 minutes) drift
in implanted marker position was limited to σ and Σ < 1 mm in all directions
[112]. Although the above mentioned studies on ABC [24, 38], did not explicitly
investigate tumor drift, it was covered by their measurements of intra-fraction
motion. During respiratory gating or Cyberknife tumor tracking, patients can
breathe freely. In the Cyberknife system, tumor/marker drifts are automatically
corrected, while in respiratory gating, imaging during dose-delivery is advisable
to detect and correct drifts.
We conclude that of all the discussed methods to limit effective respiratory
motion, abdominal compression is the most simple, and the most generally
applicable. Nevertheless, as is true of any method, complementary image guidance
is indispensible for achieving accurate tumor targeting.
10.2 Guiding the treatment set-up using tumor
surrogates or tumor visualization in CT
For practical reasons liver SBRT procedures typically use tumor surrogates for
guiding the treatment set-up, such as the diaphragmatic dome or implanted
fiducial markers. Surrogates can be imaged while the patient is positioned
on the linac couch, e.g. using a kV fluoroscopy imaging system, or acquiring
CBCT scans. Since imaging can be performed just in advance of, or even
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during treatment, it can avoid errors due to patient motion and tumor drifts.
Moreover, imaging of surrogates allows the measuring the median tumor position
in the presence of residual intra-fraction motion, in all treatment procedures.
However, if a treatment set-up is fully guided by surrogates, any undetected
change in the geometrical relation between the surrogate and the tumor will
lead to a set-up error. In this thesis we investigated set-up errors resulting
from the use of surrogates and concluded that liver-implanted markers are the
best surrogates, followed by the diaphragmatic dome, see Summary, Table 1.
Implanted fiducial markers were used in combination with a variety of equipment
[3, 79, 5, 49, 14, 87, 117]. The diaphragm has typically been used as a tumor
surrogate in combination with CBCT image-guidance [55, 52, 139]. A recent
study by Eccles et al. [39] showed that including the whole liver outline in a non-
rigid registration of a CBCT scan with the planning CT may slightly improve the
targeting accuracy. Their comparison between tumor COM displacements derived
from rigid and non-rigid registration showed differences of 0.8 mm, 0.6 mm, and
2.1 mm in CC, LR, and AP directions, respectively (SD in mm).Currently, the
procedure based on non-rigid registration is clinically unfeasible due to the limited
time available for the image guidance procedure.
Ideally, rather than imaging a surrogate, treatment set-up should be based
on the tumor imaged before dose delivery. Useful images can be obtained with
breath-hold, contrast enhanced CT, acquired on a modern multi-slice CT scanner.
In Chapter 8 we found that the baseline accuracy for procedures based on these
scans is high (σ = 0.6 mm, Σ = 1.3 mm) when compared to surrogate based
procedures (Summary, Table 1). However, in recent work we have shown that in
abdominal compression supported treatments, the tumor position in a voluntary
exhale breath-hold may deviate from the natural exhale position of a continuous
breathing [112]. Below, a method is discussed to circumvent this problem.
Alternative methods were developed for lung tumors, using respiratory correlated
sorting (4DCT) on a multi-slice CT scanner [141]. In our experience, 4DCT is a
less good alternative for liver tumor imaging, as image quality is rather poor, and
motion artifacts often affect the integrity of the tumor shape. In-room CBCT
may even be less suitable for daily tumor imaging in liver SBRT [55]. CBCT
has a lower image quality than regular fan-beam CT, which further decreases for
respiratory correlated CBCT [18]. Moreover, the time required for the acquisition
of a CBCT is incompatible with the required 30 s time window for acquisition of
a contrast enhanced scan [69].
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10.3 Guiding treatment set-up using tumor visual-
ization in CT and marker tracking by planar
fluoroscopy
Recently, we developed a new protocol for image-guided liver SBRT, combining
the advantages of contrast-enhanced CT for tumor imaging (acquired during a
voluntary breath-hold before treatment planning and each fraction) and planar
fluoroscopy for imaging implanted fiducial markers at the linac. Treatments are
carried out using an Elekta Synergy linac and SBF with abdominal compression.
Before each treatment fraction, a voluntary breath-hold contrast enhanced CT
scan is acquired outside the treatment room (as in-room CT is currently
unavailable) and the visualized tumor is registered to the treatment plan, yielding
the required treatment set-up correction for the SBF. Frontal and lateral DRRs
are generated to define the marker positions relative to the linac isocenter for
the corrected SBF set-up. After the patient is transported to the linac and
positioned for treatment, frontal and lateral fluoroscopic movies are acquired,
visualizing marker motion during a few breathing cycles. Software, developed in-
house, is then used to automatically extract the average exhale positions from the
marker tracks. Assuming that the geometrical relation between the tumor and the
markers is maintained during the period from CT scanning to patient positioning
at the linac, a final set-up correction is possibly performed which aligns the
exhale marker positions measured by fluoroscopy to those in the DRRs. During
treatment additional fluoroscopy can be used to verify the constancy of the exhale
position and to correct the treatment set-up for drifts. Further improvements may
possibly be obtained by employing an in-room CT-scanner on rails (sharing the
couch with the linac).The procedure could alternatively be performed without the
acquisition of treatment CT scans, using the planning DRR as a reference, thereby
becoming fully marker-guided. Obviously larger CTV-PTV margins would then
be required, as discussed in Chapters 7-9. Apart from improving tumor targeting
accuracy, CT scans acquired before treatment offer the possibility of adaptive
radiotherapy, see Future developments.
10.4 Future developments
10.4.1 Image guidance without ionizing radiation
In future recent developments in image-guidance technology may provide al-
ternatives to the current imaging systems which all use ionizing radiation for
imaging. If the need for ionizing irradiation can be avoided, imaging can be
performed continuously for accurate monitoring of drifts. A new type of fiducial
marker has been developed that can be localized using electromagnetic technology
(Calypso 4D Localization System, Calypso Medical Technologies Inc., Seattle,
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Washington, USA). The markers can be tracked in real-time, and offer a sub-
millimeter localization accuracy [108]. They have been successfully used in the
treatment of prostate cancer [80]. Currently, the diameter of the markers is 2 mm,
requiring a 14-gauge implantation needle. Smaller markers could make this an
attractive system for liver SBRT.
Another interesting development in image guidance technology is the integra-
tion of MR imaging and a linac [81]. MRI offers superior soft tissue contrast, which
may reduce registration uncertainty for liver tumors [90]. Also organs at risk can
be better visualized, facilitating automatic contour propagation (from treatment
planning) required for adaptive strategies [130]. Methods are described for MR
to track organ motion in real-time [75, 113, 135, 40], indicating the potential
for breathing motion management. However, MR imaging requires coils to be
positioned on the patient’s skin which can change the patient’s geography. Other
concerns are related to guaranteeing the geometrical coupling between the MR and
the linac coordinate frames. This problem could possibly be solved by integrating
some kind of kV imaging in the MR linac. Careful attention is also needed to
circumvent the problem of geometrical distortions which do not only depend on
machine parameters, but also on the size and composition of scanned objects (field
inhomogeneities, magnetic susceptibility, chemical shifts, and internal motion).
Uncorrected distortions can be in the order of 1-2 cm, while correction strategies
can reduce artifacts to 1-2 mm levels [103, 43, 21]. As clinical MR linacs are not
yet commercially available, no comparison of final targeting precision with current
techniques for liver SBRT is yet available. It is currently possible though, to
achieve a very high level of targeting accuracy using conventional equipment and
probably at a much lower cost. Above all, one of the most serious disadvantages
of using the proposed MR linac integration for liver SBRT is that only coplanar
beam orientations can be used for dose delivery. In a recent study in a group of
liver patients we demonstrated that optimized non-coplanar beam set-ups resulted
on average in a 25% higher tumor dose when compared with optimized coplanar
beam set-ups [35]. Preliminary data in an on-going study using fully integrated
beam angle and intensity optimization confirm these findings [13].
10.4.2 A liver SBRT margin calculation framework
Improvements in targeting accuracy may justify the use of smaller CTV-PTV
margins. Nevertheless, only the overall accuracy of a treatment procedure is
eventually the key to margin design [2]. Therefore a general framework for
describing the overall accuracy of treatment procedures is required. Groups in the
Netherlands developed a paradigm which became the standard for describing the
accuracy of procedures for various tumor sites [8, 118, 132, 31]. In Chapter 9 we
summarize and extend this paradigm. The accuracy of SBRT procedures was not
commonly described in terms of the paradigm, as the straightforward ITV concept
[68] was mostly used and considered a safe choice for hypo-fractionated treatments
[154]. In order to construct optimal CTV-PTV margins that satisfy a target dose
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criterion for a specified percentage of the patient population, the accuracy of a
procedure should be fully expressed in terms of systematic and random errors
[51, 62, 120, 131]. By including our latest findings [112], we obtained an almost
complete overview of all errors affecting the targeting accuracy of SBF based
treatment procedures. A framework was created to model all residual uncertainty
in the tumor position at the moment of dose delivery in any SBRT treatment
procedure [152]. In addition, we introduced a CTV-PTV margin recipe adapted
for hypofractionated SBRT based on the work of Gordon and Siebers [51] and
Herschtal et al. [62]. Currently we are testing the margin recipe using real
treatment plans, to select an optimal choice of parameters for treatment planning
practice.
10.4.3 Adaptive radiotherapy
Chapter 4 highlights our research into the problems of liver SBRT related to day-
to-day changes in patient anatomy. It was shown that correcting the treatment
set-up for tumor position did generally not prevent occasional overdoses in organs
at risk. Tumor set-up corrections occasionally resulted in a higher OAR dose
than that of an uncorrected treatment set-up. We are currently investigating
adaptive treatment strategies (ART), to create an adjusted treatment plan for
each treatment fraction, based on the contrast enhanced CT scans acquired before
each treatment fraction. For this purpose, all structures defined in the planning
scan have to be automatically propagated to the treatment scan. Commercial
software for this purpose is being developed (ABAS, Elekta AB, Stockholm,
Sweden [122], and DOSISoft SA, Cachan, France). Re-planning can be performed
on-line, between imaging and dose delivery, or off-line after dose delivery to
compensate non-optimal dose distributions in the following fractions. Off-line
methods put fewer demands on the speed of segmentation and planning methods
but are possibly less effective. Currently, we are successfully using the ‘Cycle’
method for automatic beam angle selection to construct treatment plans for
conformal RT, a method that would allow for off-line re-planning [34]. More
recently, a new inverse planning system, iCycle, has been developed for integrated
IMRT beam angle and fluence optimization [13]. This system allows for very fast
fluence optimization in an on-line setting [12].
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To accurately target a liver tumor with external radiation beams, errors in
positioning of the tumor relative to the treatment beams should be minimized.
Ideally, the tumor and beam geometry established in the treatment plan should be
fully reproduced during dose delivery. Any tumor motion relative to the beam set-
up that is left uncorrected during the treatment procedure is therefore considered
a source of errors detrimental to the targeting accuracy. We distinguish intra-
fraction and inter-fraction errors. Intra-fraction errors are tumor displacements
occurring during dose delivery, e.g. due to respiratory motion. Inter-fraction
errors are offsets, constant during a treatment fraction, but varying from fraction
to fraction, e.g. any uncorrected internal anatomical change resulting in a residual
tumor displacement. To reduce intra and inter-fraction errors, most SBRT
treatment procedures use some form of image guidance, combined with a method
of managing breathing motion. The research described in this thesis was based
on a computed tomography (CT)-guided treatment procedure for which patients
were positioned in a stereotactic body frame (SBF). CT scans were acquired before
each treatment fraction to correct the treatment set-up for tumor displacements
(inter-fraction errors) and screw-controlled abdominal compression was used to
reduce breathing-induced motion of the liver (intra-fraction errors). We analyzed
the accuracy of our own procedure, compared it to alternatives, and investigated
strategies for future application.
Image-guidance using contrast-enhanced CT scans acquired using
a single-slice CT scanner
Chapters 3 and 4 cover our image-guided treatment set-up procedure comprising
the acquisition of contrast-enhanced CT scans on a single-slice CT scanner,
before treatment planning and before each fraction. In Chapter 3 geometrical
target coverage is addressed, while Chapter 4 reports on dosimetric analyses.
The problem of respiration-related imaging artifacts is investigated in Chapter
3. Although abdominal compression reduced breathing motion, residual motion
during scanning resulted in artifacts causing uncertainties in tumor position, size
and shape, see Fig. S.1. A method was introduced to cope with the artifact
problem. The clinical target volume (CTV) delineated in a CT scan was expanded
by a margin equal to the total breathing excursion R, resulting in a volume-
denoted internal target volume plus (ITV+). The ITV+ was defined in the
planning and treatment CT scans and encompassed the space with a non-zero
probability of tumor occurrence. We showed that the planning target volume
(PTV) derived from standard margins covered (coverage ≥99%) the ITV+ in
96% of the treatment CT scans if a set-up correction was applied, while only
63% of the fractions were covered without set-up correction. We concluded that
geometrical tumor coverage can only be guaranteed in combination with standard
margins if CT-guided set-up corrections were applied at each treatment fraction.
Additionally, we derived an alternative CTV-PTV margin recipe for the CT-
guided procedure. To obtain full tumor coverage during all treatment fractions, an
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additional expansion of the planning ITV+ by 0.5·R was required, thus obtaining
a CTV-PTV margin of 1.5·R. Since the implantation of gold fiducial markers
allowed more accurate measuring of respiratory excursions R (see Chapter 5), this
recipe for margins was introduced (including 2.5 mm extra margin for additional
set-up errors) to individualized PTV construction. On average, application of the
recipe yielded individualized margins that were close to standard margins.
Figure S.1: Respiration-related imaging artifacts in a saggital reconstructed CT image,
clearly affecting the shape of the diaphragmatic dome.
In addition to the geometric analysis in Chapter 3, a dosimetric investigation
in Chapter 4 further demonstrates the need for set-up corrections. The target
shifts derived from the image-guidance procedure were used to evaluate the dose
in the treatment target volumes (copies of the PTV shifted accordingly). In
uncorrected treatment set-ups the gEUD(-5) dose parameter reduced on average
by 15.5%, while only 2.3% reduction was observed if treatment set-up corrections
were applied. The impact and frequency of dose constraint violations in organs
at risk (OAR) in the corrected and uncorrected treatment set-up procedures did
not differ.
Residual respiratory tumor motion
In Chapter 5 we investigate the effects in 12 patients of abdominal compression
on the respiratory motion of liver targets in the three principal directions. The
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liver target was defined by a group of fiducial markers implanted in the liver.
Excursions were measured on fluoroscopic videos acquired on planning day and
before each treatment fraction during unrestricted breathing and at varying levels
of abdominal compression. Abdominal compression reduced cranial-caudal (CC)
motion of the liver by 62% and anterior-posterior (AP) motion by 38% (reduction
of patient group median excursion). Left-right (LR) motion, which was usually
small during unrestricted breathing, was sometimes slightly increased. The
average excursion was reduced to below 5 mm in all directions in most of the
patients (10/12), with a maximum of 7.4 mm toward CC in one patient. It was
shown that residual excursions were relatively insensitive to small adjustments
in compression level, and that a fixed level of compression (the required screw
position established during treatment preparation) could be used during the
complete course of the treatment. Breathing excursions were consistently small
for that level.
Chapter 6 describes the respiration sensor developed in-house (the force
sensing abdominal compression plate (FSP) of Chapter 5) as it was being filed for
a patent application. The FSP is an abdominal compression plate, modified to
include a force transducer to monitor the force exerted by the screw on the plate
owing to the reactive pressure from the patient’s abdomen. We introduced the
FSP in Chapter 5 to investigate the value of directly measuring the force acting on
the patients’ abdomens, as an alternative to the standard compression measure,
the screw position. It was concluded that the screw position was preferable
to force, since the latter did not improve the reproducibility of excursion if
applied as a compression measure. However, measuring force differences between
exhalation and inhalation was useful to monitor the patient’s breathing pattern
(e.g. assessing whether the patient is breathing normally and ready for scanning
or treatment). Since the introduction of a multi-slice CT scanner to our clinic,
the FSP’s signal is put into the scanner for retrospective respiratory sorting and
prospective respiratory triggering. It is generally preferred to the vendor-supplied
pressure belt, although in a few patients it sensed the heartbeat which affected
the quality of the signal.
Guiding treatment set-up using implanted fiducial markers
Chapters 7-9 investigate how accurately treatment set-up could be guided
using fiducial markers implanted in the liver, or using other tumor surrogates,
such as vertebral bodies close to the liver, the diaphragmatic dome, and a
fixed stereotactic reference (uncorrected treatment according to the SBF set-
up established in the treatment plan). In Chapter 7 analyses are based on
fluoroscopic movies, and treatment set-up strategies are compared to a marker-
guided treatment set-up for reference. Since the markers marked a part of the
liver, which could hypothetically contain the tumor, we were able to characterize
the distribution of set-up errors for diaphragm-tip and the bony anatomy guided
methods. Moreover, by extracting the average natural exhale position of the
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markers and diaphragm tip, the influence of breathing errors was minimized. In
Chapter 8, analyses were based on contrast-enhanced CT-scans acquired in exhale,
and the registration of visualized tumors was used for reference. In this study, we
were able to measure day-to-day errors in marker-guided and diaphragm-guided
treatments accurately, while the SBF and bony anatomy based treatment set-up
errors were measured less accurately, owing to the possible influence of breath-hold
variation. The random and systematic error standard deviations (SDs) measured
in Chapters 7 and 8 are summarized in Table S.1.
Table S.1: Random (σ) and systematic (Σ) error SDs (population values in mm) of
various surrogate-guided treatment set-up correction procedures (bony = vertebral bodies
close to the liver). Errors are measured relative to the reference set-up method (second
column). σ and Σ of a marker-guided procedure depend on the distance d (mm) between
the marker and the tumor center of mass, σ =
√
(0.3 + 0.036× d) and Σ = 1.5 × σ.
Note that effective values of σ and Σ apply to all treatments with a limited number of
fractions, and should be calculated using the equations provided in Chapter 9.
 
 
surrogate reference σ   Σ  
  CC LR AP  CC LR AP 
SBF marker 2.8 1.7 2.0  4.2 2.6 3.0 
bony marker 2.2 3.2 1.4  2.9 4.1 4.1 
diaphragm marker 1.2 n.a. n.a.  3.0 n.a. n.a. 
SBF tumor 2.2 2.2 1.8  3.0 1.4 3.6 
bony tumor 2.1 1.6 1.4  2.3 1.5 2.9 
diaphragm tumor 1.6 1.6 1.5  2.3 1.2 2.1 
marker tumor (d = 20 mm)  1.0  1.2 
marker tumor (d = 50 mm)  1.4  1.8 
marker tumor (d = 100 mm)  2.0  2.4 
 
The tumor-marker comparisons (lower three rows in Table S.1) refer to the
use of a single marker as a tumor surrogate. Patients typically had three markers
implanted, but the marker group center of mass (COM) did usually not coincide
with the tumor center. It was shown that COM-based corrections were generally
better (resulting in smaller set-up errors) than using the most distant marker,
but not significantly better than using the closest marker. Furthermore, owing
to deformations in the liver tissue, it was shown that correcting the set-up for
rotations in the marker-group did not always improve the set-up precision, and
that the corrections could equally well be based on translations only. Chapter 7
shows that the use of abdominal compression did not systematically influence day-
to-day deformations, as measurements for unrestricted breathing were similarly
distributed as those for abdominal compression. The influence of the marker-
tumor distance on the error variance of marker-guided treatments was modeled
using the methods described in Chapter 9. The existing framework for the
calculation of random and systematic errors was extended to include regression
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with an independent variable (marker-tumor distance) and to combine the errors
measured in different dimensions. Chapter 9 also provides an overview of the
existing framework for the calculation of random and systematic errors, by
combining existing concepts into a single theoretical framework.
We conclude that fiducial markers are a good tumor surrogate for guiding the
treatment set-up of liver SBRT, especially when positioned close to the tumor.
For markers implanted closer than 5 cm from the tumor, set-up error SDs were
limited to σ = 1.4 mm and Σ = 1.8 mm, see Table S.1. The diaphragmatic
dome was the second best surrogate, the use of which would be able to improve
unguided treatment procedures (SBF, Table S.1). Although CC offsets in bony
anatomy were weakly correlated with those in the tumor position, bony anatomy
is generally not a reliable surrogate, as the general performance was comparable
to that of unguided treatment procedures.
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Voor het nauwkeurig behandelen van levertumoren met uitwendige radiother-
apie streeft men naar zo klein mogelijke positioneringsfouten bij het uitrichten
van de tumor ten opzichte van de bestralingsbundels. Idealiter wordt de
geometrie van de tumor en de bundels, zoals die is vastgelegd in een be-
stralingsplan, exact gereproduceerd tijdens de bestraling. Elke vorm van
tumorverplaatsing waarvoor niet gecorrigeerd wordt in de behandelprocedure,
wordt daarom beschouwd als een bron van onnauwkeurigheid. We onderscheiden
intra- en inter-fractiefouten. Intra-fractiefouten zijn resterende bewegingen die
optreden tijdens de bestraling, bijvoorbeeld ten gevolge van de ademhaling. Inter-
fractiefouten zijn ongecorrigeerde verplaatsingen die variëren van bestralings-
fractie tot bestralingsfractie maar niet veranderen tijdens één bestralingsfractie,
bijvoorbeeld fouten veroorzaakt door anatomische veranderingen in het lichaam
van de patiënt. Om intra- en inter-fractiefouten zoveel mogelijk te beperken,
maakt men in de behandelprocedure gebruik van beeldsturing en van een methode
om de ademhalingsbeweging te onderdrukken of te compenseren. Het onderzoek
beschreven in dit proefschrift is gebaseerd op een behandelprocedure die gestuurd
wordt aan de hand van ‘computed tomography’ beelden (CT) en waarbij patiënten
zijn gepositioneerd in een lichaamsomsluitend stereotactisch frame (‘stereotactic
body frame’, SBF). Aan de hand van verschuivingen waargenomen in CT beelden
wordt de positionering van een patiënt aangepast en worden inter-fractiefouten
beperkt. Intra-fractiefouten worden beperkt door de leverbeweging ten gevolge
van ademhaling te onderdrukken met abdominale compressie (regelbaar met
een schroef als onderdeel van het SBF). In dit proefschrift analyseerden we de
nauwkeurigheid van onze eigen procedure, vergeleken we die met alternatieven, en
onderzochten we strategieën die in de toekomst tot verbeteringen kunnen leiden.
Sturing op basis van contrast CT beelden, gebruik makend van
een single-slice CT scanner
Hoofdstukken 3 en 4 beschrijven de beeldgestuurde behandelprocedure, waarbij
zowel voor het behandelplan als voor iedere bestralingsfractie CT beelden met
contrastvloeistof worden gemaakt met een ‘single-slice’ CT scanner (per rotatie
wordt één vlak gescand). In hoofdstuk 3 beschouwen we het geometrisch
afdekken van de tumor met bestralingsbundels terwijl we in hoofdstuk 4 de
dosimetrische aspecten hiervan verder onderzoeken. Hoofdstuk 3 analyseert
het probleem van ademhalingsgeïnduceerde (respiratoire) beeldartefacten in CT.
Hoewel abdominale compressie de ademhalingsbeweging van de lever onderdrukt,
veroorzaakt de resterende beweging artefacten in CT beelden (zie Figuur S.1),
die leiden tot onzekerheid in de gemeten positie, afmeting, en vorm van de
tumor. Om dit probleem aan te pakken introduceerden we een methode,
die het klinisch doelvolume (‘clinical target volume’, CTV), ingetekend in CT
beelden, uitbreidt met een marge gelijk aan de grootte van de totale resterende
respiratoire beweging R. Dit resulteerde in een uitgebreider intern doelvolume
genaamd ‘Internal Target Volume Plus’ (ITV+). Het ITV+ kan in zowel
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CT beelden voor het behandelplan als voor iedere bestralingsfractie gebruikt
worden om het gebied te markeren waarin de kans op het aantreffen van de
tumor ongelijk nul is. We analyseerden in hoeverre het klinisch doelvolume
dat gebruikt werd met standaard marges voor de bestraling (‘Planning Target
Volume’, PTV, standaardmarges: 10 mm craniaal-caudaal, 5 mm axiaal)
het ITV+ geometrisch afdekte (dekkingsgraad ≥99%). In de CT-gestuurde
behandelprocedure dekte het PTV in 96% van de bestralingsfracties het ITV+
volledig af, terwijl dit slechts in 63% van de bestralingsfracties het geval was
bij een niet-beeldgestuurde procedure. We concludeerden daarom dat het
gebruik van standaard marges alleen verantwoord is in combinatie met een
beeldgestuurde behandelprocedure, waarbij de patiëntpositie voorafgaand aan
iedere bestralingsfractie wordt gecorrigeerd. Aansluitend op dit werk is een
alternatief recept voor CTV-PTV marges afgeleid dat toegepast kan worden
in combinatie met genoemde CT-gestuurde procedure. Om een volledige
geometrische dekking te kunnen garanderen, dient het ITV+ in een behandelplan
te worden uitgebreid met een marge van 0.5 · R, waarmee de totale CTV-PTV
marge 1.5 · R wordt. Met het implanteren van goudmarkers in de lever kon de
ademhalingsbeweging R nauwkeurig worden gemeten, en daarmee werd dan ook
het gebruik van dit recept (aangevuld met een marge van 2.5 mm voor overige
positioneringsfouten) ingevoerd. Het gebruik van dit recept resulteerde in de
meeste gevallen in marges die niet veel afweken van de standaard marges.
Figuur S.1: Respiratoire beeldartefacten in een sagitaal gereconstrueerd CT beeld.
Duidelijk waarneembaar is hoe de vorm van het middenrif is aangetast.
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Naast de geometrische analyse in hoofdstuk 3, toont ook het dosimetrisch
onderzoek in hoofdstuk 4 de noodzaak aan van het corrigeren van de patiënt-
positie voorafgaand aan iedere bestralingsfractie. Na het toepassen van de
positioneringscorrecties uit de beeldgestuurde procedure werd de dosering van
behandelde doelvolumes (kopieën van het PTV) onderzocht. Het bleek dat
voor de niet gecorrigeerde behandelprocedure de gEUD(-5) dosisparameter met
gemiddeld 15,5% daalde, terwijl slechts 2,3% daling werd waargenomen wanneer
wel correcties werden toegepast. Voor organen die ongewild bestraald werden
tijdens een behandeling (‘organs at risk’ OARs), werd vooraf een maximale dosis
vastgelegd die zij mogen ontvangen. Het bleek dat, zowel de frequentie als het
effect van waargenomen overschrijdingen van deze maximale dosis niet verschilden
voor de gecorrigeerde en ongecorrigeerde behandelprocedures.
Beweging van de tumor door ademhaling
In hoofdstuk 5 is het effect van abdominale compressie op de respiratoire beweging
(in drie richtingen) in een deel van de lever onderzocht bij een groep van twaalf
patiënten. Het deel van de lever werd gemarkeerd door een groep goudmarkers
die in het leverweefsel waren geïmplanteerd. De beweging werd vastgesteld aan
de hand van fluoroscopie filmopnamen (continue Röntgenopnamen) die op de dag
van de planning en voor vlak voor elke bestralingsfractie werden gemaakt tijdens
sessies met en zonder abdominale compressie. Abdominale compressie bleek de
beweging van de lever met 62% te verminderen langs de craniaal-caudale (CC) as
en met 38% langs de anterior-posteriore as (scores betreffen de mediaan van de
beweging in de patientengroep). De links-rechts beweging van de lever, die meestal
gering is tijdens vrije ademhaling, werd bij een aantal patienten enigszins vergroot.
Voor de meeste patiënten (10/12) kon de ademhalingsbeweging echter tot 5
mm worden teruggebracht. De maximale beweging die werd gemeten bedroeg
7,4 mm langs de craniaal-caudale as. Kleine aanpassingen in de schroefpositie,
waarmee het compressieniveau werd bijgesteld, hadden relatief weinig effect op
de ademhalingsbeweging; een vaste schroefpositie, zoals die werd vastgesteld op
de planningsdag, zou toereikend zijn geweest om gedurende alle behandelfracties
een consistent kleine ademhalingsbeweging te bewerkstelligen.
Hoofdstuk 6 beschrijft een uitvinding zoals omschreven in de betrokken
patentaanvraag. Het betreft een abdominale compressieplaat die is aangepast
om met behulp van een sensor de variërende kracht te meten die de patiënt
uitoefent op deze plaat. De vinding werd in hoofdstuk 5 geïntroduceerd als FSP
(‘Force Sensing abdominal compression Plate’) met als doel het bepalen van een
compressieniveau gebaseerd op kracht als alternatief voor de schroefpositie. Het
gebruik van kracht als maat bleek echter niet beter dan de schroefpositie omdat
het geen betere voorspellingen van de ademhalingsbeweging opleverde. Wel bleek
het instrument bruikbaar om de ademhaling van een patiënt te kunnen volgen,
aangezien het de krachtsverschillen tussen in- en uitademing kan registreren
(bijvoorbeeld om vast te stellen of een patiënt rustig ademhaalt als voorbereiding
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op een scan of bestralingssessie). Sinds de introductie van een multi-slice CT-
scanner op onze afdeling, wordt het signaal van de FSP ingevoerd in de scanner
om daarmee na afloop CT beelden te sorteren op basis van de daaraan gekoppelde
ademhalingsfase (4D-CT) en voor het verwerven van beelden op indicatie van de
ademhalingsfase (‘triggering’). De FSP is probleemlozer in het gebruik dan het
instrument dat voor dit doel met de CT-scanner is meegeleverd, hoewel bij enkele
patiënten de bijkomstig gemeten hartslag het signaal verstoorde.
Patiëntpositionering met geïmplanteerde markers
In de hoofdstukken 7-9 is het gebruik van goudmarkers onderzocht voor het
positioneren van de patiënt. Deze procedure werd vergeleken met het gebruik
van alternatieve tumorpositiesurrogaten, zoals wervels die zich in de nabijheid
van de lever bevinden, het middenrif, of een vaste stereotactische referentie (ofwel
een ongecorrigeerde behandelprocedure op basis van SBF coördinaten). Voor
het onderzoek in hoofdstuk 7 zijn fluoroscopie filmopnamen gebruikt en zijn
de positioneringsfouten van de laatstgenoemde procedures gemeten ten opzichte
van de markergestuurde referentieprocedure. Hoewel markers niet altijd de
tumor omsloten, kon de verdeling van markerverschuivingen wel model staan
voor de verdeling van tumorpositiefouten bij middenrif- en wervelgestuurde
en ongecorrigeerde procedures. Immers, zowel markers als tumoren waren
gelokaliseerd in een willekeurig deel van de lever. Het gebruik van fluoroscopie
filmopnamen maakte bovendien mogelijk de verstorende invloed van respiratoire
beweging op metingen vrijwel uit te sluiten. Door selecteren van filmbeelden kon
namelijk de gemiddelde positie, die het middenrif of de markers innamen wanneer
de patient had uitgeademd, nauwkeurig worden vastgesteld. In tegenstelling tot
hoofdstuk 7, kon bij het onderzoek in hoofdstuk 8 wel direct de tumorpositie
gemeten worden. Hiervoor werden CT beelden gebruikt die verkregen waren
met toediening van contrastvloeistof bij een vastgehouden uitgeademde toestand.
De dagelijkse verschuivingen van de tumor ten opzichte van andere surrogaten
kon aldus direct worden vastgesteld en daarmee de werkelijke nauwkeurigheid
van markergestuurde en middenrifgestuurde procedures. Voor de positioner-
ingsprocedures die gebruik maken van een vaste stereotactische referentie of van
wervels kon de nauwkeurigheid in hoofdstuk 8 echter minder precies worden
vastgesteld, omdat in dit onderzoek de dagelijkse variatie in de leverpositie bij
een geforceerde ademstilstand een verstorende invloed op de metingen had. De
standaard deviaties, die de verdelingen van de in hoofdstuk 7 en 8 gemeten random
en systematische fouten kenmerken, zijn gegeven in tabel S.1.
De tumor-marker vergelijkingen (laastste drie rijen in tabel S.1) hebben
betrekking op het gebruik van één enkele marker als surrogaat. Hoewel patiënten
over het algemeen drie markers geïmplanteerd kregen, viel het massamiddelpunt
van een markergroep vrijwel nooit samen met het massamiddelpunt van de tumor.
Het gebruik van het massamiddelpunt van de markergroep voor het bepalen van de
tumorpositie bleek echter wel significant beter dan het gebruik van de verstweg
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Tabel S.1: Standaard deviaties van random (σ) en systematische (Σ) fouten
(populatiewaarden in mm) van diverse surrogaatgestuurde positioneringprocedures.
Fouten werden gemeten ten opzichte van de referentieprocedure (tweede kolom). σ en
Σ van de markergestuurde procedure zijn afhankelijk van de afstand d (mm) tussen
de marker en het massamiddelpunt van de tumor, volgens σ =
√
(0.3 + 0.036× d) en
Σ = 1.5× σ. Merk op dat iedere behandeling gekenmerkt wordt door een beperkt aantal
bestralingsfracties en dat bijgevolg uitsluitend effectieve waarden van σ en Σ hiervoor
van toepassing zijn, te berekenen met de formules gegeven in hoofdstuk 9.
 
 
surrogaat referentie σ   Σ  
  CC LR AP  CC LR AP 
SBF marker 2.8 1.7 2.0  4.2 2.6 3.0 
wervel marker 2.2 3.2 1.4  2.9 4.1 4.1 
middenrif marker 1.2 n.b. n.b.  3.0 n.b. n.b. 
SBF tumor 2.2 2.2 1.8  3.0 1.4 3.6 
wervel tumor 2.1 1.6 1.4  2.3 1.5 2.9 
middenrif tumor 1.6 1.6 1.5  2.3 1.2 2.1 
marker tumor (d = 20 mm)  1.0  1.2 
marker tumor (d = 50 mm)  1.4  1.8 
marker tumor (d = 100 mm)  2.0  2.4 
 
gelegen marker, maar niet significant beter dan het gebruik van de dichtstbij
gelegen marker. Bovendien werd aangetoond dat door vervorming van het
leverweefsel, het verrekenen van de waargenomen rotatie in de markergroep, niet
altijd leidde tot een betere voorspelling van tumorpositie. Positioneringscorrecties
kunnen daarom evengoed gebaseerd worden op de translatiecomponent van de
markerpositieveranderingen. In hoofdstuk 7 werd aangetoond dat het gebruik van
abdominale compressie geen systematische invloed had op de vervormingen die
van dag tot dag gemeten werden; de verdelingen van waargenomen vervormingen
met en zonder compressie bleken niet significant van elkaar te verschillen. De
invloed van de afstand tussen de marker en het massamiddelpunt van de tumor
op de foutvariantie van een markergestuurde positioneringprocedure werd gemod-
elleerd volgens de methoden die beschreven zijn in hoofdstuk 9. Het bestaande
paradigma voor het berekenen van positioneringsfouten in de radiotherapie werd
daartoe uitgebreid met een regressiemethode die het effect van een exogene
variabele (marker-tumor afstand in hoofdstuk 8) op de foutvariantie modelleert
en een methode om de componenten van de foutenvectoren te combineren tot
een schatting van een richtingsonafhankelijke foutvariantie. Hoofdstuk 9 vat
ook het bestaande paradigma voor het berekenen van random en systematische
foutvarianties samen en plaatst het in een theoretisch kader.
We concluderen dat geïmplanteerde markers goed bruikbaar zijn als surrogaat
voor het positioneren van de tumor in een beeldgestuurde procedure. Voor
markers die dichter dan 5 cm van de tumor geplaatst werden, waren bij deze
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positioneringprocedure de standaard deviaties van fouten beperkt tot σ = 1.4
mm en Σ = 1.8 mm, zie tabel S.1. Het middenrif was het op een na beste
tumorsurrogaat. Ten opzichte van een ongecorrigeerde behandeling (SBF, tabel
S.1), geeft sturing op basis van de middenrifpositie een belangrijke verbetering.
Hoewel er wel een zwakke correlatie tussen de posities van de wervels en de
tumor waargenomen werd, zijn wervels over het geheel beschouwd toch niet goed
bruikbaar als tumorsurrogaat, en resulteerde de wervelgestuurde procedure in
fouten die qua grootte vergelijkbaar zijn met die van ongecorrigeerde procedures.
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Dankwoord
Aan de totstandkoming van dit proefschrift hebben velen bijgedragen. Naast
de zeer gewaardeerde professionele ondersteuning was persoonlijk contact en het
enthousiasme daarbij van doorslaggevend belang.
Promotoren Prof. B.J.M. Heijmen en Prof.dr. P.C. Levendag. Ben, als
promotor en begeleider was jouw bijdrage aan mijn promotie groots. Met
jouw slimme en heldere ideeën wist jij vaak orde te scheppen in de complexe
werkelijkheid. Bovendien wist je me altijd te enthousiasmeren, ook als het eens
tegenzat. Dit enthousiasme en jouw sociale instelling ervaar ik als erg plezierig,
en het heeft mij zeer gestimuleerd gedurende het onderzoek. Peter, jij legde de
basis voor dit onderzoek. Helaas kreeg jij daarbij te maken met een fysicus, die
qua eigenzinnigheid niet voor jou onderdeed. Toch heb je altijd veel vertrouwen
gehad in mijn werk. Hiervoor mijn dank.
Collega radiotherapeut Alejandra Méndez Romero, mijn onderzoekspartner.
Sandra, onze samenwerking was een avontuur. Met meer verschillen dan
gelijkenissen tussen ons, vormen wij toch een harmonie. Wij namen geen
genoegen met half werk, niet voor de patiënten, maar ook niet als het erom
ging elkaar te begrijpen. Deze kritische maar open houding was een genoegen.
We kunnen trots zijn, niet alleen op de ontwikkeling van een van de beste lever
radiotherapiebehandelingen ter wereld, maar ook op die van onze vriendschap.
Hans de Boer, vooral aan het begin van mijn onderzoek heb jij mij veel
begeleid en mij daarbij erg veel inzicht gegeven in de nieuwe materie. Complexe
concepten werden afgewisseld met cynische humor, discussies waar ik met plezier
aan terugdenk. Ik vind het jammer dat je niet bij de afronding van dit proefschrift
betrokken bent geweest.
Radiotherapeutisch laboranten René Brandwijk en Hans Joosten. Alleen met
jullie inzet en ideeën werd het mogelijk om verbeteringen van de teken- naar de
patiëntentafel over te brengen; dit gaf grote waarde aan ons onderzoek. Het zijn
uiteindelijk heel wat extra uurtjes voor jullie geworden en daarvoor ben ik jullie
zeer dankbaar.
Klinisch fysici Yvette Seppenwoolde en Evert Woudstra, dankzij jullie inzet
van de afgelopen jaren is de leverbehandeling nu in goede handen en kon ik mij
de laatste tijd meer wijden aan het onderzoek. Bovendien leverden jullie veel voer
voor discussie, dat zowel de behandeling als mijn inzicht ten goede kwam.
Hiernaast hebben velen anderen met veel toewijding steentjes bijgedragen, die
ik hiervoor wil danken: Jacco Barnhoorn, Edward Donkersloot, Wim Jansen,
Willy de Kruijf, Lars Murrer, Theodore Mutanga, Peter Nowak, Marjolein van
Os, Sarah Osman, Johan Pöll, Jacco de Pooter, Paulette Prins, Sandra Quint,
Gerard Schaap, Wilco Schillemans, Pascal Storchi, Hans Vuik, Davy Wentzler,
Roel Zinkstok, Andras Zolnay.
Ten slotte mijn ouders Freek en Fia Wunderink. Dit proefschrift is aan jullie
opgedragen omdat ik dit zonder jullie nooit zou hebben kunnen volbrengen. Freek,
de zekerheid dat er altijd iemand was die zoveel om me geeft als jij, gaf me het
vertrouwen dat ik nodig had om door te zetten. Ik kon altijd op je rekenen
met goede raad. Fia, je hebt meer bijgedragen aan dit werk, dan alleen jouw
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auteurschap doet vermoeden. Jij stond altijd voor mij klaar als privé wiskunde
docent en daarbij was geen probleem je te exotisch om er een goede aanpak voor
te bedenken.
Mijn partner Eliana Vásquez Osorio. Eliana, als collega heb je me van de eerste
letter tot aan de laatste punt bijgestaan als computervirtuoos. En als vriendin,
daar zijn geen passender woorden voor dan: ‘Yo te adoro’.
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This doctoral thesis concerns the treatment of liver cancer patients using 
external beam radiotherapy. The quality of this treatment greatly depends 
on delivering a high radiation dose to the tumor while keeping the dose as 
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is locating the tumor at the moment of dose delivery. In this work, the 
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